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ABSTRACT   
Duchenne Muscular Dystrophy (DMD) is a lethal, X-linked, recessive muscle-wasting 
disorder affecting 1 in 3 500 live male births worldwide, for which only palliative care is 
available to date. Large exonic deletions or duplications are found in approximately 70% of 
DMD patients, for which diagnostic testing is available. The remaining 30% carry point 
utations, which go largely undetected, as no testing is currently offered due to the great 
s revealed 10 small/point 
athogenic changes, 39 polymorphisms and 4 changes of uncertain significance. No 
mutation 
arrying patients in the cohort and skipping exons 45 - 55 could benefit a further 12,5%, 
ion detection in the DMD gene, to help find “family mutations”, 
us facilitating genetic counselling and ultimate determination of eligibility for mutation-
ased therapy in the future. 
m
size of the DMD gene and the logistical challenges involved.  
 
Positive outcomes of research into gene-based therapies necessitate availability of protocols 
which will extend the scope of testing to detection of point mutations. In this study, the DNA 
samples of 24 patients previously tested negative for exonic deletions with the mPCR 
method, were subjected to a complete mutation screen of the coding region of the DMD 
gene using the MLPA and hrMCA. Four deletions and 2 duplications were revealed by the 
initial screen with the MLPA. The DNA of the remaining 18 patients was then subjected to 
mutation scanning with hrMCA on the RotorGene™6000, of 96 PCR fragments 
encompassing the entire coding region of the DMD gene, amplified using M13-tailed primers, 
and subsequent sequencing of variant fragments. The analysi
p
pathogenic mutations were found in 8 patients of the cohort.  
 
The 10 disease-causing changes identified, consisted of 3 nonsense, 4 frameshifts, 1 splice-
site, 1 compound mutation (a GGTG duplication and a missense), 1 missense, and 1 point 
substitution in the Dp427promoter/exon1 region of the DMD gene. The deleterious nature of 
the mutations detected was inferred by their nature and by the output of bioinformatic 
analyses with regard to the effect on splicing, amino acid changes and regulatory 
sequences. Also, the results of family studies showed that the pathogenic mutations were 
familial in their origins and that they tracked with the disease within the families. Predictions 
of future therapeutic options revealed that by virtue of cohort selection none of the patients 
would benefit from AON-induced skipping of exon 51, which is currently undergoing clinical 
trials. However, multiexon skipping of exons 6 – 8 could benefit ~30% of the 
c
emphasizing the potential therapeutic impact of the multiexon skipping approach.   
 
The study findings suggested that hrMCA could be successfully incorporated into the 









PLAN OF THE THESIS 
This thesis is divided into five chapters. The first chapter provides an introductory 
background to neuromuscular disorders as well as a general overview of the aim of 
the study and the scientific approach to the investigation. The second chapter 
details the scientific rationale for each of the molecular investigations undertaken in 
this project. The third chapter follows with a presentation of the findings of the study. 
The fourth chapter discusses each finding with respect to the global genetic 
landscape of the DMD gene and patients. Genotype/phenotype correlations are 
discussed and future prospects for further investigations are addressed. The thesis 
is concluded in the fifth chapter, where the findings of the molecular studies are 
ummarised and placed in context of the emerging DNA-based therapies currently 




CHAPTER 1:             LITERATURE REVIEW 
 
1.1 INTRODUCTION 
Muscular dystrophies are a group of inherited disorders, caused by the lack of a 
specific protein component in the muscle tissue. Starting with identification of the 
dystrophin gene in the 1980’s, a number of muscular dystrophy genes and their 
proteins have been characterised. The impressive amount of knowledge since 
gathered on the molecular basis of muscular dystrophies has paved the way to a 
better understanding of the disease mechanisms and improved diagnosis, both in 
the clinic and in the laboratory. Availability of more reliable and informative genetic 
testing is a direct benefit of this knowledge, which allows for more effective patient 
management and accurate genetic counselling of the family.  
 
Despite the advances in medical technology, muscular dystrophies particularly the 
allelic Duchenne and Becker muscular dystrophies (D/BMD) remain lethal and 
devastating to the patients and their families. While standards of care are continually 
improving worldwide, currently available interventions are limited to the 
management of symptoms and complications. Progress in terms of therapy has 
been slow and fraught with pitfalls and setbacks. However, much research has been 
focused on genetic therapies, and in recent years a number of new experimental 
approaches appear to hold promise. Of those, read-through therapy and exon 
skipping are especially relevant to D/BMD and to this study, and will be addressed in 
more detail later in this review.  
 
Still, the first step remains identification of the disease-causing mutations. Potential 
availability of mutation-specific gene therapy marks the advent of personalised 
medicine and emphasizes the need for a rapid and accurate method of detecting 
small nucleic acid changes in D/BMD and other genetic disorders. Ideally, the 
technology should be cost-efficient, sensitive yet robust and rapid enough to fit into 
a diagnostic environment.  
 
1.2 MUSCULAR DYSTROPHIES 
Muscular dystrophies fall into the spectrum of neuromuscular diseases and are 
defined as a group of heterogeneous, inherited disorders, characterised by 
progressive weakness and wasting of skeletal muscle tissues. The classification 
scheme devised by Walton and Nattrass in 1954, based on their own clinical 
observations and still applied today, relies mostly on the distribution of muscle 
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weakness (Figure1.1), and the mode of inheritance (Walton, 1954). It identifies the 
following main groups:  
 
 Duchenne/Becker-type (X-linked) 
 Facioscapulohumeral (autosomal dominant) 
 Limb girdle (genetically heterogeneous but mostly autosomal recessive)  
 Emery-Dreifuss (X-linked, autosomal dominant and recessive sub-types)  
 Distal (autosomal dominant and recessive clinically and genetically distinct 
subgroups)  
 Oculopharyngeal (autosomal dominant) 





          Figure 1.1:  Distribution of predominant muscle weakness in different types of dystrophy. 
  A: Duchenne-type and Becker-type, B: Emery-Dreifuss, C: limb-girdle, D: facioscapulohumeral,  
  E: distal, F: oculopharyngeal. Shaded=affected areas. (Emery, 2002) 
 
Muscular dystrophies have since been mapped to 29 different chromosomal loci, 
extending the above classification into 34 distinct disorders varying in the age of 
onset, degree of severity, mode of inheritance and the primarily affected muscle 
groups (Dalkilic & Kunkel, 2003).  
 
1.3 DUCHENNE/BECKER MUSCULAR DYSTROPHY (D/BMD) (OMIM#310200) 
Also known as Meryon’s disease, DMD is one of the most common and severe of 
the inherited dystrophies, with an incidence of 1 in 3500 live, male births worldwide 
(Emery, 2001). Long before the gene and its protein were characterised, early 
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investigators noted the X-linked recessive heritability of DMD, based upon scrutiny 
of the affected family pedigrees (Meryon, 1851; Tyler, 2003). Also, early post 
mortem studies of muscle tissues and the spinal chord suggested the myogenic 
nature of the disease, with no involvement of the central or peripheral nervous 
system (Emery & Emery, 1995). The milder, allelic form of DMD, Becker’s muscular 
dystrophy (BMD), has a lower frequency (1 in 30 000 boys), a milder progression 
and longer life expectancy (Becker & Kiener, 1955; Blake & Kroger, 2000a).  
               
1.4 DISEASE MANIFESTATION  
Duchenne muscular dystrophy, usually manifests in boys between the ages of 2 and 
5 years, when parents typically notice a delay in motor milestones and symptoms 
such as frequent falling, difficulty in getting up, gait problems, toe-walking and flat-
footedness. About 50% of the affected boys cannot walk independently at 18 
months (Bushby et al., 2005).  
 
The natural course of the disease is fairly predictable, although severity varies 
between patients, depending on the causative mutation (Tuffery-Giraud et al., 2009). 
Clinical examination generally reveals calf enlargement (pseudohypertrophy), 
lumbar lordosis, which disappears on sitting, and weakness of the neck flexors. 
Most DMD patients never learn to jump with both feet together. Weakness of the 
knee and hip extensors causes the typical Gower’s manoeuvre: in an effort to 
stand up from lying on his back, the child needs to turn onto his front and push 
himself erect by moving his hands up his thighs. Muscle weakness is progressive, 
starting with proximal weakness of the lower limbs, moving onto the distal lower and 
then upper limbs, ultimately leading to wheelchair dependence (Emery, 2001; 
Manzur & Muntoni, 2009). Loss of independent ambulation, as defined in DMD 
occurs at 13 (although the mean is 9), in intermediate-type muscular dystrophy 
(IMD) between 13 and 16 and in BMD, beyond 16 years of age, though the use of 
steroids has made this data less fixed. Muscle weakness leads to scoliosis in 90% 
of the cases, with ultimate loss of sitting balance, exacerbated by formation of 
asymmetric contractures of the Achilles tendons and hips. In untreated patients, 
respiratory and cardiac complications are the cause of death at the mean age of 19 
(Bushby et al., 2010a). BMD has a later age of onset with a more diverse 
presentation and progression, in some cases showing only mild myalgia and muscle 
cramps with no weakness (Beggs et al., 1991).  
 
Cardiac involvement is seen in all D/BMD patients but generally remains 
subclinical in the early stages.  It is likely that the late presentation of cardiac 
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symptoms is due to the decrease in physical activity, relative to the progressive 
general muscle weakness. The spread of fibrosis caused by repetitive strain results 
in left ventricular dysfunction and eventual dilative cardiomyopathy, if left untreated 
(van Bockel et al., 2009). Cardiomyopathy is seen as the determinant of survival in 
BMD patients, with an incidence of approximately 72%. It is the cause of death in 
about 20% of the DMD, and 50% of the BMD patients (Manzur & Muntoni, 2009).   
 
For the most part, respiratory function in D/BMD patients is normal before loss of 
ambulation. As a rule, early loss of ambulation predicts early need for ventilation and 
respiratory failure. The respiratory function parameter in D/BMD patients is the 
forced vital capacity (FVC), which peaks shortly before loss of independent 
ambulation and progressively drops thereafter, with eventual respiratory failure 
manifesting as lowered energy levels, generalised malaise, weight loss, headaches, 
sleep disturbance, nocturnal and subsequent daytime hypercapnia. The concurrent 
increase in the frequency of respiratory infections raises the risk of death from 
respiratory failure during an infection (Bushby et al., 2005).   
 
Non-progressive cognitive impairment in DMD ranges in severity from borderline 
neuropsychological deficits to severe intellectual disability (ID). Investigators 
consistently report the full scale intelligence quotient (FSIQ) in DMD patients as 
approximately 1 standard deviation below the population mean, with FSIQ scores of 
under 70 points seen in 19–35% of DMD cases, and moderate to severe ID 
(FISQ<50) noted in 3% of DMD patients (Cotton et al., 2001; Cotton et al., 2005; 
Taylor et al., 2010). The gross anatomical morphology of DMD-affected brains 
appears normal, although Yoshioka and colleagues found slight cerebral atrophy in 
20 of the 30 DMD cases they examined, the extent of atrophy correlating directly 
with age and low intelligence quotient (IQ) (Yoshioka et al., 1980). The results of a 
study by Taylor et al. (2010) correlating FSIQ results with the location of the DMD 
mutations are highly suggestive of a link between cognitive deficits and cumulative 
loss of dystrophin isoforms expressed in the central nervous (CNS). Intellectual 
disability in BMD patients is reported infrequently, and there is speculation that since 
cognitive disabilities in D/BMD can occur before the onset of muscle weakness, 
some patients diagnosed with X-chromosome-linked mental retardation might carry 
mutations in the DMD gene (Blake & Kroger, 2000b).           
 
Dystrophin is also expressed in the retina and some DMD patients show impaired 
scotopic and photopic responses obtained by full-field electroretinogram (ERG). 
Their visual function does not appear to be seriously compromised, although a 
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degree of non-progressive, red-green colour-blindness has been documented 
(Costa et al., 2007).    
 
Long bone fractures and fractures of the vertebrae are common in D/BMD, 
because of low bone mineral density, possibly caused by relative immobility, further 
exacerbated by the long-term use of corticosteroids. Progressive loss of mobility 
along with steroid treatment can also lead to excessive weight gain, which in turn 
leads to early immobility. On the other hand, loss of appetite frequently 
accompanying respiratory failure, results in weight loss.  Constipation is a 
common complaint in older boys, due to the involvement of smooth muscle. In later 
stages, difficulty in swallowing and frequent aspiration creates further nutritional 
and even respiratory complications. D/BMD patients can also present with a 
potentially fatal ‘‘malignant hyperthermia-like’’ reaction with rhabdomyolysis, 
hyperkalaemia and myoglobinuria, upon exposure to suxamethonium or a 
halogenated inhaled anaesthetic. This rhabdomyolytic risk is a major 
consideration in their anaesthetic management, and easy access to monitoring aids 
and intensive care facilities is strongly indicated (Manzur & Muntoni, 2009). 
 
D/BMD along with other muscle disorders ranging in presentation from muscle 
cramps and myoglobinuria, to DMD-associated dilated cardiomyopathy or X-linked 
dilated cardiomyopathy (XLDCM), are also referred to as dystrophinopathies, 
since all are caused by production of defective or insufficient levels of dystrophin 
(Cardamone et al., 2008).   
 
1.5 CLINICAL DIAGNOSIS 
The assessments and interventions used in the diagnosis and management of 
D/BMD have been recently evaluated by the DMD Care Considerations Working 
Group, in an effort facilitated by the US Centers for Disease Control and Prevention 
(Bushby et al., 2010a; Bushby et al., 2010b). According to the clinical care 
recommendations, as set out by the Group, the diagnosis of DMD should be 
considered irrespective of family history, following one of three triggers:  
 
 observation of abnormal muscle function in a male child, 
 detection of increased serum creatine kinase (CK) levels (in DMD massively 
elevated by 10 – 100 x normal, since birth), a result of muscle tissue break 
down,  
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 discovery of increased transaminases (aspartate aminotransferase and 
alanine aminotransferase, which are produced by muscle as well as liver cells) 
(Bushby et al.,  2010a). 
 
The clinical diagnosis should be confirmed by: 
 Genetic testing 
Mutation detection provides conclusive evidence and diagnosis. However, a 
negative result does not negate the diagnosis of D/BMD. A good understanding 
of the test limitations is therefore required. Testing the mother’s carrier status is 
not strictly part of the diagnosis but facilitates genetic counseling of the family 
(Abbs et al., 2010). 
 Muscle biopsy 
Immunohistochemical staining for dystrophin in muscle tissue will reveal absent 
or reduced dystrophin levels, which can be used to confirm a diagnosis of 
D/BMD. In most centres however, because of the invasive nature of the 
procedure, biopsies are taken only if molecular testing is uninformative (Bushby 
et al., 2010a).  
 
1.6 TREATMENT AND CARE 
Ideally, clinical management of a D/BMD patient is a team effort coordinated by the 
muscle clinic physician and involving a plethora of specialists: orthopedic, cardiac, 
physiotherapists, dieticians, occupational therapists, psychologists, and family and 
parent/patient support groups. 
 
 Glucocorticosteriods are the mainstay of treatment for muscle weakness in 
D/BMD, best commenced at the plateau of the child’s physical performance 
but long before loss of ambulation. Careful dosage monitoring and 
prophylaxis are needed to counteract the negative effects of steroid therapy 
such as weight gain, behavioural problems, bone density reduction, and 
compromised immune function after prolonged use.   
 Physiotherapy: passive or active exercise as well as appropriate orthodesis 
to prevent and treat contractures, scoliosis and for walking and/or sitting 
postural support (seating / wheelchairs).  
 Splinting: as appropriate, depending of the degree of ambulation and ankle 
dorsiflection.   
 Surgery: possible elongation of Achilles tendons and correction of scoliosis.    
 Anasthaesia: careful preoperative assessment of cardiac and respiratory 
function and consideration of the rhabdomyolytic risk.   
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 Respiratory management: prophylaxis, prompt diagnosis and treatment of 
lung infections, positive pressure ventilation to treat hypercapnia and 
respiratory failure.  
 Cardiovascular management: regular monitoring of cardiac function 
(echocardiogram and ECG), treatment with ACE (angiotensin converting 
enzyme) inhibitors. Additional agents after onset of symptoms.  
 Monitoring of bone health: diet supplementation with vitamin D and 
calcium, intravenous biphosphonates for vertebral fractures, early 
mobilization post long bone fracture, to prevent early loss of ambulation. 
 Nutrition: weight monitoring and diet adjustments, use of mild laxatives to 
relieve constipation, intubation or percutaneous endoscopic gastrostomy 
(PEG). 
 Addressing learning and emotional difficulties: occupational and speech 
therapy, consultation with psychologists and support groups.           
 Access to adaptive technologies i.e. electric beds and wheel chairs, 
computers etc., to aid an independent and functional life (Bushby et al., 
2005; Bushby et al., 2010b).  
 
1.7 THE DMD GENE AND ITS PRODUCT 
Localisation of the gene to the short arm of the X chromosome (Xp) was achieved 
by extensive work with positional cloning and restriction fragment polymorphisms 
(Davies et al., 1983; Monaco et al., 1986; Burghes et al., 1987; Koenig et al., 1987) 
as well as cytogenetic studies of DMD-manifesting females, with balanced 
X;autosome translocations breaking at Xp21 (Verellen-Dumoulin et al., 1984). The 
full extent of the gene was eventually revealed by work with deletion-detecting 
clones on DNA of a patient with four different X-linked disorders, in whom a large 
contiguous-gene-deletion was confirmed (Francke et al., 1985). Similarly, BMD was 
shown to map to the same region of the X chromosome (Kingston et al., 1984).  
 
The DMD gene encompasses 2.5Mb of genomic sequence, with a full-length protein 
encoded by a 14kb RNA transcript (Monaco et al., 1992). This is approximately 
1.5% of the X chromosome and 0.1% of the entire genome, making the DMD gene 
one of the largest, single protein-encoding genes described in humans to date. It 
consists of 79 exons with 7 tissue-specific promoters (Figure1.2), which drive the 




 Full-length isoforms are encoded by promoters with unique first exons, spliced 
to 78 common exons:  
            Dp427M (muscle promoter) drives expression of dystrophin in the skeletal 
muscle, cardiomyocytes and to a small extent in glial cells of the brain. 
            Dp427P (Purkinje promoter), on the other hand, is expressed in the cerebellar 
Purkinje cells and at low concentrations, in skeletal muscle.    
            Dp427B (brain promoter), is expressed primarily in cortical neurons and the 
hippocampus of the brain (Blake et al., 2002; Muntoni et al., 2003a).     
             Dp427L (putative lymphocyte promoter, not included in Figure 1.2), whose status 
is uncertain but is at this time thought to be physiologically insignificant (Wheway 







Figure 1.2 Linear representation of the DMD gene and its products - adapted from  
A: The DMD gene position at Xp21 and its linear representation:   exons represented as black lines 
and promoters as arrows).  B: Linear representation of the dystrophin isoforms (Blake & Kroger, 




 Short isoforms are expressed by at least four internal promoters, which splice 
to various exons within the gene, generating protein products of 260 kDa (Dp260 
to exon 30), 140 kDa (Dp140 to exon 45), 116 kDa (Dp116 to exon 56), and 71 
kDa (Dp71 to exon 63) (Blake et al., 2002).       
 
 Alternative isoforms of dystrophin are generated through a number of 
alternative, tissue specific splicing events, such exon skipping and exon 
scrambling. These events sometimes result in the formation of circular RNA 
molecules in co-existence with linear RNA, the biological function of which is still 
unclear (Surono et al., 1999; Gualandi et al., 2003). 
 
1.7.1 Dystrophin 
Dystrophin is a large cytoskeletal protein, 427kDa in size, localized to the 
cytoplasmic face of the muscle cell membrane. It acts as a mechanical link between 
the cytoskeletal actin and the extracellular matrix (Figure.1.6) (Arahata et al., 1988; 
Hoffman et al., 1987) and plays a role in intracellular signal trunsduction (Rando, 
2001). The dystrophin molecule consists of four, main functional domains (Figure 
1.2), each with its own protein-binding capabilities (Blake et al., 2002): 
 
 The NH2-terminus, along with a part of the rod domain binds directly to, but 
does not cross-link cytoskelatal actin.  
 The central rod domain, makes up most of the protein and consists of 24 
spectrin-like repeats, interrupted by 4 proline-rich hinges. The repeats confer the 
molecule’s structural rigidity and the interspersed hinges allow its flexibility. 
Spectrin repeats 11 through 17 within the rod region constitute a second actin 
binding site.  
 The dystroglycan-binding domain consists of: 
o WW domain follows the fourth hinge of the rod region and separates 
it from the cysteine-rich and the COOH-terminal regions. It is a 
protein-binding module and is part of a number of signaling and 
regulatory molecules.  
o The cysteine-rich domain consists of two EF-hand motifs, which 
bind intracellular Ca2+ , and a ZZ domain containing a number of 
cysteine-rich residues predicted to form coordination sites for divalent 
metal cations e.g. Zn2+.  This ZZ-domain is similar to other types zinc 
finger found in nuclear and cytoplasmic proteins.  
 The COOH-terminal domain or CC-domain contains two –helical coiled coils,  
which mediate its interaction with the syntrophins.  
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The shorter dystrophin isoforms (Figure 1.2), lack parts of the actin-binding and rod 
domains but retain the cysteine-rich and the CC-terminal domains, which mediate 
binding to the dystrophin-associated proteins (dystroglycan, dystrobrevin and 
syntrophin). 
 
1.8 DYSTROPHIN-ASSOCIATED PROTEIN COMPLEX 
Initial biochemical purification of the compound from muscle led to the observation 
that dystrophin co-purifies with a group of sarcolemmal and sub-sarcolemmal 
proteins (Ervasti & Campbell, 1991; Ervasti et al., 1991).  Together, they have been 
shown to interact as the dystrophin-associated protein complex (DPC), which 
consists of dystrophin, sarcoglycans, dystroglycan, dystrobrevins, syntrophins, 
sarcospan, caveolin-3, and neuronal-type nitric oxide synthase (nNOS) (Blake et al., 
2002; Judge et al., 2006). The DPC form a scaffold connecting the actin-based 
cytoskeleton with the basal lamina, with dystrophin acting as an essential structural 
link in its assembly (Figure 1.3).  Absence or dysfunction of dystrophin therefore, 
causes instability of the DPC and an abnormally increased susceptibility to damage. 
The DPC proteins are found in various combinations depending on muscle tissue 
type and can be subdivided into three distinct protein subcomplexes, according to 
their location and binding associations within the cell and between one another: 
 
 





 The Dystroglycan Complex  
         Dystroglycan forms an essential core of the DPC, as it connects the 
cytoskeletal components of the DPC to the extracellular matrix (Figure 1.5). 
Dystroglycan is produced from a single gene and is post-translationally 
cleaved into  and  subunits (Lapidos et al., 2004). The extreme COOH 
terminus of the -dystroglycan binds directly to the WW domain and the EF 
hands of the cystein-rich region of dystrophin, emphasizing the functional 
importance of both these domains (Crawford et al., 2000).  -dystroglycan also 
binds to Grb2, providing a known signaling pathway for -dystroglycan. 
Caveolin-3, a transmembrane protein specifically expressed in muscle, also 
interacts with -dystroglycan, and may compete for the same binding site as 
dystrophin. This theory is supported by the reduced levels of dystrophin and -
dystroglycan in autosomal dominant limb-girdle dystrophy type 1C, which is a 
result of calveolin-3 mutations. On the extracellular side, the -dystroglycan 
forms an important connection to the 2-chain of laminin 2, forging a link is 
between the sarcolemma and the extracellular environment (Rando, 2001; 
Blake et al., 2002; Lapidos et al., 2004).    
 
 The Sarcoglycan Complex 
The sarcoglycans are a group of transmembrane-spanning glycoproteins, 
which co-purify as a complex within the DPC (Figure 1.3). The precise function 
of the sarcoglycans within the cell membrane remains unclear and although 
absence of the sarcoglycan-complex in mutant cells does not affect normal 
distribution of dystrophin, it appears to cause defective cell membrane 
permeability and subsequent increased fragility and degeneration (Rando, 
2001; Blake et al., 2002; Lapidos et al., 2004).  
 
 Sarcospan is tightly associated with the sarcoglycans (Figure 1.3) and the 
DPC and is thought to stabilise the dystroglycan complex in sarcolemma. It is 
not crucial for normal function of the DPC, nor is it essential for formation of 
the sarcoglycan complex. Sarcospan may have a signalling function, since it is 
a member of the tetraspanin protein family, which has been implicated in 
mediating the integrin-signaling responses in other tissues (Rando, 2001; 
Blake et al., 2002; Lapidos et al., 2004). 
 
 The Cytoplasmic (dystrophin containing) Complex 
Various isoforms of dystrobrevin bind directly to dystrophin in the brain, 
muscle and other tissue. The syntrophins bind directly to dystrophin and 
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dystrobrevin. While the precise role of dystrobrevin in this context is unclear, it 
is thought to play a role in intracellular signal transduction. The syntrophins 
possibly function as a link between the membrane-associated proteins and the 
DPC. Syntrophins also bind to the neuronal-type nitric oxide synthase (nNOS), 
which may play a role in regulation of the vascular tone in skeletal muscle 
fibres. Binding between dystrobrevin and syntrophin and by extension that 
between syntrophin and neuronal nitric oxide synthase (nNOS), is mediated by 
the CC-domain of the dystrophin molecule. In mdx mice, nNOS is known to be 
dislodged from its site in the plasma membrane and becomes cytoplasmic. 
Vasoconstriction in these mice is impaired, which is an indication of the 
importance of association between the DPC and nNOS (Blake & Kroger, 
2000a; Rando, 2001; Lapidos et al., 2004). 
 
1.9 PATHOLOGY OF DYSTROPHIN-DEFICIENT MUSCLE    
It is hypothesised that since dystrophin forms an integral part of a mechanical link 
between the extracellular matrix and the cytoskeleton, faulty dystrophin causes 
destabilization of that link and subsequent weakening of the sarcolemma  (Judge et 
al., 2006). Mechanical damage of fragilised membranes, caused by repetitive 
eccentric contractions, provokes microlesions that are thought to lead to physical 
sarcolemmal breaks or calcium leak channel openings. This in turn, elevates 
intracellular free calcium levels triggering calcium-activated proteases and 
subsequent fibre necrosis. Destabilisation of the sarcolemma is may also be linked 
to the DPC’s involvement in cellular signalling, important for microvascular function, 
muscle fibre type-determination and general myofiber homeostasis (Judge et al., 
2006). The primary manifestations of DMD are therefore thought to result from an 
imbalance between muscle fiber necrosis and myoblast regeneration, with necrosis 
as the primary pathologic feature (Deconinck & Dan, 2007). 
 
Histological analysis of muscle samples from affected patients generally reveals 
changes in the fibre size, fibre necrosis and increased amounts of fat and 
connective tissue. Degenerating fibers are often observed in clusters confined to 
segments of the muscle fiber (grouped necrosis). Necrotic or degenerating muscle 
fibers are characteristically seen in postnatal DMD muscle biopsies even before 
muscle weakness is clinically observed. In early disease, active regeneration is a 
sign of fibre necrosis, with the regenerating fibers recognized by their small 
diameter, basophilic RNA-rich cytoplasm, and large, centrally placed myonuclei. In 
later stages, this regenerative capacity is exhausted and muscle is replaced by 
connective and adipose tissue. Necrotic muscle fibers are subject to phagocytosis 
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and inflammatory cells, predominantly macrophages and CD4 lymphocytes, are 
seen at perimysial and endomysial sites (Blake et al., 2002).  
  
Immunohistochemical analysis of normal muscle shows dystrophin localised to the 
sarcolemma with uniform labelling of each fibre. In DMD, dystrophin is mostly 
absent, whereas in BMD, the fibres show reduced and/or uneven sarcolemmal 
labeling (Figure 1.4). Some muscle biopsies of DMD, show “revertant fibres”, which 
manifest low or even near normal expression of dystrophin. Immunolabelling is often 
uneven on the fibre periphery and longitudinal sections reveal only partial labeling of 
the fibre. This type of expression arises as a result of restoration of the translational 
reading frame in some cells but the mechanisms by which this occurs are uncertain 
(Sewry, 2000). Studies of revertant fibres in the mdx mouse suggest various 
mutation-dependant mechanisms which result in alternative splicing events e.g. 
‘‘exon skipping’’ (Winnard et al., 1995; Lu et al., 2000). 
 
An estimated 26% of non-manifesting carriers are reported to exhibit a degree of 
dystrophin-defective staining (E. M. Hoogerwaard et al., 2005), with occasional 
dystrophin negative fibres, or uneven labelling. In symptomatic carriers, dystrophin-
negative muscle fibres are thought to result from a skewed pattern of X-inactivation 
in the muscle (Sewry, 2000). The numbers of ‘‘negative’’ fibres are variable and 
transverse sections in young cases often show mosaic patterns  of positive and 




Figure 1.4 Examples of immunocytochemical findings in normal and dystrophin-deficient   
muscle. Normal control (A): localization to the periphery of each muscle fibre. Patients with BMD (B 
and C): low level, discontinuous protein expression. Manifesting DMD carrier (D): “mosaic” expression 
of dystrophin in different fibres. Intermediate phenotype (IMD) (E): relatively abundant revertant fibres. 
DMD (F): absent protein expression. (Muntoni et al., 2003b) 
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1.10 MUTATIONS IN THE DMD GENE 
Because of its size, the DMD gene is predisposed to mutations, approximately 65% 
of which are estimated to be exonic deletions, and 5% to 15% are duplications 
(Beggs et al., 1991). This broad estimate for the frequency of duplications has been 
put down to the variable sensitivities of the techniques used, which should change 
with the current, improved detection methods (Muntoni et al., 2003a). In a recent 
study by Kesari et al. (2008), duplications were detected in as many as 21% of 
mutation-positive BMD patients.   
 
While exonic rearrangements can occur at any point within the gene, two hot-spot 
regions have been identified: one situated towards the central part of the gene and 
includes exons 45 to 53 (hot-spot region 1), and the other at the 5’ end of the gene, 
spanning exons 2 to 20 (hot-spot region 2). Entries in the Leiden Open source 
Variation Database (LOVD) for DMD (www.dmd.nl) record the most deletions in hot-
spot region 1, with the deletion of exon 45 being most common (1.7% of all DMD 
mutations) (Aartsma-Rus et al., 2006). Deletions within the DMD gene (and other 
genes on the X chromosome) are predominantly maternally inherited, as opposed to 
duplications, which mostly originate in the male germline (Hu et al., 1990). 
Consequently, duplications are usually seen as familial cases, and the recurrence 
risk is high. Most duplications occur near hot-spot region 2, with exon 2 being most 
commonly duplicated (0.4%of all mutations) (Aartsma-Rus et al., 2006; Gualandi et 
al., 2009). Interestingly, the reciprocal deletion of the most common duplication 
(exon 2) has never been reported (White et al., 2006; Flanigan et al., 2009).  
 
Analyses of the deletion junctions indicate that they arise from rejoining of broken 
ends via nonhomologous end joining (NHEJ) of double stranded breaks (DSBs). 
DSBs arise during DNA replication and other endogenous processes, and are seen 
to cluster in DSB hot-spot regions. There is evidence to suggest that in DMD, the 
DSB-prone regions coincide with deletion/duplication hotspots, which also represent 
major meiotic recombination hot-spots (Sironi et al., 2006; del Gaudio et al., 2008).  
 
The remaining 30% of gene changes in DMD are small/point mutations, mostly 
resulting in nonsense, frame-shift or splice site mutations (Roberts et al., 1994). 
Deep intronic mutations have also been described (Béroud et al., 2004), as well as 
exonic insertions of repetitive sequences and rarely, missense mutations. 
Small/point mutations in the DMD gene do not appear to exhibit the same clustering 
effect as exonic rearrangements and as mentioned earlier, their detection continues 
to present a diagnostic challenge. However, compared to the amount of data 
available on exonic rearrangements, the information on frequencies and distribution 
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of small/point mutations within the DMD gene, is less abundant, mostly due to the 
technical difficulties in finding them. Therefore, as methods improve and data 
becomes available, currently undetected trends may be uncovered. For example, 
Deburgrave et al. (2007), found that of the 124 pathogenic point mutations identified 
in that study cohort, 20 were in exons 53, 66 and 70 or in their flanking splice sites. 
Also, the recently published genotype-phenotype analysis of  all entries in the UMD-
DMD France database (www.umd.be) reported a deficit of point mutations in exons 
32 and 48 and conversely, and excess of mutations in exons 4, 6, 7, 35, 66, and 70 
(Tuffery-Giraud et al., 2009) . Also, the CpG dinucleotide has been shown to be a 
hot spot for mutations in humans because it can undergo oxidative deamination of 
5-methyl cytosine (Krawczak et al., 1998). Tuffery-Giraud et al. (2009) report that 
43.8% (81/185) of substitutions leading to stop codons, involve CpG dinucleotides, 
with the C-to-T substitution in the CGA codon as the most common event (90%). 
The highest mutation rate was observed at a CpG site in exon 66.  Three CpG sites 
are located within exon 70 making this exon particularly prone to mutations. 
Nonsense mutations due to other types of substitutions showed a wider distribution 
along the gene (Tuffery-Giraud et al., 2009). Data gathered from a large cohort 
study by Flanigan et al. (2009) supports uniform hypermutability of CGA>TGA 
mutations but emphasises the absence of hot-spots for point mutations seen to 
segregate within families as “private mutations”.       
 
1.11 GENOTYPE VERSUS PHENOTYPE 
The severe DMD phenotype results from mutations, which cause synthesis of a non-
functional and unstable protein, as opposed to BMD, where a smaller but semi-
functional protein is produced. The disease presentation (DMD as opposed to BMD 
or IMD) is therefore not relative to the size of the mutation, as much as it is to:  
 
 Disruption of the DNA translational open reading frame (ORF)  
      The “reading frame hypothesis” can be applied to 90% of DMD cases (Monaco 
et al., 1988), and it argues that mutations, which disrupt the ORF result in more 
severe phenotypes than those, where the reading frame is retained. ORF 
disruptions cause premature termination of translation which triggers the cellular 
process of nonsense mediated decay (NMD) with its degradation of the mRNA 
and the faulty protein (if any).  
 The mutation’s position within the gene  
Disruptions of the actin-binding N-terminus and the carboxy-terminus of 
dystrophin generally cause a severe phenotype, even if the rearrangement is in-
frame. Large, in-frame deletions at the 5’ end of the gene, which stretch across 
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the actin-binding and into the middle of the rod domain (deletions of exons 3 – 
31, 3 – 25, 4 – 41, or 4 – 18) result in a DMD phenotype and account for some 
of the exceptions to the reading frame hypothesis (Nevo et al., 2003). The 
functional importance of the actin-binding domain is also emphasised by the 
DMD-causing, smaller deletions at the 5’ region, such as those involving exons 3 
– 13 (Muntoni et al., 2003b). The central and distal rod domains, on the other 
hand, appear to be almost dispensable and cases of in-frame deletions of 
approximately half of the gene have been described, with only a mild effect on 
the phenotype (England et al., 1990). Conversely, some single exon deletions 
e.g. exon 44, result in a severe DMD phenotype (Muntoni et al., 2003a). 
Mutations involving the cysteine-rich domain invariably cause DMD, whereas 
mutations located in exon 74 or higher are found in both BMD and DMD 
patients. Phenotypes can also vary between patients carrying identical 
mutations, even within one family which could be a result of the mutation’s 
epigenetic context (Aartsma-Rus et al., 2006). The schematic overview in Figure 
1.5 reflects general findings for in-frame deletions.  
 
 
Figure 1.5 Correlation between the location of in-frame deletions and the BMD or DMD 
phenotype (Aartsma-Rus et al., 2006). Schematic drawing of the dystrophin protein with its fuctional 
domains. The location of the different exons is shown underneath the protein. (B) Graphic overview of 
the relation between the location of in-frame deletions and the severity of the phenotype (Beggs et al., 
1991). 
 
The effect of an exonic deletion on the ORF and possibly the phenotype can be 
predicted, as the intron-exon boundaries have been well characterised and show 
that some exons of the DMD gene do not contain an integral number of triplet 
codons and if deleted, will result in a frame-shift of the mRNA (Baumbach et al., 
1989; Koenig et al., 1989). Such predictions are valuable to the clinician, especially 
in early diagnoses of cases with no family history, as they help to anticipate the 
disease severity and may influence the approach to treatment. Useful prediction 
tools such as the Reading-Frame Checker accessible via The Leiden Muscular 
Dystrophy Pages (www.dmd.nl), designed to predict the effect of the rearrangement 
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on the ORF. Such predictions however, can only be made reliably when based on 
the mRNA changes. Genomic DNA-based findings may not reflect the true extent of 
the rearrangements due to events such as altered or inefficient splicing. Reading 
frame predictions for duplications, based on genomic testing are not recommended, 
as non-tandem or complex duplications are being reported with increasing 
frequency (with availability of more efficient testing), and determination of the 
fragment orientation requires mRNA analysis (Flanigan et al., 2009).    
 
1.12 EXCEPTIONS TO THE READING FRAME RULE 
It has been estimated that 8 – 9% of  DMD cases violate the reading frame rule, 
(Aartsma-Rus et al., 2006) and the incidence may be much higher in BMD patient 
populations, as suggested by results of a study by Kesari et al. (2008), where as 
many as 30% had out of frame mutations. In-depth studies of such cases have 
elucidated a number of underlying mechanisms.       
 
1.12.1 Exon skipping and alternative splicing 
Alternative splicing events can cause skipping of one or more exons around the 
deletion/duplication, affecting the ORF and dystrophin production. Rearrangements 
in certain parts of the gene appear to be more likely to result in exon skipping (5’ 
end, exons 3 – 6; 3 – 7; 5 – 7 and at the 3’ end, exons 44, 45, 51, 47 – 52 and 49 – 
50) (Beggs et al., 1991; Gualandi et al., 2009). Similar genomic changes, however, 
have been seen to result in different phenotypes. This could be explained by the 
unusually large size of some of the introns in the DMD gene, ranging in size from 
107 to 248 000 bp (average intron size of 27 kb), where the deletion/duplication 
break-points can occur at different positions, disrupting regulatory sequences in 
some cases.  (Béroud et al., 2004). Gualandi et al. (2003) described a case in point, 
where deletion of a single exon 5, resulted in DMD in some, and BMD in other 
patients. Molecular scrutiny of mRNA revealed that the DMD patients produced 
circular and linear RNA with missing exons 6 and 9. The BMD patients on the other 
hand, exhibited a linear transcript only, with a probably in-frame deletion of exon 5 
(Gualandi et al., 2003).  
 
While the majority of the small/point mutations disrupt the ORF and result in a 
severe phenotype, a number of BMD patients with nonsense and frameshift 
mutations have been reported (Franz et al., 2000; Ginjaar et al., 2000; Disset et al., 
2006; Deburgrave et al., 2007). Again, alternative splicing and exon skipping events 
are the mechanisms shown to be active in some of these patients’ phenotype 
rescue. Exon-skipping is also the most common consequence of splice-site 
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mutations and may result in production of in- or out-of-frame transcripts, depending 
on whether the particular exon boundry ends with an entire codon (Deburgrave et 
al., 2007). Splice mutations can also activate cryptic splice sites and alternative 
splicing events, where intronic sequences become incorporated into the mRNA. 
Deep intronic mutations can activate entire cryptic exons (Dwi Pramono et al., 2000; 
Gualandi et al., 2003; Béroud et al., 2004; Z. Zhang et al., 2007).  
 
Studies also suggest that trans-acting splicing factors might play a role. According to 
this hypothesis, splicing within the DMD gene might be affected by individual 
differences in the levels of expression of CUG-binding proteins, which regulate 
splicing via direct binding to the gene (Sironi et al., 2003).   
 
1.12.2 Disruption of exonic splicing enhancer (ESE) sites and exonic 
recognition sequences (ERS’s)  
Splicing often involves a complex series of interactions between the sarcoplasmic 
reticulum (SR) proteins, which bind to ESE sites and ERS, which in turn recruit other 
splicing factors. Regulation of alternative splicing appears to depend on mutation-
specific creation of new, or disruption of the existing ESEs and ERS’s, or the less 
common exonic splice silencer sites (ESS) (Cartegni et al., 2002). Reports of BMD 
patients with nonsense mutations, such as those mentioned by Aartsma-Rus et al. 
(2006) in their review article, are examples of such events. The two BMD patients 
each carried a different nonsense mutation in exon 29.  This is an apparent paradox, 
as nonsense mutations generally result in severe phenotypes due to nonsense 
mediated decay (NMD). In these two patients however, the mutations disrupted 
exonic ESE sites, causing in-frame splicing out of exon 29, thus effecting restoration 
of the ORF and production of a truncated dystrophin and a milder phenotype. Once 
again, the effect is variable and depends on the strength of the particular enhancer or 
silencer sequence (Aartsma-Rus et al., 2006). ESEs are well documented in the DMD 
gene, and may be present in most exons (Caceres & Kornblihtt, 2002; Cartegni et al., 
2002). ESSs on the other hand appear less common (Disset et al., 2006). As in 
prediction of the frameshift caused by exonic rearrangements, a number of 
bioinformatic tools such as ESEfinder (Cartegni et al., 2003), RESCU-ESE 
(Fairbrother et al., 2004) or the Human Splice Finder (Desmet et al., 2009) are 
available to predict the presence of ESE motifs and to assess the consequence of a 





1.12.3 Activation of alternative translation initiation sites   
Mutation-specific activation of an alternative translation initiation ATG codon, has 
been described in a BMD patient with an out-of-frame deletion of exons 3 – 7 and no 
evidence of exon-skipping in cDNA (Winnard et al., 1995). The authors suggest that 
the mutation caused activation of an alternative translation initiation site present in 
exon 8. Activation of an alternative translation initiation site from a methionine in exon 
6 has since been directly experimentally demonstrated by Gurvich et al. (2009), in the 
context of a founder nonsense mutation in exon 1.    
 
1.12.4 Somatic mosaicism 
Apparent violation of the frameshift rule can also be seen with somatic mosaicism in 
the affected tissue. This is considered when immunohistochemical analysis of tissue 
samples reveals a dual population of dystrophin-positive and dystrophin-negative 
fibres (Hoffman et al., 1987) and molecular studies reveal two DNA populations 
(normal and mutant) in blood DNA and in muscle cDNA, in the absence of 
alternatively spliced transcripts (Deburgrave et al., 2007; Kesari et al., 2009). Since 
the large DMD gene has a high (1/10 000) rate of de novo mutations in germ line 
cells (sperm, eggs) (Caskey et al., 1980; Haldane, 2004), somatic mutations could 
occur early in embryonic development, leading to production of tissues with both 
dystrophin-positive and dystrophin-negative muscle fibres.  
 
Despite the gene’s high mutation rate, reports of male somaticism are few (Saito et 
al., 1995; Uchino et al., 1995; Deburgrave et al., 2007; Kesari et al., 2009), possibly 
due to the low mutation rate in somatic cells relative to germ line cells, or 
alternatively, poor ascertainment due to mild or unexpected clinical symptoms. An 
interesting case of somatic mosaicism was reported by Kesari et al (2009). in a 
patient presenting with acute cardiac failure, and raised CK levels in the absence of 
overt muscle symptoms. Dystrophin immunostaining of muscle biopsy material 
revealed a mosaic pattern, with a predominance of dystrophin positive fibres. DNA 
studies showed no exonic rearrangements but cDNA sequencing presented 
apparent heterozygosity for a C>T (U) change at position 8713 (r.8713c>u), 
predicted to cause a nonsense mutation in the DMD gene (Arg2905X). The mutation 
was not identified in the patient’s mother, although a number of shared 
polymorphisms were seen, confirming a case of somatic mosaicism. The 
frequencies of normal versus mutant genes were determined in blood/DNA (50:50), 
muscle/DNA (80:20) and muscle/mRNA (90:10) (Kesari et al., 2009). The 
discordance between muscle and blood, could be explained either as incidental 
segregation of more dystrophin-positive stem cells into the biopsy region or by 
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“genetic normalization”, a process whereby the necrotic fibres are replaced with 
normal stem cells, as seen in the majority of manifesting female carriers (functionally 
somatic mosaics, but due to X inactivation rather than somatic mutations) who also 
often present with cardiac symptoms. This process explains the reduction in serum 
CK levels and improvement in clinical symptoms of some manifesting carriers, with 
advancing age (Pegoraro et al., 1995; Kesari et al., 2009).  
 
1.12.5 Unusual changes  
Non-contiguous duplications, partial triplications and complex rearrangements in the 
DMD gene are being reported with increasing frequency as a result of testing with 
sophisticated technologies like oligonucleotide array-CGH and shown to have 
varying effects on the phenotype (White et al., 2002; Kesari et al., 2008; White et al., 
2006). Detailed scrutiny of the complex junctions have led investigators to suggest 
regional genomic instability, aided by the presence of repetitive elements, a stem-
loop structure, and possibly preexisting mutations, as the mechanism behind 
complex rearrangements of the DMD gene (del Gaudio et al., 2008; Oshima et al., 
2009).  
 
In most instances, the apparent violation of the reading-frame hypothesis is 
disproved upon in-depth analysis and shown to hold. The importance of 
understanding the exact genomic context of each mutation with its downstream 
effect on the transcript and the protein is thus emphasised, not only in predicting its 
phenotypic consequence, but also as relevant to application of the emerging 
personalised gene therapy.      
 
An interesting finding of a completely healthy male with a deletion of exon 16 and 
part of introns 15 and 16 has been published (exon 16 encodes for 60 amino acids 
situated within the central rod domain of dystrophin), which suggest that even large 
changes in the dystrophin gene may not always be disease-causing The 
investigators therefore caution against hasty diagnosis of dystrophinopathy in 
sporadic cases of single exon in-frame deletions (Schwartz et al., 2007). In an effort 
to avoid misdiagnosing young patients without positive family history, many 
neurology centres confirm molecular findings of isolated cases with muscle biopsies. 
 
1.13 MUTATION DETECTION  
1.13.1 Detection of exonic rearrangements 
  
The Beggs and Chamberlain multiplex PCR, is a simple and reliable method used 
to amplify selected exons across the hot-spot regions, still used in many diagnostic 
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laboratories today (Chamberlain et al., 1988; Beggs et al., 1990). In a multiplex 
reaction, each target is amplified with its own set of primers, which is a limiting 
factor, as large quantities of primers within a single PCR, result in problems such as 
dimerisation and false priming. Therefore, the multiplex PCR deletion screen for 
DMD involves at least three PCR reactions, which together amplify selected exons 
across the 5’ and the 3’ mutation hotspots. This allows for detection of ~ 95% of the 
DMD-causing deletions but all duplications and the remaining 5% of deletions 
located outside of the hotspots, remain undetected.  
 
The Salsa Multiple Ligation-dependant Probe Amplification (MLPA) test, (MRC-
Holland) is a sophisticated variant of PCR, which incorporates specific probes for all 
the exons in the DMD gene (Lalic et al., 2005; Lai et al., 2006). The output is 
analysed quantitatively and allows for detection of all exonic copy number changes. 
MLPA currently features in the The Leiden Muscular Dystrophy Pages (www.dmd.nl) 
as the recommended method for deletion/duplication detection in the DMD gene. It 
also used in this study and will be addressed in more detail in Chapter 2 (Materials 
and Methods). A number of other tests for detection of exonic rearrangements have 
been developed with varying degrees of success.  
 
The following are listed in the Leiden Muscular Dystrophy Pages as the most 
effective, following the MLPA and the multiplex PCR: 
 MAPH (Multiple Amplifiable Probe Hybridisation): as informative as the 
MLPA but more labour intensive and requires more DNA (White et al., 2002).    
 qPCR: theoretically simple but technically challenging and difficult to 
optimise in multiplex (Ashton et al., 2008).   
 Southern Blotting: along with multiplex PCR and qPCR, can be used to 
determine the deletion/duplication breakpoints (www.dmd.nl). 
 recently described high-resolution comparative genomic hybridization (CGH) 
microarray: very expensive but capable of precise detection of intronic 
breakpoints (Bovolenta et al., 2008; del Gaudio et al., 2008; Hegde et al., 
2008). It does not present a major diagnostic advantage at this point but may 
become a valuable tool with the advent of “personalised gene therapy”.   
 FISH, CA-repeat marker analysis and exon-specific qPCR: useful for 
confirmation of known mutations in carriers but not as an initial screen.  
 
1.13.2 Detection of point mutations. 
Currently, few laboratories in the world and certainly none in Africa offer detection of 
point mutations as part of a diagnostic genetic work up for DMD. However, research 
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into development of personalised genetic and other forms of therapy are beginning 
to show promise and much effort is directed at formulation of testing protocols and 
development of methodologies for point mutation detection. The Leiden Muscular 
Dystrophy Pages (www.dmd.nl) and the NCBI GeneTests (www.ncbi.nlm.nih.gov) 
list the following methods as most successful, although others have been described: 
 High-resolution melting curve analysis (hrMCA) 
HrMCA is simple and very sensitive (>98%). Although it requires specialised 
equipment with high resolution melting (HRM) capability, it is particularly cost 
effective as a pre-sequencing screen to resolve variant fragments. HrMCA is 
the technological platform used to detect point mutation in this study and will 
be addressed in detail in Chapter 2 (Materials and Methods).   
 Denaturing Gradient Gel-Electrophoresis (DGGE)  
DGGE approaches 100% detection sensitivity (Hofstra et al., 2004). 
However, it requires several PCR and electrophoresis conditions, which 
make it laborious and it difficult to automate. 
 Direct sequencing  
Direct sequencing (or SCAIP: single condition amplification/internal primer)(), 
straightforward and powerful method but it is very costly, as over 79 separate 
exon fragments must be amplified, sequenced and analysed (Flanigan et al., 
2003). 
 Single-Strand Conformation Analysis (SSCA)  
SSCA / DOVAM (SSCA/detection of virtually all mutations)() is simple, cheap 
and effective but laborious, demanding electrophoresis of over 79 PCR 
fragments each using several electrophoretic conditions (Mendell et al., 
2001; Buzin et al., 2005). 
 Denaturing High Performance Liquid Chromotography (DHPLC) 
Characteristics for DHPLC are similar to those for SSCA, although it is easier 
to automate. It does however require specific, specialised equipment 
(Bennett et al., 2001). 
 Protein Truncation Test (PTT) is an RNA-based screening method. It is 
very effective in detecting truncating mutations but requires availability of 
RNA extracted from a muscle biopsy, which is not always available. PTT 
lymphocyte RNA is possible, but more difficult to perform (Tuffery-Giraud et 
al., 2004). The cDNA fragments obtained after reverse transcriptase PCR 
(RT-PCR) can also be used for sequencing to determine the exact mutation 
(Hamed & Hoffman, 2006). 
 MyoD-induced in vitro muscle differentiation can be a source of RNA as 
well a substrate for protein expression studies in pre and post-natal 
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diagnoses of cases where DNA analyses are uninformative. This is achieved 
by transfection and subsequent forced expression of the MyoD gene in a 
non-muscle cell types to initiate the process of myogenesis. This approach of 
analysis of muscle protein in non-muscle cells, has been applied to prenatal 
and postnatal diagnosis of DMD using fibroblasts, amniocytes and chorion 
villi cells.  (Sancho et al., 1993; Davis et al., 1987; Roest et al., 1996; Roest 
et al., 1999).  
For the most part, mutation detection techniques focus on the protein coding regions 
of the DMD gene. Studies analysing other regions (promoters, 5'UTR and 3'UTR) 
have so far not revealed many changes (e.g. (Tubiello et al., 1995; Flanigan et al., 
2003). While DNA-based screening is offered most widely, RNA-based screening is 
considered most effective, as cDNA analysis can resolve all mutations resulting in 
protein truncation and those affecting RNA-splicing. The difficulty lies primarily in 
sample acquisition, as mRNA is best obtained from muscle tissue. Lymphocyte 
mRNA in this context is not ideal, as certain mutations (e.g. splice mutations) in 
lymphocyte transcripts may behave differently to those in muscle (Ferlini et al., 
1998). This is of particular relevance with the advent of personalised genetic therapy 
as establishing the downstream effects of the mutation is imperative for therapy 
design e.g. antisense oligonucleotide (AON) design for exon skipping.       
1.13.3 Haplotyping 
This is a DNA-based approach to identify the risk chromosome in cases where no 
mutation could be found with other methods. The original restriction-fragment-length 
polymorphism (RFLP) assay (Bakker et al., 1985), has been refined to construction 
of a risk haplotype using informative small tandem repeats (STRs) in and around the 
DMD gene.  
 
1.14 DMD CARRIERS: GENETIC AETIOLOGY AND TESTING     
DMD female carriers, although unaffected, have CK levels 2 -10 times the upper 
level of normal in over 50% of the cases. It is estimated that approximately one fifth 
of female carriers show some signs of the disease (Hoogerwaard et al., 1999). 
These symptoms range widely from mild cramps on muscle exertion, calf 
pseudohypertrophy, varying degrees of muscle weakness (sometimes slowly 
progressive), to severe weakness and wheelchair dependence in rare cases. 
Impaired cognitive and/or cardiac function can be a part, or an exclusive 
manifestation of the disorder. Apart from a few cases associated with chromosomal 
rearrangements, most girls have been assumed to be affected as a result of skewed 
X inactivation, though this is not supported by the recent report of Soltanzedeh et al. 
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(2010), where no definite link could be established between the phenotype in  
female carriers and the pattern of X-linked inactivation. Muscle weakness, if present, 
is asymmetric and proximal, involving the pelvic girdle rather than the shoulder 
girdle in most cases, and can lead to misdiagnosis as the limb-girdle variety of 
dystrophy. Age of onset is variable, ranging from the first to fourth decade, with early 
onset (before the age of 15) linked to a more severe involvement. As is the case 
with male patients, carriers of BMD are less frequently and less severely affected 
than carriers of DMD (van Essen et al., 1997).   
 
A DMD gene mutation in a female can be inherited from a carrier or a 
somatic/germline mosaic mother, or from a germline/somatic mosaic father. 
Alternatively, her mutation could have arisen de novo in the ovum or sperm from 
which she arose or in her own germline or somatic cells. Approximately 1/3 of DMD 
cases result from new mutations and the a priori carrier risk for mothers of sporadic 
cases is estimated at 66%. Absence of other affected family members and low 
maternal blood CK levels reduce this risk. An affected child of a non-carrier mother 
can be a result of a new mutation in the ovum from which the child arose or of 
somatic mosaicism in the affected child. Sporadic cases arising from somatic and/or 
germline mosaic mother are also seen as new mutations, as are mutations which 
originated in a germline of a mosaic grandfather, which were passed onto the 
mother. The recurrence risk of a germline mosaic mother of an affected child lies at 
an estimated 5 – 10% (Bakker et al., 1989; van Essen et al., 1992). Identification of 
exonic rearrangements in females is now possible with quantitative analyses such 
as the MLPH and MLPA. In cases where no mutation is detected in the proband, 
haplotype analysis is used to track inheritance of the risk chromosome.  
 
Immunohistochemical staining of muscle tissue can be helpful in ascertaining 
D/BMD carrier status where neither mutation detection nor haplotyping is 
informative. In absence of a genetic diagnosis, it is essential in differentiating 
between manifesting DMD female carriers from autosomal forms of muscular 
dystrophy. A young, dystrophic female with normal muscle dystrophin 
immunolabelling is unlikely to be a manifesting carrier of DMD. This, however, may 
not be the case in older females, due to genetic normalization (Webster & Blau, 
1990; Hoogerwaard et al., 2005).  
 
1.15 GENE-BASED THERAPY  
Much of the research into gene therapy for DMD has been facilitated by studies on 
two naturally occurring models of DMD: the dystrophic golden retriever dog (GRMD) 
 24
mdx mouse (Banks & Chamberlain, 2008).  It must be emphasised that that not all 
of the therapeutic approaches discussed under the broad heading of “gene therapy” 
can truly be classified as such, as some use conventional pharmacological agents 
and others target the transcript rather than the underlying gene (Lim & Rando, 
2008). In this context, the term is used loosely to describe treatments developed 
specifically to target genetic disorders.  
 
The approaches to development of genetic therapies can be roughly divided into two 
main fields: gene replacement and gene modification (Lim & Rando, 2008). Gene 
replacement strategies (viral vectors, utrophin upregulation, myoblast and stem-cell 
transplantation), aim at delivery of a normal copy of the gene directly to the affected 
tissue, either as naked DNA in a viral vector (Wolff et al., 2005; Blankinship et al., 
2006), or as a gene copy in a myoblast or stem cell (Farini et al., 2009). Proof-of-
principle experiments on animal models (the mdx mouse), have been conducted 
and demonstrate that dystrophin expression can be restored to varying degrees to 
single muscles, muscle groups (limbs) or the entire body. The major advantage of 
this strategy is that it can be applied to patients regardless of the underlying 
mutations. Although the research is showing promise, much work still needs to be 
done to overcome the mechanical and practical difficulties of gene delivery to the 
muscles, the immunological concerns and the high cost. The other approach to 
genetic therapy, namely, gene modification, also referred to as mutation- or gene-
based therapy is currently receiving much attention. Exon skipping and read-through 
of stop codons, discussed below in more detail, have reached the point of phase II 
clinical trials. In terms of their application and delivery, these strategies are seen as 
less difficult and risky as well as significantly cheaper than the gene replacement 
approaches. Effectively, as identification of the particular mutation is the basis for 
this approach, “personalised gene therapy” is becoming a reality and is of 
particular relevance to this study.       
 
1.15.1 Exon skipping 
The theoretical basis of exon skipping is the naturally occurring phenomenon of 
restoration of the ORF by mutation-triggered alternative splicing mechanisms, such 
as those seen in BMD patients with frameshift mutations. Also, characterisation of 
the DMD gene and dystrophin with its functional domains, and experimentation with 
truncated mini-genes on mdx mice has shown that a degree of dystrophin 
functionality is preserved with parts of the protein missing (Phelps et al., 1995; 
Harper et al., 2002). Therefore, the aim of exon skipping therapy is restoration of the 
ORF and amelioration of the phenotype from DMD to BMD, by induced splicing out 
(or skipping) of one or more exons. Modification of dystrophin mRNA splicing is 
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achieved with the use of antisense oligonucleotides (AONs, also known as 
“molecular patches”). These small DNA or RNA analogues attach to mRNA 
sequences crucial to the splicing process and induce alternative splicing out of 
targeted exons (exon skipping) (Manzur & Muntoni, 2009) (Figure 1.6). The 
sequences targeted by the AONs include 5’ and 3’ consensus splice sites and intra-
exonic splice regulatory sequences (Lim & Rando, 2008). The feasibility of this 
approach was tested in the initial in vitro studies on human muscle and the in vivo 
gene model in mdx mice (Mann et al., 2001; Lu et al., 2003). Subsequently, much 
work has been done using in vivo animal models, in search of the optimal 
oligonuclear conditions and strategies to improve efficiency of delivery, with minimal 
toxicity and immunogenicity.  
 
Modifications to the chemistry of AONs are still required to increase their half-life 
and to prevent the cleavage of RNA-RNA hybrids by RNAse H. The most commonly 
used chemistries for exon-skipping antisense oligonucleotides are 2’O-methyl RNA 
with a negatively charged phosphorothioate backbone (2’OMePS) (Lu et al., 2003) 
and uncharged phosphorodiamidate morpholino oligomers (PMO) (Fletcher et al., 
2007), because both are stable and non-toxic.  
 
 
       Figure 1.6 Exon skipping to restore the ORF.  
 
Exon 51 is the focus of the first clinical trials, as AONs able to effect efficient 
skipping of exon 51 have been identified. Also, skipping of this single exon would 
restore the ORF in patients with deletions of exons 50, 52, 52–63, 45–50, 47–50, 48 
– 50 and 49–50, which comprise 13% of the DMD population. Two independent, 
proof-of-concept and safety trials on DMD patients, both targeting exon 51, have 
been successfully completed. Intramuscular injections of the 2-O-methyl AON 
PRO051 were administered by the group in Netherlands and the AVI-4658 
morpholino approach was adopted by the Muntoni group in the Imperial Collage of 
London (Kinali et al., 2009; van Deutekom et al., 2007). Both studies yielded good 
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results without drug-related adverse events. These encouraging results led to the 
initiation of further trials by both groups. The phase I/II open-label study using 
subcutaneous administration of PRO051 aimed to evaluate the safety profile of 
PRO051 and its ability to induce specific exon 51 skipping and novel dystrophin 
expression, has been recently completed. The preliminary data showed good 
tolerability and induction of dystrophin expression in a dose related manner. The 
published results of this study are however still pending. The results of a similar trial 
in the United Kingdom involving intravenous infusions of AVI-4658 at escalating 
doses is due to be completed in the first half of 2010 (http://www.clinicaltrials.gov). 
Systemic delivery of the AONs over an extended period of time will however truly 
test the promise of this therapy (Aartsma-Rus & van Ommen, 2009; Guglieri & 
Bushby, 2010).  
 
Successful application of exon 51 skipping, will lead to design, development and 
testing of AONS for skipping other single exons. However development of AONs 
specific to each individual mutation, in a gene this size, is a tremendous endeavor, 
with its risks of variable effect and an immune response to possible newly created 
epitopes. Since it has been shown that dystrophin can maintain some of its essential 
function with large parts of the gene (and protein) missing, the feasibility of 
designing a cocktail of AONs, capable of inducing double- or multi-exon skipping in 
approximately 60% of all DMD cases, is under investigation. Multi-exon skipping 
experiments have been conducted with encouraging results on animal models: 
studies with mdx4cv mice, which require skipping of exons 52 and 53 (Mitrpant et 
al., 2009), and the canine muscular dystrophy dog model (CXMD), where skipping 
of exons 6 and 8 corrects the splice mutation in exon 7 (Yokota et al., 2009). Also, 
an AON cocktail targeting all exons between 45 and 55 has already been tested on 
human cells in vitro, however, effective skipping of this number of exons is yet to be 
achieved (van Vliet et al., 2008).     
 
Theoretically, large duplications in the DMD gene should be an ideal target for the 
exon skipping therapy, as skipping of the duplicated exons should result in 
production of the wild type protein. Experiments on cultured muscle cells from 
duplication-carrying DMD patients, transfected with AONs targeting the duplicated 
exons, showed some degree of success. Further work is however required, as 
specific targeting of the duplicated, as opposed to the constitutive exons (or both) 
has proved problematic in cases (Aartsma-Rus et al., 2007).   
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An interesting approach towards a more permanent repair has been tested in cell 
cultures and the mdx mouse, where AONs in tandem with a modified U7 small 
nuclear RNA are expressed from an adeno-associated virus (Goyenvalle et al., 
2009). Again, more work is required, as the problems accompanying the gene 
replacement therapies are also relevant here (Trollet et al., 2009).   
     
1.15.2 Exon editing 
Small oligonucleotides are also the basis of another form of therapy, known as 
oligonucleotide-mediated gene editing or gene repair, which aims at correcting 
small, in-frame mutations such as nonsense, missense and splice-site mutations 
(Igoucheva et al., 1998). It is based on the hypothesis that in the presence of an 
oligonucleotide exactly matching the genomic sequence, except for the single base 
mismatch, the cellular repair systems can be induced to modify the mutated 
genomic sequence in a proportion of cells, possibly through mismatch repair 
enzymes (Gamper et al., 2000; Andersen et al., 2002). This should result in a 
normal transcript and a full-length protein. The originally used small DNA sequences 
flanked by 2’-methyl RNA sequences (chimeroplasts) have been superseded by 
short all-DNA ologonucleotides, which anneal to one strand of the genomic 
sequence and have been shown to yield more reproducible results and are cheaper 
and simpler to synthesise. In vitro and in vivo experiments on the mdx mouse model 
(nonsense mutation in exon 23) and in the golden retriever dog (splice mutation at 
exon 7) have shown that this oligodeoxynucleotide (ODN)-mediated gene repair 
technology is capable of successful modification of single base changes in genomic 
DNA and thus correction of dystrophin expression at the sarcolemma, with wild-type 
dystrophin detectable at the site of the injection for up to 48 weeks. The clear 
advantage of this therapy is its permanence without the need for ongoing drug 
administration, although this is yet to be fully established by determining the 
therapeutic effect of a single dose administration. Also, while the findings are 
encouraging from the proof-of-concept viewpoint, the efficiency of gene expression 
achieved in these animal models was low, at only 20% at the injection site. Systemic 
delivery generally yields even lower levels and therefore much research is focused 
on optimal ODN design and on improving the efficacy and efficiency of delivery 
(Bertoni, 2005; Robinson, 2009).    
 
Recently Maguire et al. (2009), took the ODN-mediated gene repair a step further 
with an experiment on mdx5cv mice, in which the repair takes place ex vivo, in cell 
cultures enriched with myoblasts. Mdx5cv mice have a single point mutation (A to T), 
which creates a donor splice site within exon 10 and gives rise to a 53-base deletion 
 28
in the transcript, which in turn causes a frameshift and a stop codon in exon 11. In 
normal muscle, the presence of damaged fibres activates the surrounding resting 
precursor cells into active myoblasts, which divide rapidly and effect regeneration of 
the injured tissue. Cycles of damage and regeneration are more frequent in DMD-
affected tissue, creating an abundance of myoblasts. The authors speculate that 
isolated myoblasts subjected to ODN-mediated gene repair, could be transplanted 
back into the muscle, creating long-term restoration of dystrophin expression. To 
facilitate oligonucleotide binding and higher levels of gene repair, the investigators 
attempted to further strengthen the reaction by the use of RNAi to knock down the 
Msh2 protein, a known inhibitor of gene repair. While the results of the experiment 
with primary myoblast-enriched cell cultures showed significant gene repair and 
increased dystrophin production, purified myoblasts proved less susceptible to both 
repair and Msh2 knockdown. The proposed explanation is the difficulty in genetic 
manipulation of progenitor cells in general, due to natural barriers including lower 
transfection efficiencies and dosage-dependent toxicity (Maguire et al., 2009). This 
however, does not negate the possible potential of this approach and reinforces the 
need for further experiments.  
 
The main challenges of exon skipping and editing therapies lie in overcoming the 
efficiency of delivery, as according to the best estimates, 30 – 40% of normal levels 
of dystrophin are needed to effect an improvement in clinical signs and symptoms 
(Neri et al., 2007). Coupling AONs with carrier molecules such as nanopolymers of 
polyethylene glycol and polyethyleneimine or polyactide-co-glycolic acid 
nanospheres and cationic core shell nanoparticles, have shown some promise, 
although potential toxicities have yet to be established (Williams et al., 2008; Sirsi et 
al., 2009). The nature and position of the target sequence (e.g. exonic or intronic) 
also play a significant role.  Another current limitation of AON therapy is the inability 
to target the heart in mdx mouse at doses suggested for clinical applications 
(Townsend et al., 2008). Recent studies have suggested incorporation of peptide or 
chemical moieties with the AONs to facilitate cell uptake and prevent disruption of 
cardiac sarcolemma, cardiac hypertrophy and dysfunction in mdx mice (Townsend 
et al., 2008; Wu et al., 2008; Yin et al., 2008).   
 
1.15.3 Nonsense read-through 
According to the Human Gene Mutation Database, nonsense mutations account for 
~12% of all mutations causing human inherited disease (Mort et al., 2008). They 
arise as a result of single point alterations, which create in-frame UAA, UAG or UGA 
codons in mRNA coding regions, leading to premature termination of translation and 
 29
subsequent nonsense-mediated decay (NMD). NMD is a quality-control 
mechanism, whereby aberrant mRNA molecules containing premature termination 
codons (PTCs) are degraded to prevent accumulation of incomplete, potentially 
toxic protein fragments (Figure 1.7). Pre-mRNA splicing in the nucleus, leads to 
placement of several proteins, including UPF3, on the CBC-bound mRNA, 20–24 
nucleotides upstream of exon–exon junctions, to form the exon junction complex 
(EJC). During translation of normal transcripts, the EJC is remodelled and CBC is 
replaced by 4E, which promotes mRNA export to the cytoplasm. If a transcript 
contains a PTC, the ribosome stalls and is converted into a surveillance complex, 
which is hypothesized to consist of the 40S ribosomal subunit bound to NMD 
effector molecules (UPF1-3 and SMG1-7). This surveillance complex acts as a link 
between the premature translation termination factors (eRF1 and eRF3) and the 
general cellular mRNA decay machinery. Recognition of a stop codon as premature 
rather than normal appears to depend on its location relative to the downstream 
sequence elements and associated proteins. Natural stops are typically located 
within terminal exons, whereas PTCs lie more than 50 - 55 nucleotides upstream of 
the last exon–exon boundary (Maquat, 2004).  While EJCs located in an open 
reading frame upstream of exon-exon junctions may facilitate ribosomal recruitment 
prior to displacement by a "pioneer" round of translation, EJCs located downstream 
of a nonsense codon (and 20–24 nucleotides upstream of splice junctions) (Chang 
et al., 2007) are not displaced because the ribosome is released from the transcript 
before reaching it. These remaining EJCs function as tags for recruitment of UPF1, 
followed by the mRNA's transport out of the nucleus and into the cytosol where the 
RNA is degraded by, for example, the exosome complex. NMD, however, does not 
appear to be an invariable consequence of a PTC. Indeed, PTCs located either less 
than 50–55 nucleotides upstream of the last exon–exon junction or downstream of 
this junction generally fail to elicit NMD (Behm-Ansmant et al., 2007). Also, even 
when NMD is triggered, some 5 to 25% of nonsense mutation-containing mRNA 
routinely escapes NMD (Isken & Maquat, 2007). The pathological effects of these 
mutations are therefore thought to be due to degradation of the newly synthesized 
PTC-containing mRNA by NMD, and also in part to the failure of the small amount of 
the PTC-containing mRNA that escaped NMD, to yield a (semi-) functional protein 
(Khajavi et al., 2006). 
 
Aminoglycosides are a group of antibiotics, which bind to the 30S or 50S subunits 
of the bacterial ribosome and can induce misreading of the mRNA codons, as part 
of their mechanism of action. This capability has been studied as a potential 
mechanism to read through disease-causing nonsense mutations in humans, as 
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theoretically, this should lead to generation of a full-length proteins with a single 
amino acid substitution, thus correcting the primary genetic defect. The initial 
experiments were conducted on cystic fibrosis, where read-through of known 
disease-associated nonsense mutations in the transmembrane conductance 
regulator (CFTR) gene, was achieved in cell lines exposed to high doses of 




Figure 1.7 Model for nuclear nonsense mediated decay. CBC: cap-binding complex, EJC: exon 
junction complex, PABP2: nuclear poly(A)-binding protein, PABP: cytoplasmic poly(A)-binding protein,  
TAP: mRNA nuclear export mediator, 4E: translation initiation factor eIF-4E (Wilkinson & Shyu, 2002).    
 
In 1999, the first in vivo evidence of phenotypic suppression of a premature stop 
codon was obtained by subcutaneous injection of high doses of gentamicin into 
transgenic mdx mice carrying a nonsense mutation in exon 23 of the DMD gene 
(Barton-Davis et al., 1999). Subsequent evaluation of gentamicin as a treatment for 
cystic fibrosis proved it be of limited clinical use, due to its known oto- and 
nephrotoxicity in high doses, as well as the need for regular intramuscular and 
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intravenous administration (Clancy et al., 2001; Politano et al., 2003). Under 
investigation, is a newly developed aminogylcoside (NB54), with a higher read-
through efficacy and an improved toxicity profile in different cell lines, as compared 
to gentamicin. However, further studies in animal models are required before 
considering its potential applicability (Nudelman et al., 2009).  
 
The results of the experiments with aminoglycosides did show that read-through of 
PTCs could be achieved biochemically, which prompted a search for a molecule 
with a more suitable profile of low toxicity and higher read-through efficiency 
(Politano et al., 2003). Two high-throughput screens of approximately 8000 000 
molecules were conducted against a luciferase reporter that harbors a UGA PTC, 
identifying PTC124 as a candidate for further development (Welch et al., 2007).  
 
Ataluren (PTC124) is a 284.24Da, achiral, 1,2,4-oxadiazole linked to fluorobenzene 
and benzoic acid rings. It has no structural similarity to aminoglycosides and is orally 
bioavailable when prepared in aqueous suspension. Findings of experiments with 
stable cell lines harbouring LUC-190 nonsense alleles showed that, as seen in 
studies with aminoglycosides, the efficiency of read-through in response to Ataluren 
differed according to the sequence of the stop codon: the UGA codon showed the 
most efficient read-through, followed by UAG and UAA (Figure1.8). The nature of 
the nucleotide following the nonsense codon (the +1 position) also appeared to 
influence its termination efficiency. Similarly to gentamicin, Ataluren was most active 
with a pyrimidine (especially cytosine, C) in the +1 position. The UGAG termination 
context was the only efficiently suppressed exception to this trend. Ataluren was 
shown to be a more powerful nonsense suppressor than gentamicin, exhibiting 4 to 
15-fold increase in levels of in vitro read-through. Additional experiments with LUC-
190 constructs established that Ataluren did not suppress multiple proximal 
nonsense codons even at exposure levels far exceeding those achieving maximal 
activity, and that continuous exposure to Ataluren maximized and maintained 
suppression activity. Suppression of nonsense alleles was also evident in Ataluren-
treated and untreated human and mouse primary muscle cell cultures. Restoration 
of correctly localized dystrophin expression at the myofibre membrane was noted at 
all concentrations by immunohistochemistry with the antibody recognizing the 
carboxy-terminal dystrophin epitope (Welch et al., 2007; Peltz et al., 2009) 
(Figure1.9).  
 
Protection against contraction-induced injury is seen as the best predictor of long-
term therapeutic outcome in DMD. In the same study, Welch et al. (2007) used the 
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mean percentage drop in force after five eccentric contractions of extensor digitorum 
longus (EDL) muscles, as an indicator of contraction-induced injury in dystrophic 
mice. Administration of Ataluren orally, and in the form of intraperitoneal injections 
into the EDL muscles were assessed respectively at 2, 4 and 8 weeks. Partial 
protection against contraction-induced injury was seen at only 2 weeks, without 
significant change at 4 and 8 weeks. A combination of oral and intraperitoneal 
dosing, resulted in further improvement, where protection against contraction 
induced injury observed in the treated mice was comparable to that of the wild-type. 
The combined oral and intraperitoneal dosing also demonstrated significant 
reductions in serum creatine kinase levels after 2 weeks, which were maintained for 
up to 8 weeks. 
 
 
           Figure 1.8  PTC124 suppresses premature nonsense codons.  
a and b: cultured HEK293 cells harbouring various LUC-190 nonsense alleles, treated with    
increasing concentrations of PTC124 (a) or gentamicin (b) for 16h and assayed for luciferase   
activity. c and d: synthetic LUC mRNAs, with different PTCs, subjected to varying  
concentrations of PTC124 (c) or gentamicin (d), and assayed for luciferase activity after 4h  
(Welch et al., 2007). 
 
.  
Figure 1.9 Immunohistochemistry of myotubules from primary cell cultures derived 
from muscle  biopsies. The effect of adding varying amounts of  PTC124 on levels of 
detectable dystrophin (green).  Myosin (red) levels remain unchanged (Welch et al., 2007). 
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The authors therefore concluded that treatment with Ataluren leads to decreased 
muscle fragility in animal models. Recovery of dystrophin production and function 
was demonstrated by western blotting. Full length dystrophin was detected in 
muscles of both wild type and ataluren-treated mdx mice, with the mdx mice 
exhibiting dystrophin levels 25 – 30% of that in the wild type (Welch et al., 2007).     
 
The exact molecular mechanism of the drug’s action is not as yet clear (Welch et al. 
2008). However, in an effort to elucidate the compound’s mechanism of nonsense 
suppression, experiments designed to monitor its effects on the translation and 
stability of nonsense-containing mRNAs were carried out. The results indicate that 
Ataluren has a negligible if any effect on the synthesis and stability of cellular 
mRNAs and does not exhibit off-target transcriptional activity. It also does not 
manifest any antibacterial activity (Welch et al., 2007). It is believed that the drug’s 
selectivity for read-through of premature as opposed to normal stop codons, is a 
result of the positional and mechanical differences between the two termination 
processes. Welch et al. (2006) tested this hypothesis by experiments monitoring the 
accumulation of truncated, full-length and read-through luciferase polypeptides in 
drug-treated HEK293 cells. They found a truncated product in untreated cells, a full-
length product after treatment with Ataluren, and no product of the size expected, 
after read-through of a normal termination codon. Similar analyses in the same 
study also failed to detect polypeptides corresponding to putative read-through 
products in multiple tissues isolated from Ataluren-treated human subjects, rats and 
dogs. The investigators thus concluded that Ataluren acts on premature and not 
normal stop codons, even at the drug levels far exceeding the optimal therapeutic 
dose. Absence of toxic side effects was an important observation, as well as the 
apparent lack of effect on the NMD pathway, which, considering the importance of 
NMD as a genomic surveillance mechanism, is seen as a component of its safety 
(Hirawat et al., 2007).    
 
Recently, a question arose as to Ataluren’s actual capability to induce nonsense 
suppression. In cell-based assays similar to those used by Welch et al. (2006), it 
was shown that Ataluren is capable of stabilising the firefly (Fluc) luciferase protein, 
implying that its initial discovery as a nonsense suppressor may have been biased 
by this effect (Auld et al., 2009). This hypothesis, however, has been rejected (Peltz 
et al., 2009) due to the differences in the respective assay conditions and most 
importantly, the fact that the efficacy of Ataluren in the study by Welch et al. (2006), 
was validated in actual dystrophin deficient muscle in vitro and in vivo (Welch et al., 
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2007). The therapeutic potential and efficacy of Ataluren is under investigation in 
clinical trails for DMD, cystic fibrosis and haemophilia A/B (www.ptcbio.com).   
 
The promise and potential availability of Ataluren as therapy for a sub-population of 
DMD patients, served as the initial trigger for undertaking this project, as eligibility 
for treatment can only be determined by identification of the putative mutations in 
each patient. The phase I and II clinical trials of Ataluren for DMD showed good 
safety and tolerability (Hirawat et al., 2007). However, the preliminary results of the 
phase IIb clinical trial revealed no statistically significant change in the 6-minute walk 
distance within the 48-week duration of the study, though the drug was well 
tolerated and no trial patients discontinued treatment due to an adverse 
event. Additional efficacy analyses in the subgroup of patients receiving lower doses 
are currently underway. Ataluren development will also continue for other indications 
including cystic fibrosis and haemophilia (Allamand et al., 2008; Kerem et al., 2008) 
(www.ptcbio.com). 
 
1.16 ANIMAL MODELS 
 
1.16.1 The mdx mouse  
Much of what is known about the molecular biology of dystrophin and its associated 
proteins along with their interactions and the role of inflammation in regeneration 
and fibrosis, has come from studies on animal models.  A number of mammalian 
models have been used to this end, some naturally occurring and some engineered, 
chosen according to the type and purpose of the research at hand. The naturally 
occurring dystrophin-deficient mouse (C57BL/10ScSn-DMDmdx/J), commonly 
referred to as the mdx-mouse, with a nonsense mutation in exon 23 has been the 
most widely utalised model for the study of molecular pathogenesis and the effects 
of gene manipulation and cell transplantation in DMD. Mdx mice have only a slightly 
shorter life span than the wild type mice. There is has less muscle fiber 
degeneration, more regeneration, and less fibrosis than seen in DMD patients. 
Despite that, it has served extremely well as a model in which to study mechanisms 
of disease and potential gene, cell, and experimental drug treatments. A number of 
allelic variants of the mdx mouse have been discovered and the specific mutations 
identified, although the original mdx strain remains the most widely chosen DMD 
rodent model. A number of variant strains have also been created to study the 
effects of different mutations and phenotypes and effects of experimental drug 
treatments: 
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 mdx variants (termed mdx2Cv, mdx3Cv, mdx4Cv, and mdx5Cv), recovered from a 
cross of male mice (C3H.X25 _ C57BL/6Ros) treated with mutagen N-ethyl-
nitrosourea, and female C57BL/10Sn.mdx animals. 
 mdx52, with a disruption (deletion) of exon 52 to mimic a patients with exonic 
rearrangements. 
 mdx double mutants, generated by crossing mdx mice with mice deficient in 
proteins such as utrophin, MyoD, -dystrobrevin, 7 integrin and  parvalbumin. 
These were created to test the roles of these proteins/factors in the muscle 
function and disease pathology, and to be used as animal models in 
experiments for potential therapies (Willmann et al., 2009).  
 
1.16.2 The Golden Retriever Muscular Dystrophy dog (GRMD) has also become 
a recognized animal model of DMD and is widely used for the experimental 
evaluation of new treatments prior to human clinical trials. The GRMD carries a point 
mutation in the 3’ consensus splice site of intron 6, leading to skipping of exon 7, 
consequently disrupting the open reading frame in exon 8 and creating a premature 
stop codon. Unlike the mdx mouse, GRMD dogs suffer from a rapidly progressing, 
fatal disease similar to DMD in humans. There is, however, a large variation in 
disease severity as some pups survive only for a few days, while others are 
ambulant for months or even years. As seen in DMD patients, GRMD dogs display 
selective muscle involvement although the most affected muscles in dogs (i.e. 
tongue, masticatory and trunk muscles) are different to those of humans. In addition, 
myocardial involvement in the GRMD dog very closely matches the cardiac 
complications observed in DMD patients. Recently, the Golden Retriever mutation 
was transferred on to the Beagle, which is a more suitable canine model because of 
its smaller size and extensive prior use in research. Canine dystrophinopathies have 
been reported in many other purebred and mixed breed dogs (Shelton & Engvall, 
2005; Willmann et al., 2009).  
 
1.16.3 The dystrophic cat carries a naturally occurring deletion of the muscle 
dystrophin promoter and lacks approximately 200 kb of the dystrophin gene, 
resulting in development of extensive muscle hypertrophy. The cats eventually die 
due to compression of the esophagus by the hypertrophied diaphragm or because 
of impaired water intake caused by glossal hypertrophy, which then leads to renal 
failure. Histological analysis has reveals localized foci of necrosis and regeneration 
but no signs of fibrosis. Thus, the pathology of the dystrophic cat does not resemble 
DMD as closely as the GRMD dog because it lacks the hallmarks of generalized 
muscle wasting (Shelton & Engvall, 2005).  
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Recently (2008), “TREAT-NMD”, a European Network of Excellence, compared the 
currently used mammalian animal models for DMD with the aim of selecting and 
recommending the most appropriate ones for preclinical efficacy testing of new 
therapeutic strategies. The mdx and GRMD models emerged as the best suited 
animal models for preclinical therapy testing. The particular advantages of using the 
mdx mouse over other mouse models include the good understanding of its muscle, 
cardiac and respiratory pathology gathered over time from studies and publications, 
the reproducibility of the phenotype, commercial availability and the relatively low 
cost.  Importantly, the mdx model has been used to demonstrate efficacy of several 
potential treatment strategies including small molecule pharmaceuticals (PTC124) 
as well as gene correction and cell replacement approaches.  
 
There are a number of significant factors against the use of the GRMD model, such 
as the high degree of variability in disease severity between breeds and among 
littermates and a subsequent high number of animals required to substantiate any 
conclusions about the treatment efficacy. This model is expensive due to the high 
cost of breeding and the need for a veterinary facility to treat large-sized animals. 
However, dog models closely resemble the human disease and are becoming 
appropriately characterized having already been used in tests on treatment efficacy.  
 
Therefore, the recommendation by ‘‘TREAT-NMD” is to use the mdx mouse as the 
model of choice for pre-clinical tests and proof-of-concept studies. The GRMD 
model is recommended in well controlled experimental settings, when using 
complementary tests, such as those used in supportive therapy for respiratory and 
cardiac functions, or as an alternative to mdx for specific experimental therapeutic 
approaches such as the use of stem cells or the testing of viral vectors (Willmann et 
al., 2009). 
 
1.17 THE LOCAL PERSPECTIVE 
The genetic service for DMD was the first of its kind offered nationally by the 
government health services at the Groote Schuur Hospital (GSH) and the Division of 
Human Genetics, University of Cape Town (UCT). The service has continued since 
its inception in 1987 and through the transition to the National Health Laboratory 
Service (NHLS).  
 
The early testing protocol involved tracking inheritance of the putative chromosome 
in the affected families using linkage markers and the multiplex PCR (mPCR) 
deletion screen was introduced later. However, before implementation of the 
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Multiple Ligation-dependant Probe Amplification (MLPA®) in 2007, studies with 
linkage markers were the strategy of choice for determining female carrier status 
and as such, comprised a large part of the referral base.  
 
In total, 1749 individuals from 571 DMD families have been referred for testing to 
date. Of those, 1264 individuals from 89 families were either referred for linkage 
analysis only, or were excluded from testing for reasons such as an autosomal 
recessive inheritance pattern or insufficient or inadequate sample quality. The 
MLPA® has superseded the mPCR deletion screen as a test for exonic 
rearrangements in DMD, as it offers a broader mutation detection range and can be 
used for carrier testing in females, to a large extent removing the need for linkage 
analysis. Its implementation has significantly improved mutation detection rate, as 
can be seen from the data in Table 1.1, even though comparatively few individuals 
have been tested with the MLPA® (40 patients) as opposed to the mPCR (445 











485  cases 
FAMILIAL SOLATED FAMILIAL ISOLATED FAMILIAL ISOLATED 
41/101(41%) 135/344(39%) 4/6 (67%) 16/34(47%) 45/107(41%) 151/378(40%)
Deletion pick up rate:     
176/445(40%) 
Del/dup pick up rate: 
20/40(50%) 
Del/dup pick up rate: 
196/485(40%) 
 
Table 1.1 Detection rates of exonic rearrangements with mPCR and MLPA in the diagnostic 
service at GSH.   
 
The Duchenne service is now offered by two academic centres in South Africa, 
namely, the NHLS at GSH in Cape Town and in Johannesburg, with their academic 
links to UCT and the University of Wittwatersrand respectively. Both serve the state 
and private hospitals and clinics, as well as clinicians in private practice. Many of the 
patients tested at GSH are referred from the developmental and especially the 
neuromuscular clinics at the Red Cross War Memorial Children’s Hospital (RXH) in 
Cape Town. The hospital, as South Africa's leading centre for post-graduate 
specialist paediatric medical and surgical training, offers specialised care facilities 
and high levels of expertise. “The Guidelines for Medical approach to Care of 
Children with DMD – Guidelines from the Neuromuscular Clinic”, authored by 
A/Professor Jo Wilmshurst, head of Paediatric Neurology at RXH (and a clinical co-
investigator in this study), and approved by PANDA (Paediatric Neurology and 
Development Association of Southern Africa) offer a clear guide as to the 
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appropriate and achievable standard of care within the South African context,   
based on the recommendations set by international bodies (i.e. US Centres for 
Disease Control and Prevention, DMD Care Considerations Working Group).   
 
It is therefore fitting that a long-standing genetic service for DMD, with links to 
academic centres with specialist clinics, should offer testing which is comprehensive 
and as informative as possible to both to the patient and his family. Complementing 
the MLPA for exonic deletions/duplications, with a screen for small/point mutations 
in the DMD gene, would create such a service. This will be of value to the patients 
and their families not only from the genetic counselling point of view but also by 
preparing the groundwork for application of mutation-based therapies in the future.   
 
This said, while the systems and expertise in most tertiary centres (and in the 
private sector) in South Africa are in keeping with the international standards, easy 
access to such facilities at a primary care level and in rural areas is still limited to 
many. Those patients able to take full advantage of the available care can live 
relatively comfortably and productively well into their thirties. However the social 
problems of the African context get in the way of every patient receiving timeous 
intervention. Community health issues such as HIV and especially TB, add a further 
challenge to the care of a South African DMD patient. The Muscular Dystrophy 
Foundation SA, who funded this project, is a subsidiary of the International Muscular 
Dystrophy Association and is actively involved in helping to support and educate all 
South African families affected with DMD.     
     
1.18 AIMS AND OBJECTIVES 
1.18.1 Aims 
To test for the presence of small/point mutations in the dystrophin gene of DMD 
patients previously reported as deletion-negative, as determined by mPCR, for the 
purpose of mutation profiling, family counselling and future determination of eligibility 
for gene-based therapies.     
 
1.18.2 Objectives 
 To re-test the entire cohort of 24 DMD-affected boys for large 
deletions/duplications using the MLPA, as all had been reported deletion-
negative, based on the results of the mPCR deletion hotspot screen.  
 To amplify the entire coding region of the DMD gene of each 
deletion/duplication-negative patient using 96 primer sets designed for 
subsequent hrMCA.  
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 To screen for variant fragments with hrMCA in a high-throughput, closed-tube 
format using RotorGene™6000 (Corbett Life Science, Australia). 
 To sequence all hrMCA variants in search of sequences changes.  
 To perform bioinformatic analyses of the sequence variants to determine: 
o disease association, by determining possible downstream effects of the 
mutation on the transcript and the protein  
o mutation-induced alteration of restriction enzyme sites, which may be 
useful for future testing of family members.   
 To perform family studies (where possible) of patients in whom pathogenic 
mutations are detected, for the purpose of authenticating “family mutations” 
and for genetic counseling of the families.  
 To establish a prospective laboratory testing protocol for patients such as 
those in the project cohort, for possible incorporation into the testing repertoire 
of the diagnostic component of the Division of Human Genetics (NHLS, Groote 
Schuur Hospital). 
 To perform population studies, where required, to aid in determining possible 























CHAPTER 2:  MATERIALS AND METHODS 
 
2.1 STUDY COHORT 
The full study cohort consisted of 24 unrelated boys, diagnosed with D/BMD on the 
basis of clinical presentation, elevated CK levels and in some cases, muscle biopsy 
results. The data presented in Table 2.1 was gathered by communication with 
clinicians and by perusal of the request forms. All 24 boys had tested negative for 
exonic deletions with the mPCR hotspot screen, as part of a diagnostic investigation 
for DMD. Of those, 19 had been referred for testing by the muscle clinic at the RXH, 
and 5 had been referred via other avenues.  
 
Table 2.1 The complete study cohort  
  












isolated CK  
muscle 
biopsy 
1 DMD83.1MTH ?D/BMD 24 ? 7 calf hypertrophy isolated ? not done 
2 DMD306.1GV DMD ? ? ? 
Learning difficulties 
from early on isolated ? not  done 
3 DMD342.2RIC DMD 18yrs 18 months 2 years 
in-toeing, slight  calf 
hypertrophy isolated 35950 
dystrophin 
negatiave 
4 DMD347.1RIC ?D/BMD ? ? ? 
Neuropathy of 
uncertain type, 
wheelchair bound isolated ? ? 
5 DMD352.2BRE DMD 19yrs 12 months ~2years 
waddling,falling, calf 
hypertrophy familial 5570 
dystrophin 
negative 
6 DMD357.1MAS DMD ? ? ? ? familial ? not done 
7 DMD372.1DIN DMD 24 ? ? ? isolated ? not done 
8 DMD378.1TEM DMD 24yrs <5yrs 5 yrs 
Learning difficulties, 
calf hypertrophy, 
waddling gait isolated 3465 not done 
9 DMD386.1ZIP DMD 16 ? ? Calf hypertrophy familial ? ? 
10 SMS389.1PIE DMD ? ? 
presented for 
testing at 
10yrs ? familial 2910 ? 
11 DMD402.1PET DMD 19yrs no details 7 yrs 
calf hypertrophy, 
waddling gait familial 14130 
dystrophin 
negative 
12 DMD411.1PET DMD Died ? ? ? familial ? 
Dystrophin 
negative 
13 DMD414.1PHI DMD 21yrs 14 months 10yrs waddling,toe-walking isolated 31650 
dystrophin 
negative 
14 DMD420.1SIY DMD 17yrs 1 yr 3 yrs 
severe course, 
posterior cardiac 
infarction,   
good intellect isolated 11712 not  done 
15 DMD 423.1NIC DMD 18yrs 14 mo 7yrs 
calf hypertrophy, 




d 20yrs ? ? 
Late presentation, last 
seen in 2002,   ? 1567 not done 
17 DMD433.1LUN DMD ? ? ? ? familial ? not done 
18 DMD447.1THA ?D/BMD 25 ? ? ? familial ? ? 
19 DMD457.1MOG DMD 16yrs 18months 18months 
Poor respiratory 
function, overweight, 
stopped walking at 
11yrs Isolated 15624 
dystrophin 
negative 
20 DMD501.1NAZ DMD 12yrs <2 yr 5 yrs 
calf hypertrophy, 
waddling gait isolated 6778 
 dystrophin 
negative 
21 DMD530.1THA DMD 15yrs 10 mo 7 yrs 
calf hypertrophy, 
waddling, toe-walking familial >10000 
dystrophin 
negative 
22 DMD548.1THE DMD 10yrs 11months 5 yrs 
ADHD, borderline 
cardiac function Isolated 12900 
Dystrophin 
negative 
23 DMD550.1SHA DMD 16yrd 1yr 4yrs Typical pattern Isolated >1000 
dystrophin 
negative 
24 DMD552.1RIV DMD 12yrs 12 mo 3yrs 
calf hypertrophy, 




Blood for DNA extraction was also collected from healthy male volunteers to be 
used anonymously as wild type test controls. The project was approved by the 
University of Cape Town Ethics Committee (REF 416/2008). 
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2.2 SAMPLE COLLECTION AND DNA EXTRACTION 
Fresh EDTA-anticoagulated blood samples were collected where possible, and DNA 
was extracted from buffy coats using the Gentra® PureGene® Blood kit (Qiagen, 
Germany) or the Maxwell® 16 System (Promega, USA, UK) for automatic nucleic 
acid extraction, as per the manufacturers’ instructions. In cases where fresh blood 
could not be obtained, previously extracted DNA was retrieved from the DNA 
Registry at the Division of Human Genetics (Institute of Infectious Diseases and 
Molecular Medicine, Medical School, UCT, REF 230/2010). The patients’ consent 
for inclusion in the study had been obtained either as part of the NHLS, or the 
Division of Human Genetics’ protocol for informed consent (Appendix A), in keeping 
with the tenets of the Declaration of Helsinki (2008). Mutation-positive samples for 
use as controls in the MLPA runs and also for validation of the HRM approach were 
obtained from the divisional DNA Registry. 
  
2.3 SCREENING FOR EXONIC REARRANGEMENTS 
In view of the limitations of the mPCR method, the entire study cohort of 24 DMD 
patients was re-tested for exonic rearrangements with the SALSA Multiple Ligation-
dependant Probe Amplification (MLPA®) test from MRC-Holland (www.mrc-
holland.com). The advantages and limitations of the procedure are addressed in 
Appendix B1 and B2. 
 
2.3.1 MLPA® Principle 
MLPA is a sophisticated variety of mPCR, where simultaneous amplification of up to 
40 target fragments is achieved with a single primer pair. Each DNA fragment of 
interest is targeted by an MLPA® probe consisting of two oligonucleotides 
(hybridization sequences), which recognise adjacent target sites on the DNA 
(Figure 2.1). One of the oligonucleotides contains the sequence recognised by the 
forward primer, and the sequence on the other is recognised by the reverse 
primer. The SALSA MLPA® probes range in size from 130 to 490 nucleotides (nt), 
and are prepared by restriction enzyme digestion from phage M13 derived clones 
(www.mrc-holland.com). The length of the amplification product is adjusted with the 
aid of a “stuffer sequence”, positioned between the hybridization sequence and the 
primer sequence in one of the oligonucleotides. This allows for a clear resolution of 
the subsequent PCR product. It is also possible to prepare cheaper synthetic 
MLPA® probes for research purposes, the design protocols for which are available 
online (www.mlpa.com). The lengths of fragments generated by synthetic probes 
however, have to be limited to 90 -160 nt due to their comparatively inferior quality.  
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              Figure 2.2 The 4 steps of an MLPA® procedure (www.mrc-holland.com). 
 
The first step of a standard MLPA® reaction (Figure 2.2) is denaturation of the test 
DNA and hybridization of both probe oligonucleotides to the target sequence. 
Ligation into a complete probe will follow only after the target sequence is found. 
Next, PCR primers act to amplify the fragment. In this way, it is the ligated 
oligonucleotides, and not the DNA or the unbound probe oligonucleotides, which are 
amplified. In absence of the DNA target, there will be no ligation of a complete probe 
and no PCR product formation. The fluorescent labelled primers (FAM) allow for 
MLPA® product separation by capillary electrophoresis. A comparison is made of 
peak heights (Figure 2.2, step 4) generated from the test sample and a reference 
(wild type) sample, and the differences reflect copy number changes.      
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2.3.2 MLPA® quality control 
The quality and reliability of MLPA® results is controlled both internally and 
externally. Internal quality control is achieved by the presence of quantity control 
fragments (Q-fragments), denaturation control fragments (D-fragments), as well as 
genomic and sex chromosome-specific reference probes in all MLPA probe mixes. 
An unusual appearance of the control fragments can be an indication of unreliable 
results. Each assay is also controlled externally, by inclusion of reference samples. 
The details of the quality control aspect of an MLPA® assay are available online 
(www.mrc-holland.com → MLPA® procedure → Interpretation of MLPA® Results). 
The main aspects are also outlined in Appendix B3.  
                
2.3.3 MLPA® Probes  
Two probe mixes were required to screen all 79 exons in the DMD gene. The cohort 
was tested with the MLPA® probe mix version P034-A2 and P035-A2, containing 55 
and 54 probes respectively (including control fragments), the details of which are set 
out in  Appendix B4 (also downloadable from www.mrc-holland.com → Products → 
Complete Product List → DMD).  Two MLPA® reactions (one per probe mix) were 
therefore set up for each patient. 
  
2.3.4 Sample preparation         
The concentrations of all test and control DNA samples were measured with the 
NanoDrop® ND-1000 Spectrophotometer (NanoDrop® Technologies) and brought to 
a working concentration of 50 – 100 ng/l in 1 X TE buffer (10mM Tris-HCl pH 8.2 + 
0.1 mM EDTA), as recommended in the MLPA® protocol (downloadable from 
www.mrc-holland.com → MLPA® reaction → MLPA®  DNA - Detection/ 
Quantification protocol).  Each MLPA® run included reference DNA from 3 wild type 
males, and 2 mutation positive samples: a deletion of exons 45 to 53 and a 
duplication of exons 45 to 53 selected from the DNA Registry.    
 
2.3.5 MLPA® reaction set-up  
All MLPA® reactions were set up according to the same basic protocol. This, along 
with any changes made to the reagents and probe sets (which are regularly 
updated), as well as additional information and tips on the reaction set up and 
subsequent product resolution and result interpretation, is clearly set out in the 
documentation provided with every MLPA® kit (downloadable from www.mrc-
holland.com → MLPA® reaction → MLPA®  DNA - Detection/ Quantification 
protocol).   
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The test was performed according to the manufacturers’ instructions, with the 
exception of using half of the prescribed volumes, throughout the assay. This 
change features as a possible alternative in the MLPA® protocols online (www.mrc-
Holland.com) and has been validated in-house by the Molecular Human Genetics 
diagnostic laboratory at NHLS GSH. This cost-saving adjustment has also been 
reported by other laboratories (Lalic et al., 2005).  
 
The brief outline of the MLPA® method is as follows: 
 DNA denaturation:  98°C for 5 minutes. 
 Hybridization: DNA + SALSA probemix + MLPA® buffer at 95°C for 
1min, followed by 16 hrs at 60°C. 
 Ligation: addition of ligase mix at 54°C and incubation at 54°C for  
           15 min, ligase inactivation at 98°C for 5 min. 
 PCR: ligation reaction mix + primers + dNTPs + polymerase 
 Capillary electrophoresis and product analysis. 
 
2.3.6 MLPA® product separation 
MLPA® products were prepared for capillary electrophoresis by mixing 0.7μl of the 
product with 9 μl of HiDi formamide and 0.3 μl of the ROX500 size standard (Applied 
Biosystems, USA), followed by denaturation at 80°C for 2 min and rapid cooling on 
ice for 5 min. Electrophoresis was carried out on the ABI 3100 Genetic Analyzer 
(Applied Biosystems, USA) using a 36cm capillary and POP-4 polymer (Applied 
Biosystems, USA). The specific instrument settings and trouble shooting guidelines 
are available online at www.mrc-holland.com → MLPA® Procedure → Fragment 
Separation. 
 
2.3.7 Data analysis and interpretation 
The generated data files were analysed using the GeneMapper v3.0 software 
(Applied Biosystems, USA). The resulting electropherograms were initially 
scrutinized visually for missing peaks representing exonic deletions in males, since 
the DMD gene is X-linked. Duplications in males and copy number variations in 
female heterozygotes result in a 35-50% reduction/increase in the relative peak 
area, making visual recognition possible in most cases. It is however not a reliable 
way of data interpretation and a statistical analysis of data files for copy number 
variations was performed using the Coffalyser program recommended by MRC-
Holland (www.mrc-holland.com). All data normalization steps are built-in functions of 
Coffalyser, as is correction for the probe length-dependent decrease in peak 
area/height (the ski-slope effect). Probe–ratios between 0.7-1.3 were read as 
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normal, in keeping with the definition by MRC-Holland. Normalization was performed 
on data which run within the same experiment and tested with the same probe mix. 
It is also recommended to normalise samples extracted with the same method, 
although it was not possible in this cohort, as some samples had been retrieved 
from the DNA Registry’s long-term storage facility.  
 
2.4 SCREENING FOR SMALL/POINT MUTATIONS 
All 18 patients in the cohort who tested negative for exonic rearrangements with the 
MLPA®, were further investigated for small/point mutations in the DMD gene.    
 
At present, searching for point mutations in this vast gene is considered beyond 
realistic capabilities of many diagnostic laboratories, though a number of mutation 
screening technologies have been described in an attempt to reduce the burden of 
sequencing. This includes single strand conformational polymorphism (SSCP) 
analysis (Mendell et al., 2001; Buzin et al., 2005), denaturing gradient gel-
electrophoresis (DGGE) (Hofstra et al., 2004) and denaturing high performance 
liquid chromatography (DHPLC) (Bennett et al., 2001). However, in addition to the 
expense, labour intensity and specialized equipment, all of these methods involve 
post-PCR sample handling and some require additional processing by enzymatic or 
chemical reactions and subsequent toxic waste disposal. More recently, assays 
such as DOVAM (detection of virtually all mutations) and single condition 
amplification/internal primer (SCAIP) sequencing have successfully achieved 
sequencing of all the exons and the flanking intronic regions of the DMD gene 
(Buzin et al., 2005; Flanigan et al., 2003). Again, even with an aid of robotics and 
bioinformatic software, the expense and time required especially during data 
analysis, is considered too great for full integration into the local routine diagnostic 
process.  
 
High resolution melting curve analysis (hrMCA) is a powerful new technology 
currently receiving much attention, capable of high throughput detection of 
mutations, polymorphisms and epigenetic differences in double stranded DNA. The 
mutation detection sensitivity of hrMCA is comparable or superior to the 
prescreening techniques mentioned above and it is inexpensive, rapid and accurate. 
Also, the technology has already been successfully applied to the DMD gene by 
Almomani et al. (2009). HrMCA was therefore chosen as a pre-sequencing 




2.4.1 HrMCA background and principle  
High resolution melting curve analysis (hrMCA) is based on the natural process of 
DNA denaturation or “melting” upon exposure to a gradual increase in temperature; 
DNA unwinds and dissociates from a double stranded (dsDNA) to a single stranded 
(ssDNA) molecule. The reaction takes place in the presence of a DNA intercalating 
dye, which is included in the preceding PCR reaction set up, and fluoresces only 
while incorporated into dsDNA. The melting process can be monitored by measuring 
the gradually diminishing amount of fluorescence during strand dissociation and a 
melting curve is derived by plotting fluorescence versus temperature (Figure 2.3).  
 
 
              Figure 2.3 Fundamentals of a typical HRM (high resolution melt) plot.  
              Fluorescence decreases as DNA intercalating dye is released from double-stranded DNA  
              during “melting” into single strands. The midpoint of the melt phase, at which the rate of  
              change in fluorescence is greatest, defines the temperature of melting (TM) of the particular  
              DNA fragment under analysis (CorProtocol™ 6000-1-July06).   
 
Melting curve scrutiny has, until recently, been used mostly to determine the melting 
temperature (Tm) of amplified dsDNA, which is defined as the temperature at which 
50% of dsDNA has dissociated to ssDNA, under standard conditions. It has also 
been recognized that the precise shape of the melting curve is a function of the DNA 
sequence. The observed thermal denaturation profile is characteristic of a specific 
PCR product and is dependent on its sequence length, base and GC content (HRM 
Assay Design and Analysis Booklet, www.corbettlifescience.com).  
 
2.4.2 HRM curve shape, shift and data normalization 
Sample differentiation based on hrMCA, is based on two main characteristics of the 
melt curve:  
 The curve shape, where the actual shape of the curve is examined. 
 The curve shift, i.e. the thermal offset of a curve from other curves.  
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Before the curves are plotted, the HRM raw data is normalized. The fluorescence 
axis (Y) is normalized onto a 0 to 100% scale, which allows all the curves to be 
compared with the same starting and ending fluorescent signal level to aid 
interpretation and analysis. Normalisation of the temperature (X) axis, known as 
“temperature shifting” is applied by the analysis software of some instruments e.g. 
Idaho Technology HR-1™ and the Roche LightCycler® 480 (White & Potts, 2006; 
Herrmann et al., 2007). This has the desired effect of compensating for well-to-well 
temperature measurement variations between samples. It is particularly useful when 
analysing heterozygous samples, because their curves have a complex shape and 
often become more easily discriminated after temperature shifting normalization. 
Differences between curves of homozygous samples on the other hand, become 
obscured by temperature normalisation, since the differentiating feature of the curve 
is its temperature shift and not a change of shape. Temperature normalisation can 
therefore detrimental for a number of applications such as discrimination of 
homozygous SNPs or mutation screening in sex-linked disorders (such as DMD). 
Although homozygous samples have identical HRM curve shapes, they can usually 
be discriminated by observing a change in their respective TMs, provided that 
temperature shifting normalization is not applied and the HRM temperature data is 
precise enough (Krypuy et al., 2006; White & Potts, 2006; Herrmann et al., 2007). 
The RotorGene™6000 (Corbett Research, Australia), used for hrMCA in this study 
does not use temperature shifting normalization, as the rotor format (as opposed to 
the heating block on the others), allows for sufficiently precise collection of 
temperature data due to minimal well-to-well thermal variation 
(www.corbettlifescience.com). Important considerations for the hrMCA experiment 
design and the factors affecting the outcome are set out in Appendix C1 and C2.  
 
2.4.3 Validation of the hrMCA approach  
Before commencement of the study, the hrMCA approach was validated for this 
application on the RotorGene™6000, by testing 4 DNA samples from DMD-affected 
patients with known point mutations in exons 3, 16, 34 and 56. The DNA was 
sourced from the DNA Registry at the Division of Human Genetics, UCT, and the 
mutations had been detected during   previous research conducted, using SSCP, 
DHPLC and cycle sequencing.  
 
While successful application of the HRM technology for detection of small changes 
in the DMD gene had already been described by Almomani et al. (2009), a 
validation run was performed to make sure that a similar approach using the 
available instrument (RotorGene™6000) as a platform, was a viable undertaking. 
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The relevant test and wild type DNA samples were amplified with the Sensimix HRM 
kit (Quantace) and WAVE Leiden DMD primers (Bennett et al., 2001), which were 
available at the Division of Human Genetics, UCT at the time, and subjected to 
hrMCA on the Rotor-Gene™6000. PCR and hrMCA was performed on all 4 of the 
relevant exons in each of the 4 patients, in order to test the specificity as well as 
sensitivity of the method. The instrument settings were as described below.  
 
2.4.4 PCR primers  
Following the validation study, 96 sets of hrMCA-optimised primers with M13 tails 
were used to amplify all 79 exons of the DMD gene, with their respective flanking 
intronic regions in each of the 18 samples. The primer sequences were obtained 
through an online enquiry to the Leiden Muscular Dystrophy Pages (www.dmd.nl) 
and subsequent personal communication with Prof. Egbert Bakker of Leiden 
University in the Netherlands (Almomani et al., 2009).  The primers were 
manufactured by Integrated DNA Technologies (IDT), Whitehead Scientific (Pty,) 
Ltd. All primer sequences with their annealing temperatures and the resulting PCR 
fragment sizes are tabulated in Appendix C3. 
       
2.4.5 PCR and hrMCA experiment set-up 
PCR amplification and hrMCA of 96 fragments was performed on the DNA of each 
of the 18 deletion/duplication negative patients (18 x 96 = 1728). The PCR and 
hrMCA were performed consecutively in a closed-tube system and in real-time, on 
the RotorGene™6000. The reactions were set up in 0.1 ml PCR tubes and run on 
the 72-well rotor. A single run tested 8 exons on 6 patients, 2 wild type male controls 
and a DNA-free control (blank). Therefore, full hrMCA on 6 patients required 12 test 
runs. Sample uniformity is essential to the success of this analysis. The test and wild 
type DNA were brought to the required concentration (100ng/µl) with nuclease-free 
distilled water (Promega, USA).  
 
A reaction per 0.1 ml PCR tube consisted of 100 ng test DNA, 10pmols of each 
(forward and reverse) primer, 12.5 µl of the Sensimix HRM  (Quantace), I µl of 
EvaGreen (Biotum Inc., included in the Sensimix HRM™), made up to a total 
volume of  25.0 µl with nuclease-free distilled water (Promega, USA).  The PCR 
cycling parameters were as follows:  10 minutes at 95°C, 45 cycles of 15 seconds at 
95°C, 30 seconds at the annealing temperature for the primer set (Appendix C3) 
and 40 seconds at 72°C.  
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The HRM fluorescence data for the amplicon scanning was collected from 65°C to 
87°C at a temperature transition rate of 0.1°C with a 2 second hold at each step. 
Amplification data was set to acquire to the green channel at the end of each 
extension step, with auto-gain optimization before the first acquisition. After 
exponential background subtraction, fluorescence data was normalized between 0% 
and 100%. The HRM data on the RotorGene™6000 automatically acquires to the 
HRM channel, with the selected option for automatic gain (sensitivity) optimization, 
at the fluorescence value of less than 70 units.  
 
2.4.6 HRM data analysis  
The melting curves generated were analyzed by a combination of the 
RotorGene™6000 series analysis software set at the default confidence threshold of 
90%, and visual scrutiny of the melting profiles. Since the PCR and HRM on the 
RotorGene™6000 take place in real time and in a closed-tube system, there is no 
need to check for the presence of PCR product with checking gels or any type of 
post PCR manipulation. Unsuccessful PCR reactions with no or late amplification 
were simply terminated or excluded from HRM analysis and repeated. A number of 
factors can influence the DNA melting profile and must be considered during the 
analysis. This is addressed in detail in Appendix C2.    
 
2.5 CYCLE SEQUENCING 
           Sequencing of the variant fragments detected by hrMCA was performed on the 
GeneAmp®9700 thermocycler (Applied Biosystems, USA) in the sense and 
antisense direction, using the BigDye®Terminator v3.1 mix (Applied Biosystems, 
USA) and universal M13 sequencing primers (all primer sequences are listed in 
Appendix C3). HR-MCA is a non-destructive method, and the EvaGreen™ dye 
(Biotum Inc.) does not interfere with post HRM fragment manipulation. All amplicons 
with variant melting profiles could thus be sequenced directly from the original PCR 
reactions. The pre-sequencing PCR product clean-up was performed using the 
NucleoSpin® Extract II columns (Macherey-Nagel, Germany), according to the 
manufacturer’s instructions. The presence of all the putative variants detected was 
confirmed by repeat PCR and cycle sequencing.   
 
2.5.1 Sequencing reaction set-up  
A sequencing reaction per 0.2ml PCR tube included 50 – 100 ng of PCR product, 
3.2 pmole forward or reverse M13 primer, 1µl of BigDye®, Terminator v3.1, and 2µl 
of the X5 sequencing buffer (Applied Biosystems, USA), in a total volume of 10µl 
with nuclease-free distilled water (Promega, USA). The cycling parameters were as 
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follows: 5 minutes at 95°C, 40 cycles of 15 seconds at 95°C, 15 seconds at 50°C 
and 4 minutes at 60°C.  
 
2.5.2 Sequence resolution and analysis 
 
The sequencing products were run on the ABI3100 Genetic Analyzer (Applied 
Biosystems, USA) and the output files analysed with the BioEdit Sequence 
Alignment Editor and the NCBI Basic Local Alignment Search Tool (BLAST) both 
freely available online (www.ncbi.nlm.nih.gov). The sequences were compared to 
the Leiden coding reference sequence (www.dmd.nl), based on the GenBank 
reference file NM_004006.1 of the Dp427m dystrophin isoform (with one difference: 
12505G>A). The DMD gene genomic reference sequence used, was generated in 
collaboration with the NCBI's RefSeqGene project, record NG_012232.1, as the 
basis for the description of sequence variants in the DMD gene. All sequence 
variants identified in this study were described according to the Human Genome 
Variation Society’s (HGVS) recommendations (den Dunnen & Antonarakis, 2000) .  
 
2.6 BIOINFORMATIC ANALYSES  
Over and above the BioEdit and the NCBI BLAST programs, the mutations detected 
were subjected to select bioinformatic analyses to gain insight into their downstream 
effects and possible disease association. It must be emphasised that the results of 
such analyses must be seen as indicators of probable effects rather than definitive 
proof thereof. The final effect of a given mutation may be influenced by a 
combination of factors, not necessarily taken into account during a computational 
search for a specific effect.    
 
2.6.1 Effect on the translational open reading frame (ORF)    
The exonic changes detected with the MLPA in 6 patients of the cohort were 
assessed for their effect on the ORF. An indication of whether or not an exonic 
rearrangement maintains or disrupts the ORF is intended to help in anticipating the 
disease severity, which may influence the approach to treatment, especially in 
isolated cases.  
 
The predictions were made with the aid of the Reading-frame Checker program 
which is freely accessible online via the Leiden Muscular Dystrophy Pages 
(www.dmd.nl) (Aartsma-Rus et al., 2006). The UMD-DMD France, which is the 
Locus Specific Data Base (LSDB) for DMD (www.umd.be), was also used for 
reading-frame predictions and takes into account the impact of the mutation on the 
junctional codon, i.e. even if the translational reading frame is maintained and the 
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two exons are in the same phase, a premature stop codon could be generated at 
the junction (Tuffery-Giraud et al., 2009). The predictions are based on the exon 
phasing of the DMD gene and direct translation of mRNA, generated by the deletion 
/duplication of exons, as selected by the user. The program creators caution that the 
reading frame predictions of changes detected by DNA-based testing cannot be 
used as evidence for the effect the change will have at the RNA level, as for 
example, additional exons may be missing in the transcript, due to the disruption or 
deletion of the splicing signals. Alternatively, intronic sequences may be recognised 
as exons due to mutation-activated cryptic splicing signals (Dwi Pramono et al., 
2000; Caceres & Kornblihtt, 2002; Disset et al., 2006). The Leiden program creators 
also caution against predicting the effect of duplications detected by genomic DNA 
testing, as non-contiguous and complex duplications which are not easily detectable 
at that level, are being reported with increasing frequency (Kesari et al., 2008; 
Gualandi et al., 2009). More accurate predictions can therefore be achieved with 
RNA-based results.  
 
2.6.2 ESE-finder and Human Splicing Finder (HSF)  
Bioinformatic analyses to search for a possible effect on the splicing elements were 
carried out with the ESE-finder (Cartegni et al., 2003) and Human Splice Finder v2.4 
(HSF) (Desmet et al., 2009) programs, both available online. The programs were 
used to confirm the deleterious effect of the mutation detected in the consensus 
splice site of intron 18 in patient DMD372.1DIN (c2293-1G>A), as well as the 
compound mutation found in exon 55 of patient DMD357.1MAS 
[c.8028_8031dupGGTG; c.8044G>T]. HSF analysis was also performed on the 
missense mutation in exon 7 of patient DMD389.1 (c.587T>C) and the silent 
mutation in exon 26 of patient DMD447.1THA(c.3513A>G). Similarly, the nonsense 
mutations in exons 7 and 47 of patients DMD552.1RIC and DMD411.1PET 
respectively, were analysed with HSF for an effect on splice elements and the 
possibility of exon skipping, which is relevant to eligibility for read-through therapy. 
The nonsense mutation in exon 34 of patient DMD352.2BRE (c.4729C>T) had been 
previously analysed for this effect by Nishiyama et al. (2008).  
 
Bioinformatic analyses for a possible effect on splicing can help shed light on the 
nature and effect of a mutation. It is known that exon-intron junctions are defined by 
weakly conserved intronic cis-elements: the 5’ splice site, 3’ splice site and branch 
site, which are important but not necessarily sufficient for accurate splicing. 
Additional intronic and exonic cis-elements required for correct splice-site 
identification act by either stimulating (enhancers) or repressing (silencers) splicing, 
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and may be especially relevant for regulating alternative splicing. Exonic splicing 
enhancers (ESEs), in particular, appear to be prevalent, and may be present in most 
exons (Cartegni et al., 2002). Nonsense, missense and even translationally silent 
mutations can disrupt exonic splicing enhancers (ESEs) and cause altered splicing 
resulting in changes with significant effects on the gene product e.g. exon skipping. 
Since predictions of the downstream effects of a mutation in most cases, are made 
on DNA-based sequence information, the prevalence of mutations which cause 
aberrant splicing may be underestimated. Different classes of ESE consensus 
motifs have been described, but they are not always easily identified (Cartegni et al., 
2002).  
 
ESE-finder (http://exon.cshl.edu/ESE/) is a web-based resource that facilitates rapid 
analysis of exon sequences to identify putative ESEs responsive to the human SR 
proteins (serine/arginine-rich proteins) SF2/ASF, SC35, SRp40 and SRp55, and to 
predict whether exonic mutations disrupt such elements (Cartegni et al., 2003). The 
HSF software, freely available via the UMD-DMD France website 
(http://www.umd.be/HSF), includes new algorithms derived from the UMD to allow 
the evaluation of the strength of the 5’ and 3’ splice sites and branch points. It 
includes already published algorithms for identification of cis-acting elements, such 
as those incorporated into RESCUE-ESE and ESE-Finder as well as new algorithms 
designed to use available or newly created matrices (Desmet et al., 2009). To allow 
the study of virtually any human sequence, HSF includes all genes and alternative 
transcripts as well as intronic sequences that were extracted from the Ensembl 
human genome database (http://www.ensembl.org/).  
 
2.6.3 SIFT (Sorting of Intolerant From Tolerant) analysis 
The SIFT program (www.sift.jcvi.org) was used to further investigate the possible 
pathogenicity of the amino acid substitution caused by the missense mutation in 
exon 7 (c.587.T>C) of patient DMD389.1PIE. This was done using the SIFTBlink 
single protein tool option, using the NCBI protein Reference Sequence: 
NP_003997.1, with the amino acid of interest in position 196, at a 0.05 threshold for 
intolerance.  
 
The SIFT analysis was performed as a missense mutation does not necessarily lead 
to an appreciable protein change. An amino acid may be replaced by another amino 
acid of very similar chemical properties, in which case, the protein may still function 
normally ("quiet" or “conservative” mutation). Alternatively, the amino acid 
substitution could occur in a region of the protein which does not significantly affect 
 53
the protein secondary structure or function. SIFT is a multi-step algorithm which 
classifies amino acid substitutions using a sequence homology-based approach. For 
a given protein sequence, SIFT compiles a dataset of functionally related protein 
sequences by searching a protein database using the PSI-BLAST algorithm 
(Altschul et al., 1997) and builds an alignment from the homologous sequences with 
the query sequence. Each position in the alignement is scanned with a calculation of 
probabilities for all possible 20 amino acids at that position. These probabilities are 
normalized by the probability of the most frequent amino acid and are recorded in a 
scaled probability matrix. SIFT predicts a substitution to affect protein function if the 
scaled probability, also termed the SIFT score, lies below a certain threshold value. 
Generally, a highly conserved position is intolerant to most substitutions, whereas a 
poorly conserved position can tolerate most substitutions (Kumar et al., 2009). The 
SIFT algorithm was developed at the Fred Hutchinson Cancer Center, and the SIFT 
server has been transferred to the J. Craig Venter Institute. 
 
2.6.4 The Transcription Element Search System (TESS) 
The single base substitution in the Dp427promoter/exon 1 region in patient 
DMD548.1THE, was analysed with the TESS program (www.cbil.upenn.edu), for 
possible disruption of transcription factor binding site/s (TFBs), which may 
negatively affect expression of the DMD gene.   
 
TESS is a web tool for predicting transcription factor binding sites in DNA 
sequences. It can identify binding sites using site or consensus strings and 
positional weight matrices from the TRANSFAC, JASPAR, IMD, and our CBIL-
GibbsMat database. TESS can be used to search own sequences or user-defined 
cis-regulatory modules (CRMs) genome-wide, near genes throughout genomes of 
interest. The process of gene regulation includes binding of transcription factors 
(trans-elements) to short sequences of DNA (cis-elements). The presence of a 
factor bound to a location in the promoter region of a gene can increase or reduce 
its expression. Each transcription factor recognizes a family of similar sequences, 
usually about 4-10 bases long with varying degrees of conservation at each position. 
The bonds formed with the DNA sequences are stronger with some than with others 
and identification of a good binding site in the gene promoter suggests the possibility 
that the corresponding factor may play a role in the regulation of that gene. 
However, the sequences recognised by transcription factors are typically short and 
allow for some amount of mismatch. Because of this, binding sites for a factor can 
typically be found at random every few hundred to a thousand base pairs. TESS has 
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features to help sort through and evaluate the significance of predicted sites (Schug, 
2008). 
 
2.7 POST-PCR MIXING AND HRM 
To test if an improved detection rate can be achieved, PCR amplification of all 96 
fragments was repeated on DNA from 4 of the 8 patients in the study with no 
pathogenic mutations detected by the initial hrMCA, as well as on DNA of a wild 
type male.  The PCR products of each test was mixed with that of the wild type and 
subjected to hrMCA, after a denaturing and cooling step to facilitate heteroduplex 
formation. The presence of polymorphisms was a specific inclusion criterion for this 
experiment, in order to compare the degree of variance in mixed and unmixed 
amplicons. 
 
Theoretically, post-PCR mixing should not be required on the RotorGene 6000, 
since hrMCA data is not automatically temperature normalized, as is the case with 
block-based instruments, which is known to obscure homo- or hemizygous changes. 
However, post-PCR mixing was shown to result in a significantly improved mutation 
detection rate in the study by Almomani et al. (2009). The melting profiles of variant 
fragments in heteroduplexes with the wild type were more easily detectable as such, 
than the same variants previously missed in the unmixed reactions. Although the 
Almomani et al. (2009) study had been conducted using a block-based instrument 
(Light Scanner®, Idaho Technology),  a similar experiment was carried out to test if 
an improved detection rate can be achieved with the RotorGene™6000 in this study.  
 
2.7.1 Post-PCR mixing reaction set up  
Both the wild type and test samples were amplified in 25µl reactions, as described 
above. Equal volume aliquots (8.3µl) of the test and the wild type reactions for each 
exon, were mixed together in a new 0.1µl PCR tube. The mixed PCR product was 
denatured at 95°C and allowed to cool to 15°C, before hrMCA. In this way, both the 
original PCR reactions (test and wild type) and the tube of amplicon mix, contained 
equal volumes of PCR product (16.6µl). All three (the test, the wild type and the 
mix), were subjected to hrMCA simultaneously at the settings above, for the sake of 
comparison of their melting profiles in the same run.   
 
2.8 FAMILY STUDIES  
DNA for family studies was available from the relatives of 7 mutation-positive 
probands: DMD352.2BRE, DMD411.PET, DMD83.1MYH, DMD357.1MAS, 
DMD342.2RIC, DMD372.1DIN and DMD389.1PIE. Therefore, in order to gather 
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further evidence in support of the deleterious nature of these sequence alterations, 
DNA of the relatives was tested for the presence of the putative mutations detected 
in the probands. This was done by PCR, hrMCA and cycle sequencing, as per the 
protocols described above. To demonstrate an alternative, cheaper approach to the 
detection of “private” mutations, restriction enzyme (RE) analysis was used instead 
of sequencing in family DMD 411. In the context of this study, hrMCA was used as a 
pre-sequencing amplicon screening tool and as such, was not required for mutation 
detection in the family studies, for which direct sequencing was the better approach. 
Rather, hrMCA was included for the academic purpose of a complete analysis and 
comparison of the melting profiles generated by various individuals with their 
respective genotypes.   
 
2.8.1 Restriction Endonuclease (RE) analysis  
RE analysis can be used as an easy, quick and inexpensive way to confirm the 
presence or absence of a family mutation, which changes a RE recognition site. The 
Webcutter 2.0 (http://bio.lundberg.gu.se/cutter2) is a free on-line tool for finding 
restriction map nucleotide sequences and which can be used to determine if a 
mutation changes a RE recognition site. It operates via a seamless interfaces to 
NCBI's GenBank, a DNA sequence database, and New England Biolab’s REBase, a 
restriction enzyme database. This approach was demonstrated on the family of 
patient DMD 411.1PET, who was found to carry a nonsense mutation in exon 47 of 
the DMD gene (c.6905G>A). Webcutter 2 program (free online), the mutation was 
shown to destroy a restriction recognition site for TspRI enzyme in the amplicon 
containing exon 47. The site is situated at position 148 in the 399bp amplicon of wild 
type DNA, creating two fragments of 148bp and 251bp in length respectively.  
 
PCR amplification of exon 47 of the DMD gene was performed on the DNA of 
patient DMD411.1PET, his mother, his affected brother and a male wild type, using 
the primers and PCR reaction protocol as described for hrMCA analysis earlier.  
 
A RE reaction per 0.2ml PCR tube contained 100 – 200ng PCR product, 10 units of 
the TspRI enzyme (New England Biolabs), 10X NEBuffer 4 (New England Biolabs), 
supplemented with 100x BSA (bovine serum albumin) made up to a total volume of 
15 µl with nuclease-free distilled water (Promega, USA). Each reaction mix was 
incubated in a water bath for 2 hours at 65°C to activate the enzyme. The RE 
digests were then resolved by gel electrophoresis, where 3µl of each sample was 
mixed with 3µl of a GelRed™ (Biotum Inc)/Bromothymol Blue loading buffer 
(1:1000) and loaded into wells of a 2.5% agarose gel, made with 1xTAE buffer (Tris-
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acetate EDTA, pH8.0). The loaded gel was run in 1XTAE buffer at a 100V, for 30 
minutes and visualized using the UVIPRO gel documentation system (UVITEC Ltd., 
UK). The restriction pattern of each sample was compared to that of a wild type and 
an uncut PCR product. A 100bp molecular ladder was also run alongside for size 
estimation. The results were interpreted accordingly.   
 
2.9 POPULATION STUDIES 
In addition to bioinformatic analyses, population studies were carried out on the 
mutations in patients DMD548.1THE (c.-85T>C) and DMD389.1PIE (c.587T>C) 
respectively. Both cases were isolated, with no family history of DMD, as per the 
available information. Neither mutation was found recorded in the Leiden LOVD, or 
found in published material (Aartsma-Rus et al., 2006).  
 
Two anonymised population cohorts were selected from the DNA Registry of the 
Division of Human Genetic, UCT: a cohort of 17 MLPA-negative DMD-affected 
patients and a cohort of 75 DMD-unaffected males. Both the cohorts consisted of 
South African individuals of various ethnicities (Caucasian, African, Cape Malay, 
Indian and mixed ancestry).  The DMD-affected cohort in particular was small in size 
due to the selection requirements, as only MLPA-tested patients with a definitive 
clinical diagnosis of DMD were included (also excluded were the patient in the study 
cohort), considerably reducing the number of eligible subjects. Also, in addition to 
bioinformatics and family studies the absence of a sequence alteration should be 
demonstrated in at least 200 wild type individuals, before a confident argument can 
be made towards its pathogenic nature (Frederic et al., 2009), which extended 
beyond the constraints of this study.     
 
2.9.1 Experiment setup 
Exon 1 and exon 7 were PCR amplified in the DNA of both cohorts as well as the 
two mutation positive patients, using the HRM primers and the previously described 
PCR protocol. The presence or absence of the mutations, were then determined by 
RE analysis as follows: 
 
 Variation c.-85T>C in exon 1 created an additional restriction recognition site 
for TspRI enzyme at position 221 of the 405bp-long amplicon, resulting in 
restriction sites at positions 19, 94 and 221 of the amplicon.  Four fragments 
were thus created: 19bp, 75bp, 125bp and 186bp in length. The restriction 
sites for the TspRI enzyme in the wild type (or variant-negative) amplicon 
were at positions 19 and 94 of the amplicon, creating 3 fragments: 19bp, 75bp 
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 Variation c.587T>C in exon 7 created a restriction recognition site for enzyme 
MspI (Fermentas) at position 184 of the 296bp-long amplicon, creating two 
fragments: 112pb and 184bp in length. No restriction recognition site for MspI 
enzyme was noted within the wild type (or variant-negative) amplicon. RE 
analysis was carried out on both the affected and the wild type cohorts as 
follows: a reaction per 0.2ml PCR tube contained 100 – 200ng PCR product, 
10 units of the MspI enzyme (Fermentas), 10X Buffer Tango (Fermentas) , 
made up to a total volume of 20 µl with nuclease-free distilled water (Promega, 
USA). Each reaction mix was incubated in a water bath for 2 hours at 37°C to 
activate the enzyme. The RE reaction products were resolved by gel 

























C HAPTER 3: RESULTS 
 
3.1 MLPA® analysis 
 
Analysis with the MLPA® revealed 6 exonic changes previously undetected with the 
mPCR, of which 4 were deletions and 2 were duplications (Table 3.1). The disease-
causing nature of large lesions in the DMD gene is widely recognized and no further 
investigations were therefore conducted to prove pathogenicity. It was also noted 
that the large deletion of exons 61 – 79 in patient DMD306.1GV may extend beyond 
the DMD gene, exceeding the detection range of the DMD MLPA®. Determining the 
deletion cut off was however not pursued further in this study. Examples of the 
GeneMapper and Coffalyser output for multiexonic changes found in patients 
DMD457.1MOG and DMD420.1SIY, are given in Figures 3.1, 3.2 and 3.3. 
  
While further investigations are not required to demonstrate the disease causing 
nature of large rearrangements, it is necessary to confirm the MLPA results in some 
instances. Multiexonic deletions of consecutive exons detected with the MLPA are 
generally accepted as such, however it is necessary to authenticate the presence of 
single exon deletions with another test method, as possible MLPA® assay artifacts or 
point mutations in the target sequence can interfere with probe attachment. The 
deletion of exon 7 in patient DMD414.1PHI, was thus confirmed by single PCRs of 
exons 6, 7 and 8, using the HRM primers and the PCR protocol for small/point 
mutation detection described in Chapter 2.  
 
                                ex22   ex23   ex24   ex25   ex26   ex27   ex28    ex29   ex30 
 
Figure 3.1 MLPA® electropherogram for DMD457.1MOG, probe set PO34–A2: deleted exons 22, 
23, 24, 25, 26, 27, 28, 29 and 30. 
 
Both duplications (DMD420.1SIY and DMD530.1THA) were confirmed by repeat 
MLPA®. In addition, the single duplication of exon 1 in patient DMD530.1THA was 
further authenticated by testing DNA extracted from a fresh blood sample along with 
the old DNA, as well as that of an affected sibling, in the same MLPA® run. All three 
samples manifested the duplication upon analysis with the Coffalyser program. 
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                             Table 3.1 Exonic rearrangements detected with the MLPA®. 
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deletion        
(ex22 - 33) 
c.2804-?_4674+?del 
 
central rod domain 










deletion        
(ex 61 -79) 
c.9085-?_(*2691_?)del  
central rod domain  














duplication    
(ex 3 -36) 
c.94-?_5154+?dup 
actin-binding 
domain and central 































                             
                               ◊ The deletion may extend beyond the DMD gene and its effect on the ORF or applicability any potential therapy cannot be predicted 
with the data available here.    
                             ◊◊ The reading-frame predictions based on DNA findings may not reflect the actual changes at the mRNA level. Predictions for  
                                  duplications are particularly risky, and non-tandem or complex duplications are frequently reported and the orientation of the 







     
                  ex11    ex12     ex13     ex14     ex15    ex16    ex17   ex18    ex19   ex20 
                         ex31   ex32    ex33    ex34    ex35   ex36 
 
Figure 3.2 MLPA® electropherogram for DMD420.1SIY, probe set PO34- A2: duplicated exons 3, 4, 5, 
6, 7, 8, 9, 10 
                 Ex3                                     ex30 
 
   Figure3.3 Coffalyser chart for DMD420.1SIY, probe set P034-A2. 
 
3.2 HrMCA  
3.2.1 HrMCA validation run  
All 4 of the known mutation-containing fragments manifested shifted melting profiles, as 
compared to the wild type samples. Also, variations were seen only in the mutated 
exons and not in the other exons tested per patient, successfully validating the use of 
the RotorGene™6000 for this application.    
 
3.2.2 HrMCA screen. 
HrMCA analysis of 1728 PCR amplicons from 18 deletion/duplication negative boys in 
the cohort, revealed 240 (14%) variants, as selected by the RotorGene™6000 analysis 
software and by visual scrutiny of the melting profiles. In total, 53 of these fragments 
were subsequently confirmed as variant by cycle sequencing. The high number of 
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fragments falsely selected as variant had been attributed to the variable quality of the 
available DNA, as fresh blood samples for DNA extraction were not available in every 
case. Other aspects which influence the outcome of hrMCA are addressed in detail in 
Appendix C. Also, the criteria applied for variant selection erred on the side of caution, 
to avoid missing disease-associated mutations. 
 
3.3 CYCLE SEQUENCING AND BIOINFORMATIC ANALYSES  
Of the 53 hrMCA variants detected, 10 were identified as disease-causing (Table 3.2), 
39 were previously reported polymorphisms (Aartsma-Rus et al., 2006; Tuffery-Giraud 
et al., 2009) (Table 3.3) and 3 were changes of uncertain clinical significance (Table 
3.4).   
 
3.3.1 Disease associated mutations  
Among the 10 pathogenic changes identified, 3 were nonsense, 3 frameshift, 1 splice 
site, 1 compound mutation (splice/frameshift and missense), 1 missense and 1 point 
substitution in the Dp427 promoter/exon1 region of the DMD gene. Of those, only 2 
nonsense mutations (c.4729C>T and C.6905G>A), featured in the Leiden LOVD and 
the remaining 8 were novel (Aartsma-Rus et al., 2006; Tuffery-Giraud et al., 2009). The 
changes were shown to cause alterations to RE sites in 8 cases, with the Webcutter 2.0 
software (http://bio.lundberg.gu.se/cutter2), offering RE analysis as a tool for easy 
mutation detection in the relatives who may present for testing in the future (Table 3.2).   
 
Truncating mutations in the DMD gene are generally expected to be pathogenic and 
therefore no further analyses for evidence of disease-association were carried out on 
the 3 nonsense and 3 frameshift mutations detected in this study (highlighted in yellow 
in Table 3.2). It is however possible for a nonsense mutation to disrupt the normal 
splicing process and thus create an alternative rescue transcript (Nishiyama et al., 
2008). None of the nonsense mutations detected in this study were shown to have this 
effect, according to the results of bioinformatic analyses with the Human Splice Finder 
v2.4 program (HSF) (Desmet et al., 2009).  
 
Only 1 of the 3 nonsense mutations detected in this project involved a CGA codon 
(c.4729C>T), with the other 2 located at non-CpG sites: an AT:CG transversion at 
c.620T>G in exon 7 and a GC:AT transition at c.6905G>A in exon 47. It has been 




























1 DMD552.1RIV c.620T>G 7 
NONSENSE 
p.(Leu207X) MnlI +  
Dp427c, Dp427m, 
Dp427p 
actin-binding domain ?NEW 
2 DMD352.2BRE c.4729C>T   34 
 
NONSENSE 
p.(Arg1577X) SfaNI -  
Dp427c, Dp427m, 
Dp427p, Dp260 
central rod domain 
repeat 12 NO* 
3 DMD411.1PET c.6905G>A 47 
 
NONSENSE 
p.(Trp2302X) TspRI -   
Dp427c, Dp427m, 
Dp427p, Dp260, Dp140 
central rod domain 
repeat 18 NO** 
4 DMD550.1SHA c.503delC 6 
 
FRAMESHIFT 
p.(Ala168fsX2) MwoI - 
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Dp427p actin-binding domain ?NEW 
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       * (Aartsma-Rus et al., 2006), **(Sedlackova et al., 2009) 
      Yellow: nonsense mutations            Blue: frameshift mutations        Pink:  splicing mutations         Green: other mutations 
        
 
 63
shown that the CpG dineucleotide is a hot-spot for mutations in the human genome, 
because of its vulnerability to spontaneous deamination of 5-methyl cytosine to     
thymidine (Krawczak et al., 1998). C>T transitions in the CGA codon are reported as 
the most prevalent stop mutation class in the DMD gene and the CGA codon 
presents 23 out of 28 nonsense mutation targets in the coding region of the gene 
(Flanigan et al., 2009; Tuffery-Giraud et al., 2009). 
 
Table 3.3 Previously reported polymorphisms. 
SEQUENCE CHANGE EXON FREQUENCY 
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intronic - in a 
patient  with a 
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Similarly accepted as pathogenic were the mutations affecting splicing (highlighted 
in pink in Table 3.2). The alteration of the consensus splice acceptor site of intron 18 
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in patient DMD372.1DIN (c.2993-1G>A), was listed as such based on its location 
and the fact that a G>T change in the same position was listed as probably 
pathogenic in the DMD LOVD (Dubourg et al., 1999). Furthermore the ESEfinder 
analysis (Cartegni et al., 2003) for this mutation was strongly indicative of a 
disrupted splice acceptor site, with a drop in the motif score from 9.37680 in the wild 
type to 2.1300 in the mutant (Figure 3.4). 
 
The compound mutation identified in exon 55 of patient DMD357.1MAS 
[c.8028_8031dupGGTG; c.8044G>T], was also listed as a splicing alteration, though 
the duplication of the GGTG motif could cause either a splicing or a frameshift 
aberration, possibly exacerbated (or ameliorated) in its effect by the missense 
mutation 12 bases downstream. Bioinformatic analysis with the HSF (Desmet et al., 
2009) revealed possible alterations to the splicing elements by creation of 
alternative acceptor splice sites, disruption of the SRp40 splice enhancer site and 
creation of new splice silencer motifs. Figure 3.5 is the graphical representation of 
the HSF output for the mutant (DMD357.1MAS) as compared to the reference 
sequence of exon 55 with its flanking intronic regions. 
 
















Figure 3.4 ESEfinder output for the splice site mutation c.2293-1G>A in patient DMD372.1DIN  




SPICING ENHANCER MATRICES             SPLICING SILENCER MATRICES        OTHER MATRICES  
 
 
Figure 3.5 Graphical representation of the output from the Human Splicing Finder (HSF) 
program    for the comparison of the reference sequence of exon 55 in the DMD gene with  that 
of the mutant in patient DMD372.1PIE (Desmet et al., 2009). Empty boxes = this potential splicing 
element is present in both sequences; Full boxes = this potential splicing element is present only in the mutant 
sequence or with a reduced value in the reference sequence; Doted boxes = this potential splicing element is 
present only in the reference sequences or with a reduced value in the mutant sequence (none present). 
 
A novel missense mutation was identified in exon 7 of patient DMD389.1PIE 
(c.587T>C). Missense mutations are infrequent in the DMD gene, comprising 
approximately 1 – 4% of the small lesions (which in turn account for ~ 30% of all 
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DMD mutations) (Tuffery-Giraud et al., 2004; Flanigan et al., 2009). Differentiating 
between benign and deleterious amino acid substitutions is often difficult. In this 
case, the output of computational analysis with the SIFT program (Sorting the 
Intolerant From Tolerant), listed the Leucine to Proline amino acid substitution in 
position 196 of the protein, as “not tolerable” (Figure 3.6).(Kumar et al., 2009). 
Further suggestion of the pathogenic nature of this mutation is its location in exon 7, 
as most of the missense mutations reported in the DMD gene, cluster in exons 2 – 8 
and 62 – 70 (Aartsma-Rus et al., 2006; Tuffery-Giraud et al., 2009). The missense 
mutation identified as part of the compound mutation in exon 55 in patient 
DMD357.1MAS (c.8044G>T), was also analysed with the SIFT program. The 
Alanine to Serine change in this context was found tolerable, though as mentioned 
earlier, it may be of significance in its co-segregation with the GGTG duplication in 
exon 55.  
              
               Predict Not Tolerated   Position   Seq Rep    Predict Tolerated 
 
 
Threshold for intolerance is 0.05.   Amino acid color code: nonpolar, uncharged polar, basic, acidic.  
Capital letters indicate amino acids appearing in the alignment, lower case letters result from prediction.  
'Seq Rep' is the fraction of sequences that contain one of the basic amino acids. A low fraction indicates the 
position  is either severely gapped or unalignable and has little information. Expect poor prediction at these 
positions. 
 
Figure 3.6 The SIFT (Sorting Intolerant From Tolerant) analysis output for the missense 
mutation c.587T>C in patient DMD389.1PIE. The putative amino acid change from Leucine to 
Proline in position 196 is predicted as “not tolerated” .  
 
 
The sequence alteration found in patient DMD548.1THE (c.-85T>C) was listed as 
pathogenic due to its location in the highly conserved Dp427m promoter/exon 1 
region of the DMD gene. The conserved nature of the surrounding motif was noted 
with the aid of the UCSC Genome Browser (http://genome.ucsc.edu) (Figure 3.7), 
where T and 7 of the adjacent bases appear conserved in all 5 of the mammalian 
species. It is therefore likely that the mutation disrupts one of the transcription and/or 




Figure 3.7 Output screen from the UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) 
Assembly. The red arrow points to the position of the T>C change (c.-85T>C) in patient DMD548.1THE 
(position 33229514). 
 
Analysis with the TESS (www.cbil.upenn.edu) program for identification of 
transcription factor binding (TBF) sites shows a considerable decrease in the 
number of possible sites in the mutant as opposed to the wild type sequence (Figure 
3.8). The analysis output is strongly suggestive of the change disrupting the MEF-2 
(Human Myocyte-specific Enhancer Factor 2) TFB site, specifically the aMEF-2 
isoform, (red arrow in Figure 3.7), which has a high likelihood score (La) of 18 and is 
not listed under the mutant sequence. The aMEF-2 is a MyoD-induced transcription 
activating factor for expression of muscle specific genes in the cardiac, smooth, 
skeletal muscle; placenta, brain, lung and kidney. Additional bioinformatic tools as 
well as mRNA expression studies from muscle may be required to elucidate the 
possible role of this mutation in the disease pathogenesis of this patient. 
 
3.3.2 Polymorphisms 
The non-pathogenic nature of 36 of the 39 previously reported polymorphisms 
(Aartsma-Rus et al., 2006) identified, was confirmed by their presence in multiple 
patients including those with disease associated mutations (Table 3.3). This 
confirmation was not possible in 3 cases (c.2168+13T>C, c.11046+119A>G and 
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c.*477_480dupTACA), which were found in 3 respective patients with no pathogenic 
mutations.    
 
DMD548.1THE ( c-85T>C - mutant sequence) 
 
 











               Binding site matches 
 
 
             
 
Figure 3.8 The “annotated sequence” output of analysis with TESS.   
The red arrows point to the TFB site for aMEF in + and - strand    
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3.3.3 Variants of uncertain significance     
The study findings also revealed 3 changes of uncertain significance:  c.3513A>G, 
c.8668+19A>G and c.*1903_*1906delTTAA. These were initially dismissed as 
probable polymorphisms as c.3513A>G is a silent mutation, c.8668+19A>G was 
found in patient DMD537.1MAS along with a disease associated mutation and 
c.*1903_*1906delTTAA is located in the 3’UTR close to other mutations listed as 
polymorphisms in the DMD LOVD (Aartsma-Rus et al., 2006). This assumption can 
however not be made with any degree certainty for the following reasons: 
o all 3 alterations are novel  
o 2 of the 3 were detected in patients with no other disease associated 
changes and the possibility of more than one pathogenic change in a patient 
cannot be excluded     
o intronic mutations as well as silent mutations may disrupt splicing elements 
and cause altered splicing  
o the 3’UTR in the DMD gene is fairly conserved and mutations therein can be 
disease associated (Greener et al., 2002a). 
The silent mutation was shown not to have any significant effect on the splicing 
elements as per analysis with the HSF programs, which points towards it being a 
polymorphism. No further analysis was carried out on the remaining 2 changes, as 
expression studies on mRNA are required to provide a more meaningful and 
definitive prediction regarding any pathogenic effect.  
 
3.4 POST-PCR MIXING AND HRM 
The post–PCR mixing experiment did not result in detection of any additional 
variants possibly missed with the initial hrMCA. However, the value of this exercise 
on the RotorGene™6000 is uncertain, as the results were inconsistent (Figure 3.9). 
Previously detected polymorphisms became more obviously variant after post-PCR 
mixing in some cases, and equally or less obvious in others. A heteroduplex showed 
an altered curve shape in most instances, but did not necessarily appear more 
variant or easily detected than the initial homoduplex. This may be due once again, 
to the variable sample quality. 
 
3.5 FAMILY STUDIES   
The allele segregation analyses within 6 families of probands with putative 
mutations, revealed that the mutations tracked with the phenotype. The mutation 
segregation within the relatives was then compared to the individual haplotypes 
previously constructed as part of the diagnostic work-up for the families using 
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intragenic microsatellite markers. The putative mutations were thus shown to track 
with the affected haplotypes (Table 3.5).  
 
 
                A 
 
                                                                         ºC  
Colour Name Genotype Confidence %
 
test exon 49 Variation 46.28 
 
post mixing exon 9 Variation 76.86 
 
wild type exon 9 control 100.00 
               
                B 
 
                                                                 ºC               
Colour Name Genotype Confidence %
 
test exon 66 Variation 82.24 
 
post mixing exon 66 Variation 73.76 
 
wild type exon 66 control 100.00 
 
Figure 3.9 Examples of the variable results of the post-PCR mixing hrMCA 
experiment    on the RotorGene™ 6000. A: Sequence variant in exon 9 
(c.960+50delG) - less prominent after pos-PCR mixing. B: Sequence variant in  
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/ = the mother carries the haplotype of an affected child, which does not necessarily make her a carrier in absence 
of other affected individuals in the family.    
 
RE analysis was included in the family studies for family DMD411 to demonstrate its 
use and the results concurred with both the hrMCA and the sequencing analysis of 
the proband.  The family pedigree and the RE analysis of family DMD411 includes 
an affected sibling (DMD411.3DIH) who presented for testing subsequent to the 
hrMCA analysis on the DNA of his mother and brother (Figures 3.10, 3.11, 3.12). 
    
 72
    A 
 
         B 
 
 
Colour Name Genotype Confidence % 
 wild type exon 47 control 100.00 
 DMD411.2.MRS exon47 Variation 59.82 
 DMD411.1.PET exon47 Variation 55.56 
 
             Figure 3.10 HrMCA analysis of family DMD411 with a nonsense mutation in exon 47 
       A: fluorescence normalized curve, B: a difference curve                  
                   
                                                                  G 
 
             
 
Figure 3.11 A section of the sequencing electropherogram of the affected proband  









                    500bp 
                                               
                        1000bp 
 
                                  
                
                                    
                                 
           Figure 3.12 RE analysis and pedigree of family DMD411.  The mutation c.6905G>A  
           destroys the TspRI RE site in the affected boys and the affected allele of their mother.  
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3.6 POPULATION STUDIES  
The PCR and RE analyses of the population cohorts of affected and wild type 
samples tested negative for both mutations (c.-85T>C in 5’UTR and c.5878T>C in 
exon 7 of the DMD gene), providing further (though not conclusive) evidence 
towards the pathogenic and private nature of the mutations.  
 
3.7 POTENTIAL ELIGIBILITY FOR GENE- BASED THERAPY 
 
Based on the mutation type in relation to the exon phasing of the DMD gene (Figure 
3.13), an attempt was made at determining theoretical eligibility for potential gene 
modification therapy options for each of the 16 mutation-positive patients in the 
cohort (Table 3.6). This was a purely academic exercise, as determining eligibility 
for any mutation-based therapy requires knowledge of the mutation’s effect at the 
transcript level. Also, the selection was made superficially, not taking into account 
factors other than the mutation type, which must be considered in application of a 
mutation-based therapy to an individual e.g. feasibility of the specific AON design, 
efficient delivery to the site of expression, the immunogenic aspects etc. A number 
of options are given per patient, some theoretically capable of restoring the wild type 
protein, and some aiming at restoration of the ORF by internal truncation of the 
DMD gene and production of a partially functional protein, leading to amelioration of 
the phenotype. Consideration was primarily given to the gene-modification 
strategies, as they appear closest to clinical application at this time (Guglieri & 
Bushby, 2010). 
 
Theoretically, restoration of the wild type protein is achievable with the gene 
modification approach is some cases. For example, exonic duplications, such as 
those in patients DMD530.1THA and DMD420.1SIY in this cohort, are considered 
an excellent target for exon skipping, as skipping of the duplicated exons (as 
opposed to the constitutive ones) should restore the original gene structure and 
function (Aartsma-Rus et al., 2007). Effective readthrough therapy for nonsense 
mutations should also restore production of full length (or close) dystrophin, with 3 
patients (DMD552.1RIV, DMD352.2BRE and DMD411.1PET presenting as potential 
candidates) (Guglieri & Bushby, 2010). Even more attractive, though at this stage, 
further from successful application, is long term restoration of the wild type protein at 
a genomic level achieved by exon editing with short oligodinucleotides (Gamper et 
al., 2000; Andersen et al., 2002). This has been described in relation to classic 
splice site mutations such as that in patient DMD372.1DIN, as wells as to point 
substitutions resulting in nonsense or missense (DMD552.1RIV, DMD352.2BRE, 
DMD411.1PET and DMD389.1PIE).  
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Amelioration of the phenotype however, by skipping exons and creating an internally 
truncated but partially functional protein, is currently seen as the most promising of 
the gene modification therapies for DMD, with single exon skipping of exon 51 
reaching the stage of phase IIb clinical trials (Guglieri & Bushby, 2010; van 
Deutekom et al., 2007). In this cohort, single exon skipping could benefit 6 patients 
(Table 3.6), though different AONs are required in each case (DMD378.1TEM, 
DMD457.1MOG, DMD530.1THA, DMD352.2BRE, DMD411.1PET and 
DMD83.1MTH). 
 
            Figure 3.13 Exon phasing of the DMD gene (Beroud et al., 2007). The phase of each  
            Exon is represented by the shape of extremity of the box representing the exon.  
            Left end of exons:     1) dark blue vertical line: exon starting at the 1st nucleotide of a codon  
                                              2)  light blue curve: exon starting at the 2nd nucleotide of a codon   
                                              3) purple arrow: exon starting  at the 3rd nucleotide of a codon.  
            Right end of exons:   1) dark blue vertical line: exon ends at last nucleotide of a codon  
                                              2) light blue curve: exon ends by at the 1st nucleotide of a codon 
                                              3) purple arrow:  exon ends by the 2nd  nucleotide of a codon.     
 
 
Multiexon skipping of two sets of AONs on the other hand, could present a 
therapeutic option for a number of the patients in this cohort. Skipping exons 6 – 8 
has been successfully achieved in proof of concept experiments with the CXMD dog 
model (Yokota et al., 2009). In this study, multiexon skipping of exons 6 – 8 could 
benefit 5 patients. This includes patient DMD83.1MTH, with a frameshift mutation in 
exon 9, because of the spontaneous skipping of exon 9 achieved along with exons 
6, 7 and 8 in the experiment with and without AONs for skipping exon 9.  The 
feasibility of multiexon skipping of exons 45 – 55 has also been assessed (though 
unsuccessfully, so far) and if achieved, could benefit 3 patients tested in this study 
cohort (van Vliet et al., 2008).  The DMD gene modification approach will not be 
beneficial to all DMD patients. In this cohort, the therapeutic avenues for 2 patients 
were difficult to predict by virtue of the mutation type and location. Depending on the 
effect of the point substitution in the Dp427m/exon1 promoter region of patient 
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DMD548.1THE, one of the gene replacement approaches may be a better 
therapeutic option (Jorgensen et al., 2009; Mendell et al., 2009; Sonnemann et al., 
2009). The deletion of exons 61 – 79 in patient DMD306.1GV possibly extends 
beyond the DMD gene. If that is the case, even the DMD gene replacement may be 
of limited value.   
 











DMD306.1GV deletion (ex 61-79) _*  
DMD378.1TEM deletion (ex 5 – 7) 
 
single exon skipping (exon 8),  




deletion (ex 7) multiexon skipping (e.g. exons 6,8)** BMD 
 
DMD457.1MOG 
deletion  (ex22 - 33) single exon skipping (exon 21) BMD 




duplication (ex 1) single exon skipping of duplicated exon 1 wild type protein 
DMD552.1RIV 
nonsense codon TAA 
(exon 7) 
nonsense readthrough, multiexon skipping  
(e.g. exons 6 – 8)**, 
exon editing. 
**** 





nonsense codon TGA 
(exon 34) 
nonsense readthrough, 









nonsense codon TAG 
(exon 47) 
nonsense readthrough, 
single exon skipping (exon 47),  
multiexon skipping (45 -55)***, 
exon editing 
*** 




frameshift (delC in 
exon 6) 
multiexon skipping 




frameshift (delCG in 
exon 9) 
single exon skipping (exon 9), 




frameshift  (dup 
GGTG) and missense 
in exon 55 
multiexon skipping 
(eg. exon 45 – 55)*** BMD 
DMD342.2RIC 
 
frameshift  (dupA in 
exon 56) 
multiexon skipping  




(splice acceptor site 
intron 18) 
 
splice site editing,  
multiexon skipping  
(e.g. exons 2 – 19) 
 
wild type protein 
DMD548.1THE 
T>C substitution in 
Dp427m 
promoter/exon1 
gene editing or replacement **** ? 
DMD389.1PIE missense in exon 7 
multiexon skipping 
(e.g. 6 – 8)**, 
exon editing 
BMD or wild type 
protein 
 * The deletion may extend beyond the DMD gene and its effect on the ORF or applicability of any 
potential therapy cannot be predicted with the data available here.  
 ** The concept of skipping exons 6 – 8 has been successfully proven using the CXMD dog model. The 
experiment also showed spontaneous skipping of exon 9. (Yokota et al., 2009).  
*** The feasibility of multiexon skipping of exons 45 – 55 has been assessed. While not successful at 
the initial stage, further investigation is under way (van Vliet et al., 2008).  
**** In this case, it is possible that the transcription process of the DMD gene is inefficient, 
necessitating gene replacement or repair at the genomic level.  
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CHAPTER 4: DISCUSSION 
 
Investigation of the entire coding region of the DMD gene in 24 affected boys 
revealed disease-causing mutations in 16 cases, providing genetic confirmation of 
clinical diagnoses, not achieved with routine diagnostic testing.  
 
Six exonic rearrangements were identified with the DMD MLPA in respective 
patients; 4 of which were deletions and 2 duplications. These changes had not been 
detected by diagnostic testing with mPCR, due to the limitations of the test, which 
screened only selected exons for deletions within the deletion hot-spots. 
Furthermore mPCR did not have a quantitative component and could not be used to 
detect duplications (Beggs et al., 1990). However, the deletion of exons 5-7 in 
patient DMD378.1TEM had been missed with the mPCR despite the presence of 
exon 6 in the mPCR screen. This was most probably caused by the poor resolution 
of mPCR products for exons 4 and 6 on agarose gel electrophoresis, as the PCR 
fragments were of similar size.  
 
The deleterious nature of large lesions in the DMD gene is widely accepted and 
therefore no further investigations were conducted to prove disease association. 
However, single exon changes detected with the MLPA, require authentication, as 
assay artifacts or point mutations can interfere with MLPA probe attachment. For 
this reason, the deletion of exon 7 found in patient DMD414.1PHI, was confirmed 
with an alternative technique i.e. single exon PCRs of exons 6, 7 and 8.  
 
It was not deemed necessary to authenticate deletions of multiple consecutive 
exons found in patients DMD378.1TEM (exons 5 – 7), DMD457.1MOG (exons 22 – 
33), and DMD306.1GV (exons 61 – 79). It must be noted though, that in the latter 
case the deletion may extend beyond the DMD gene, which exceeds the detection 
range of the DMD MLPA assay. In a male, involvement of another gene could be 
demonstrated by testing for the presence or absence of X-linked markers, or 
possibly by a more sophisticated technology such as CGH-microarray for copy 
number variations of the DMD gene and the surrounding regions (Hegde et al., 
2008). Possible involvement of other genes in this patient’s disease presentation 
could not be gleaned from the limited available clinical data. There was however 
indication of a learning disability from an early age, which was interesting 
considering the location of this lesion in the distal part of the DMD gene (exons 61-
79), which was likely to affect all the dystrophin isoforms including the Dp140 and 
Dp71. This finding was consistent with reports in the literature of a link between 
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lesions affecting the Dp140 and especially the Dp71 isoform and intellectual 
disability in DMD patients. This has been hypothetically linked to the abundant levels 
of Dp140 and Dp71 in the foetal brain, which may be of relevance to cognitive 
development (Bushby et al., 1995; Bardoni et al., 2000; Felisari et al., 2000; Taylor 
et al., 2010). Interestingly, learning disability also featured in the clinical data of 
patient DMD378.1TEM with a deletion of exons 5-7. Mutations located at the 5’ end 
of the gene which affect the full-length dystrophin isoforms (including the Dp427c in 
the brain) are not generally associated with intellectual disability, which if present, is 
mild in most such instances (Muntoni et al., 2003b). The overall mean IQ in DMD 
patients however, is about one standard deviation below the normal mean and in 
absence of a detailed clinical description, an indication of “learning disability” may 
not refer to intellectual disability as such.  
 
The exonic duplications in patients DMD420.1SIY (exons 3 – 36) and DMD530.1 
THA (exon 1) were found located in the 5’ hot-spot region, which is the predominant 
hot-spot for duplications (Aartsma-Rus et al., 2006). Both were confirmed with 
repeat MLPA runs. In addition, the duplication of exon 1 in patient DMD530.1THA 
was confirmed by testing DNA extracted from a fresh blood sample, as well as that 
from an affected brother, also shown to carry the duplication.   
 
The limited available clinical data of the cohort, allowed for few correlations between 
the phenotype and the affected dystrophin domain or isoform. However, the reading 
frame hypothesis held for all but 1 of the large lesions detected. The genotype-
phenotype correlation in patient DMD420.1SIY with a duplication of exons 3 – 36, 
appeared to violate the reading frame hypothesis, as according to the exon phasing 
of the DMD gene (Beroud et al., 2007), this was an in-frame change, which involved 
part of the actin-binding domain and the adjacent central rod domain. It should 
therefore theoretically cause a BMD phenotype, when in fact, according to the 
clinical data available, the patient presented with a particularly severe disease 
course. This discrepancy was however not surprising, as the reading frame 
predictions made here, were based on the results of genomic DNA testing, and 
could not be used as evidence for the effect of the change at the transcriptional 
level. Furthermore, the frequency of reports of non-tandem duplications, triplications, 
and complex changes in the DMD gene is increasing with the current, improved 
detection methods (del Gaudio et al., 2008; Oshima et al., 2009). Such changes will 
in many instances not manifest their true nature on DNA-based analysis and 
therefore reading frame predictions for duplications detected with DNA-based MLPA 
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testing is discouraged (White & den Dunnen, 2006; White et al., 2006; Kesari et al., 
2008; Flanigan et al., 2009).  
 
The identification of 6 previously undetected large lesions reiterated the superior 
nature of the MLPA as a mutation detection tool for exonic rearrangements in the 
DMD gene, as compared to the mPCR assay, still used in many diagnostic centres. 
The MLPA analysis offers a wider detection range and better definition of the 
deletion/duplication breakpoints, as it features all 79 exons of the DMD gene. Very 
importantly, the quantitative component of the assay allows for improved 
determination of female carrier status without the need for linkage analysis, which is 
more expensive and can be less informative. Incorporation of the MLPA into the 
genetic service at the NHLS in Cape Town has certainly had a positive impact on 
carrier status determination, as the majority of referrals are isolated, as opposed to 
familial DMD cases. The MLPA therefore, unlike linkage analysis, allows for 
determination of carrier status in the mothers of deletion/duplication positive boys 
with 99% accuracy. 
  
Disease-causing small/point mutations were detected in 10 of the remaining 18 
patients of the cohort using hrMCA. These included 3 nonsense, 3 frameshift, 1 
splice site, 1 compound mutation (splice/frameshift and missense), 1 missense, and 
1 point substitution in the Dp427m promoter/exon1 region of the DMD gene. Only 
two of the 10 mutations (c.4729C>T and c.6905G>A, both nonsense) were 
previously reported in the DMD LOVD (Leiden Open source Variation Database) 
(Aartsma-Rus et al., 2006). All were unique to their specific families or in the cases 
where no family DNA was available for testing, to the probands.  
 
The 3 nonsense mutations were found in patients DMD552.1RIV, DMD352.2BRE 
and DMD411.1PET in exons 7, 34 and 47 respectively. The expected consequence 
of a PTC-causing mutation is protein truncation with its associated nonsense 
mediated decay (NMD), however, nonsense mutations have also been known to 
cause secondary alterations to splicing, resulting in skipping of the mutated exon 
and production of a semi-functional protein (provided that the skipped exon does not 
create a frame-shift) and a milder phenotype in some cases (Zhang et al., 2003; 
Disset et al., 2006; Deburgrave et al., 2007; Nishiyama et al., 2008). The nonsense 
mutation c.4729C>T in patient DMD352.1BRE had previously been studied for this 
effect and found not to cause altered splicing (Nishiyama et al., 2008). Analysis of 
the remaining two (c.620.T>G and c.6908G>A) with the Human Splice Finder v2.4 
software (HSF) (Desmet et al., 2009) did not indicate potential secondary splicing 
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alterations. Establishing whether a nonsense mutation creates an alternative rescue 
transcript has an obvious therapy implication for drugs which induce nonsense 
readthrough, thus emphasising the importance of accurate assessment of eligibility 
for treatment by analysis of mRNA extracted from muscle tissue. 
   
The 3 frameshift mutations, expected to cause truncation by downstream PTCs and 
subsequent NMD, were found in patents DMD550.1SHA, DMD83.1MYH and 
DMD342.2RIC. All 6 of the PTC-associated mutations detected in this study 
(frameshift or nonsense), were accepted as pathogenic and no further analyses 
(other than family studies) were carried out to prove disease-association.  
 
A classic splice site mutation was detected in patient DMD372.1DIN, where the G>A 
change (c.2293-1G>A) was shown to disrupt the consensus splice acceptor site, 
using the ESEfinder software (Cartegni et al., 2003). The second line of evidence 
towards the deleterious nature of this mutation, was the fact that a previously 
detected G>T change at the same site was recorded as pathogenic in the DMD 
LOVD (Aartsma-Rus et al., 2006).  
 
The compound mutation found in exon 55 of patient DMD357.1, on the other hand 
was not as obvious in its nature. Sequence analysis revealed an alteration involving 
insertion of a GGTG motif, along with a G>T missense mutation 12 bases 
downstream. The insertion was annotated according to the HGVS recommendations 
(den Dunnen & Antonarakis, 2000), as a duplication of a repeat motif at the 3’ most 
position in the query sequence, with GGTG being the first 4 bases of exon 55. 
Because of the size of the insertion and the surrounding sequence, it was not 
certain whether the mutation caused a frameshift or altered a splice site. Analysis 
with the HSF however, was suggestive of an aberration in the splicing process, 
caused by creation of alternative splice sites, new ESS (exonic splice silencer) 
motifs and disruption of ESE (exonic splice enhancer) sites. The missense mutation 
downstream, is a possible exacerbating (or ameliorating) factor which may disrupt 
splice regulating sequences, though the amino acid change taken on its own, 
appeared tolerable according to SIFT analysis (Sorting Intolerant From Tolerant) 
(Kumar et al., 2009). However, determination of the actual effect of both mutations 
on the transcript, be it a splice variation or a frameshift, requires RNA-based studies 
on muscle biopsy material.  
 
The missense mutation identified in exon 7 of patient DMD389.1PIE (c.587T>C), 
resulted in an amino acid substitution of Leucine to Proline. According to 
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computational analysis with the SIFT program, this was not a tolerable change in the 
context of the highly conserved residue of the actin-binding domain, which implied 
pathogenicity. Analysis with the HSF program was not indicative of a significant 
effect on the splicing elements. Missense mutations are rare in both DMD and BMD 
patients, reported at a frequency of approximately 1 – 4% of all small lesions (which 
make up ~ 30% of all mutations in the DMD gene) (Aartsma-Rus et al., 2006; 
Tuffery-Giraud et al., 2009). The missense cases reported in the DMD LOVD, 
cluster in the actin–binding domain of dystrophin encoded by exons 2 – 8, and the 
cystein-rich domain encoded by exons 62 – 70, defining a possible hot-spot 
(Aartsma-Rus et al., 2006; Tuffery-Giraud et al., 2009). The location of the missense 
mutation detected in exon 7 in this study was in keeping with this trend, further 
pointing towards its pathogenicity. Previously recorded missense mutations in the 5’ 
end of the DMD gene were mainly associated with the Becker phenotype, and those 
at the 3’ end, with DMD. According to the limited clinical data available, the patient 
was diagnosed with DMD but presented for testing at 10 years of age. This is 
however not necessarily due to late onset of symptoms (as in a BMD phenotype), as 
in some cases, the socio-economic and cultural aspects of the South African context 
obstruct access to early diagnosis and intervention.  
 
The single base substitution was identified in the Dp427m promoter/exon1 region of 
the DMD gene (c.-85T>C) in patient DMD548.1THE (Tubiello et al., 1995). In the 
absence of mRNA studies, the link between this change and the DMD phenotype 
appeared somewhat tenuous. However, the T>C alteration fell within a highly 
conserved motif, as noted with the aid of the UCSC Genome Browser 
(http://genome.ucsc.edu). Also, the analysis output of the TESS (Transcription 
Element Search System) program, was strongly suggestive of the change disrupting 
the MEF-2 (Human Myosite-specific Enhancer Factor 2) TFB site, specifically the 
aMEF-2 isoform, which is a transcription activating factor for expression of muscle 
specific genes in the cardiac, smooth, skeletal muscle, placenta, brain, lung and 
kidney. Additional bioinformatic tools as well as mRNA expression studies from 
muscle may be required to elucidate the possible role of this mutation in the disease 
pathogenesis of this patient (Navankasattusas et al., 1992; Yu et al., 1992).   
 
DNA was available from relatives of 7 probands and the disease-causing mutations 
were shown to track with the affected phenotype in all 7 families. Comparison with 
the diagnostic records of microsatellite analyses within the families showed that the 
changes also tracked with the affected haplotypes. This in itself is not proof of 
pathogenesis, as polymorphisms also track with haplotypes. More importantly, the 
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family studies served to establish the origins of the mutations as familial, by 
demonstrating their presence in the mothers of the affected probands. Furthermore, 
finding the deleterious changes in the mothers of isolated cases (families DMD83, 
DMD342 and DMD372), changed their empirical carrier risk of 70%, to a confirmed 
positive carrier status. Interestingly, the sister of proband DMD357.1MAS had been 
shown to carry a recombinant haplotype. She however tested positive for the 
pathogenic mutation in exon 55 ([c.8028_8031dupGGTG; c.8044G>T]) and closer 
scrutiny of the haplotype revealed that the recombination breakpoint lay downstream 
from exon 55, at the 3’ end of the DMD gene between the STR HI and STR 3’CA 
microsatellite markers (Beggs & Kunkel, 1990; Tyson et al., 1996).  
 
No DNA was available for testing from healthy male relatives, with the exception of 
family DMD342, where sample DMD342.3FOE was extracted from amniocytes of 
the male foetus for a prenatal diagnosis. The foetus, previously found to carry the 
unaffected haplotype, tested negative for the mutation (c.8284dupA) in this study. 
No further information regarding the affection status of the subsequently born child 
was available, as the family were infrequent attendees at the muscle clinic. The child 
had however not presented at the clinic to date, which is a likely indication of the 
absence of DMD. This, along with the fact the mutation was a frameshift alteration, 
supported the conclusion that the c.8284dupA is disease-causing.   
 
Population studies in affected and unaffected cohorts were performed on the 
missense (c.587T>G) and the Dp427 promoter/exon 1 (c.-85T>C) mutations, in an 
effort to gain further supporting evidence towards (or against) their possible 
pathogenicity. Definitive evidence was however not found, as the changes were 
absent from both cohorts. Detection of a sequence change under investigation in the 
affected as opposed to the wild type cohort could be indicative of a deleterious 
mutation (or even a possible founder effect if found in more than one family). On the 
other hand, its presence in the wild type cohort could point towards non-
pathogenicity, bearing in mind, that the population cohort size fell somewhat short of 
the minimum size required for this type of investigation (at least 200 individuals) 
(Frederic et al., 2009).  
 
All of the mutations identified, were communicated to the relevant clinicians, for 
delivery to the probands and their families. The result delivery protocol stipulated 
that other family members seeking testing for the mutations detected in this 
research setting should be directed for testing in the diagnostic, accredited 
environment.   
 82
In addition to the pathogenic changes, 39 sequence alterations previously reported 
as polymorphisms were identified (Aartsma-Rus et al., 2006). The non-pathogenic 
nature of 36 of these changes was verified by their presence in multiple patients, 
including those carrying disease associated mutations in other exons. No such 
verification was possible in 3 cases (c.2168+13T>C, c.11046+119A>G and 
c.*477_*480dupTACA) as each of the variants was found in one respective patient, 
in the absence of a co-segregating pathogenic mutation.  
 
Finally, 3 apparently novel sequence alterations of uncertain significance were 
identified, initially dismissed as polymorphisms. The silent mutation c.3513A>G in 
exon 26 of patient DMD447.1THA was computationally analysed with the HSF 
program and found to have no significant impact on the splicing elements within the 
fragment, increasing the likelihood of it being non-pathogenic. The sequence 
variation located in intron 58 (c.8668 + 19A>G) was also regarded as a 
polymorphism, since it was found in patient DMD357.1MAS, who was shown to 
carry a pathogenic mutation in exon 55 (the splice and missense mutation discussed 
earlier). This may however not be correct, as the possibility of more than one 
pathogenic change in a patient could not be excluded. Iintronic mutations in the 
DMD gene have been shown to cause disease by activating cryptic splice sites 
which incorporate intronic sequences into the mRNA thus creating a frameshift. 
These “pseudoexon mutations” are gaining the status of a newly recognized 
mutation type in DMD (Béroud et al., 2004; Gurvich et al., 2008). It was therefore 
dangerous to dismiss an intronic mutation as insignificant, based purely on its 
location outside of a coding region. Another mutation of an uncertain significance, 
initially dismissed as a polymorphism, was found in the 3’UTR of the DMD gene in 
patient DMD433.1LUN (c.*1903_*1906delTTAA) in the absence of other disease-
causing mutations. However, a growing body of evidence has revealed that 
dysfunctional translational regulation of gene expression can be linked to disease 
pathophysiology. The translational ability of mRNA is controlled by sequence sites, 
signals and motifs residing in the 5’ and 3’ UTRs of eukaryotic genes and involves 
mechanisms such as alterations in the stability of the mRNA, its accessibility to the 
ribosomes, its circularization and interaction with the translation machinery 
(Chatterjee & Pal, 2009). The 3’UTR of the dystrophin gene specifically, exhibits a 
high degree of conservation, implying that changes in the sequence can be 
deleterious (Greener et al., 2002b).  
 
Characterization of the downstream effects and clinical significance of ambiguous 
sequence variants such as the 3 changes described above requires additional 
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bioinformatic analyses and is most effectively achieved by analysis of mRNA 
transcripts extracted from muscle tissue, which extended beyond the scope and 
limitations of this study.  
 
Extrapolation of mutation frequencies in this small cohort, to the DMD-affected 
population in South Africa cannot be made with any degree of confidence. However, 
truncating point mutations comprised 60% (6 patients) of the small pathogenic 
changes found in this study (half of which were nonsense mutations) and 20% (2 
patients) involved splicing, which was largely in keeping with the detection 
frequencies reported in the literature, where over 60% of all reported small lesions in 
the DMD gene are nonsense and frameshifts and approximately 25% are splice 
mutations. Disease-causing missense mutations are reported at the lowest 
frequency of 1 – 4% of the small lesions, and 1 was found in this study (Aartsma-
Rus et al., 2006; Flanigan et al., 2009; Tuffery-Giraud et al., 2009).  
 
No disease-associated mutations were identified in 8 patients of the cohort (this 
includes the 4 patients with changes of uncertain significance). The reasons for this 
may be threefold. Firstly, the clinical diagnosis was not confirmed with muscle 
biopsies in 4 cases and in the absence of genetic diagnoses, clinical reassessments 
may be warranted. Secondly, there was the technical consideration of the quality of 
the DNA used for analysis. Fresh DNA was not available in all cases and long-term 
stored DNA extracted with a number of methods and reagents, had to be used. This 
was not ideal, as sample uniformity is important for reliable hrMCA and may 
therefore have resulted in missed variants. Lastly, some of these patients could 
carry deep intronic point mutations which create novel splice sites and result in the 
inclusion of intronic sequences in the mRNA. These “pseudoexon mutations” cannot be 
picked up with DNA-based testing and the methods used here. Also, the large size of 
the DMD introns still precludes direct intronic sequencing as a practical assay. 
Consequently, the presence of pseudoexons must be determined by analysis of mRNA 
from muscle tissue (Gurvich et al., 2008).   
 
At this time, sophisticated high throughput technologies like next generation 
sequencing are on the horizon as the point mutation detection tool for entire genes, 
including the introns (Chou et al., 2010). Also, the ultimate tool for detection and 
elucidation of the full extent of copy number variations in the DMD gene is 
microarray technology with its capability of locating intronic breakpoints, deep 
intronic mutations and complex rearrangements involving other genes. (del Gaudio 
et al., 2008; Oshima et al., 2009). The changes detected in studies using these 
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sophisticated platforms, emphasise the complexity of some mutations underlying the 
DMD phenotype and help to elucidate the underlying mechanisms. For the moment 
however, financial limitations place the microarray and next generation sequencing 
technology out of reach of many diagnostic laboratories. Until such time as these 
testing platforms become affordable and more widely applied in laboratory medicine 
(in developing countries), the MLPA, along with an inexpensive and easily 
performed pre-sequencing screening tool like hrMCA, can become easily 
incorporated into the diagnostic setting and serve to provide previously unavailable 
information and a more comprehensive genetic service for DMD.  
 
By and large, the endevour of small/point mutation detection in the DMD gene has 
been confined to research projects, as the expense and logistical challenges of 
setting up and sustaining a service for small mutation detection in this enormous 
gene, has been considered beyond realistic capabilities of most diagnostic 
laboratories. However, this line of thinking is shifting, with the potential availability of 
mutation-based therapies, the application of which necessitates the knowledge of 
the genetic basis of the disease in each affected individual. The decision to use 
hrMCA as a pre-sequencing screening tool for detection of small/point sequence 
variations in the DMD gene in this project was based on its ease, reasonable price, 
availability of specialized instrumentation and its capability to resolve single base 
variations with the sensitivity and reproducibility required for a diagnostic application 
(Krypuy et al., 2006; Krypuy et al., 2007; Takano et al., 2008; Yan et al., 2010).   
 
While relatively quick and easy, the success of hrMCA is wholly dependant on a 
number of factors, as addressed in detail in Appendix C1 and C2. Besides the 
importance of availability of a suitable instrument and a sound experiment design, 
the experience of hrMCA as a technological platform in this project, revealed 
sample-to-sample uniformity as the prevailing theme at every level of the 
experiment, and the key to meaningful findings. The important lesson learned, was 
that troubleshooting of any (optimised) hrMCA experiment must start with assuring 
sample uniformity, from the DNA extraction method, to the amount of starting DNA, 
the rate of amplification and the amount of fluorescence at the beginning of the melt. 
A reliable comparison of DNA melting profiles can only be made between samples 
extracted and amplified in a similar manner. The importance of comparing uniformly 
extracted DNA was effectively demonstrated in this study. The wild type DNA from 
fresh blood samples was extracted manually with the PureGene blood kit (Qiagen) 
and was initially HRM-tested against test samples extracted with unknown methods, 
retrieved from the long-term storage facility in the Division of Human Genetics’ DNA 
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Registry. The mediocre results obtained, were thought to be caused by degradation 
of the old DNA and fresh blood was requested, where possible. Fresh blood 
samples were obtained from 2 patients and DNA was extracted with the Maxwell16 
automatic extractor (Promega). Upon hrMCA, every exon tested appeared 
significantly variant from the wild type. The problem was solved by repeated DNA 
extraction from frozen buffy coats using the PureGene kit (Quiagen), and hrMCA 
comparison of test and wild type DNA extracted with the same method.   
 
Similarly, standardization of the starting amount of DNA in every sample within a run 
was found to have a significant effect on the resulting hrMCA. Meticulous sample 
dilution with the same diluent (in this case, nuclease-free distilled water) and careful 
spectrophotometry was found to be essential. Varying concentrations of DNA will 
affect the amount of fluorescent signal emitted by the dsDNA intercalating dye, 
which will in turn affect the shape and shift of the fluorescence-normalized melting 
curve. Uniform amplification efficiency between samples is also a consideration 
during hrMCA analysis, as it correlates with the amount of the resulting PCR product 
and hence, the strength of the fluorescent signal. The amplification log phase 
beyond cycle 30 is an indication of insufficient or a degraded sample.    
 
It was found that the sample-to-sample uniformity principle should also be applied 
during data analysis, when adjusting normalization regions. Ideally, the regions 
should have a default position for each amplicon, relative to its melting temperature. 
In a high throughput analysis, such as that for the large DMD gene, the melting 
temperature range is set fairly broadly to accommodate a number of different 
amplicons with varying melting temperatures in one run. The positions of the 
normalization regions are therefore adjusted for each amplicon, which affects the 
curve shape and shift and therefore variant recognition. The recommended 
approach used in this study, was to set the regions over a temperature range of ~ 
10°C, with Region 1 set at a point where the lines of the sample and control curves 
showed uniform melting (parallel), and Region 2 set after complete melting of the 
samples and controls (no fluorescence). Complicated melting curves such as those 
for fragments 3a or 23c in this project, were best analysed separately by adjusting 
the normalization regions for each melting domain.  
 
The advantage of using an instrument like the RotorGene™6000 (Corbett Life 
Science) is the ability to run real-time PCR amplification and subsequent HRM 
consecutively in a closed-tube system, without the need for post-PCR manipulation. 
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Besides reducing labour-intensity, the risk of introducing errors and contamination is 
also reduced, which is of value in a diagnostic setting.         
 
Theoretically, variant curves should be seen only in fragments with DNA sequence 
alterations. The experience of this project showed however, that this was not quite 
the case in practice, as recognition of a variant melting profile was in some 
instances tricky. Melting curve interpretation is to some extent operator dependant 
and factors such as sample uniformity, DNA quality, number of melting domains etc. 
affect the melting profile. In this study, 14% of the amplicons were marked as variant 
and subsequently sequenced (240 out of 1728). It was however anticipated that this 
percentage should drop when working with fresh, uniformly extracted test and 
control DNA. The variant selection criteria also erred on the side of caution, in an 
effort to avoid missing disease-causing mutations. However, considering the high 
number of amplicons scanned, the figure of 14% still represented a considerable 
reduction in the burden of sequencing, as compared to other methods, such as  
direct sequencing (though it has its own advantages), and a considerable reduction 
in cost at ~R7.00 per reaction as opposed to ~R100.00 (S.A. currency) per fragment 
sequenced.  
 
The post-PCR mixing experiment was performed to test if mutation detection could 
improve with heteroduplex formation, as was found in the study by Almomani et al. 
(2009). This did not result in the identification of additional sequence changes, 
although the value of the exercise here is uncertain, due to the inconsistency of the 
results. Previously detected polymorphisms became more obviously variant after 
post-PCR mixing in some cases, and equally or less obvious in others. A 
heteroduplex showed an altered curve shape in most instances, but did not 
necessarily appear more variant or easily detectable than the initial homoduplex.  
 
No temperature normalization of the data takes place on the RotorGene™6000, due 
to its rotary format and exquisite thermo-optical accuracy, as claimed by the 
manufacturers and also as shown by studies comparing the RotorGene™6000 to 
block-based HRM platforms. In theory, this should remove the need for post-PCR 
mixing as the melting behaviour of homo- or hemizygous changes usually exhibits a 
temperature rather than a shape shift, which is obscured by temperature 
normalisation on block-based instruments (White & Potts, 2006; Herrmann et al., 
2007). Also, post-PCR mixing introduces a post-PCR manipulation step, significantly 
extending the length of the procedure and increasing labour intensity and the 
chances of introducing errors. However, post-PCR mixing should be considered as 
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a second step, if no pathogenic change is found with the initial hrMCA, as the assay 
can be designed in a way which will allow post PCR mixing after the initial PCR and 
hrMCA. The experience of this study showed that the PCR products with the 
EvaGreen dsDNA intercalating dye remain stable for a period of time, if frozen or 
refrigerated in the dark (Mao et al., 2007). Corbett Life Sciences do however 
suggest in their protocols, that class 4 SNPs may be more easily detectable with 
post-PCR mixing (http://www.corbettlifescience.com). All but 1 single base alteration 
detected in this study fell into the class 1 or 2 category, with the single class 3 SNP 
detected in exon 49 (c.7200+ 53C>G). Class 4 SNPs are the least prevalent in the 
human genome (Kwok et al., 2007) and none were identified in this cohort.  
 
In light of the long term aim of this study, an attempt was made at scrutiny of each 
pathogenic alteration found, for therapy eligibility using the exon phasing of the DMD 
gene (Beroud et al., 2007; Tuffery-Giraud et al., 2009) and the mutation type as the 
selection criteria. In this cohort, skipping of single exons was thought to potentially 
benefit 6 patients, though different AONs would be required in each case (exons 1, 
8, 9, 21, 34 and 47), highlighting one of the difficulties of the exon skipping 
approach. 
 
The concept of exon skipping as a therapy is based on the natural phenomenon 
seen in some BMD patients, where mutation-induced, spontaneous skipping of 
exons affects restoration of the ORF, resulting in a milder phenotype (Kesari et al., 
2008). AON-induced skipping of exons and creating an internally truncated but 
partially functional protein is currently seen as the most promising of the gene 
modification therapies for DMD (Aartsma-Rus & van Ommen, 2009). Specifically, 
AON-induced single-exon skipping of exon 51 has been a major research focus. 
The unpublished results of the independent phase I/II clinical trials in the 
Netherlands and the United Kingdom, as well as the preliminary outcomes of the 
phase IIb clinical trials have shown good tolerability and induction of dystrophin 
expression (van Deutekom et al., 2007; Guglieri & Bushby, 2010). It is estimated 
that approximately 15% of all DMD patients, could benefit from skipping exon 51, 
though unfortunately, by virtue of the cohort selection, none of the patients in this 
study could benefit from this particular therapy, as it targets patients with exonic 
deletions in the 3’ deletion hotspot.  
 
To provide a truly personalised gene-based therapy many different AONs must be 
designed and tested according to the nature and extent of the primary lesion. This 
will however result in creation of many types of truncated dystrophin of variable 
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functional activity and effect on the phenotype. Also, the new exon junctions may 
create novel epitopes with immunogenic properties (Lu et al., 2003). The design, 
testing and approval of a range of AONs therefore, carriers with it the obvious issues 
related to cost and applicability.   
 
Multiexon skipping, on the other hand, where a single cocktail of AONs could be 
applied to a range of mutations, is an alternative approach to single exon skipping 
and could hold a significant clinical impact. Applied to the findings in this project, 
skipping of exons 6 - 8 could theoretically be beneficial to 5 (~30%) of the 16 
mutation-positive patients: DMD414.1PHI, DMD552.1RIV, DMD550.1SHA, 
DMD83.1MTH and DMD389.1PIE). Successful proof of concept experiments for 
multiexon skipping of exons 6 – 8 have been conducted in the CXDM dog with a 
spice mutation in exon 7 (exons 6 – 8). The experiment on the CXMD dog, achieved 
widespread rescue of dystrophin expression with weekly or biweekly systemic 
intravenous injections of a three-morpholino cocktail over the course of 5 to 22 
weeks. Interestingly, in the same study, Yokota et al. (2009) described spontaneous 
skipping of exon 9 along with exons 6, 7 and 8, consistently achieved with and 
without AONs for exon 9. If a similar effect is seen in human patients, DMD83.1MTH 
with a frameshift mutation in exon 9 may also benefit from this therapy (Mitrpant et 
al., 2009; Yokota et al., 2009).  
 
Another 2 patients (12.5%) in this study cohort could benefit from the already 
experimentally designed (though not yet unsuccessfully tested), therapy with a 
cocktail of AONs for multiexon skipping of exons 45 – 55 (DMD411.1PET and 
DMD357.1MAS (van Vliet et al., 2008).     
 
Exonic duplications, such as those detected in patients DMD530.1THA and 
DMD420.1SIY in this cohort, are thought to present an excellent target for exon 
skipping therapy, as AON-induced splicing out of duplicated exons (but not the 
constitutive exons), should result in restoration of the wild type message and protein 
(Aartsma-Rus et al., 2007; Gurvich et al., 2008). Also, exon skipping of the 
duplicated exons and restoration of the wild type does not carry with it the possible 
functional variability or the immunological risks of the newly created truncated 
protein. A similar principle applies to pseudoexon mutations (none were detected in 
this study cohort), as AON-induced exon skipping of intronic sequences should also 
restore production of the wild type protein.     
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Besides the importance of designing AONs capable of achieving sufficient levels of 
exon skipping for a therapeutic effect and are target-specific with good safety and 
tolerability profiles, a major challenge lies in optimization of systemic AON delivery. 
Also, in order to optimize AON target sequences in humans, a better understanding 
is required of the mechanisms through which antisequences interfere with RNA 
splicing. Another current limitation of AON therapy is its inability to target the heart in 
the mdx mouse at doses suggested for clinical applications (Townsend et al., 2008). 
Recent studies have suggested incorporation of peptide or chemical moieties with 
the AONs, to facilitate cell uptake and prevent disruption of cardiac sarcolemma, 
cardiac hypertrophy and dysfunction in mdx mice (Townsend et al., 2008; Wu et al., 
2008; Yin et al., 2008).   
 
Another, though more distant alternative to exon skipping for some patients, is the 
oligonucleotide-mediated gene editing or gene repair, which aims at correcting in-
frame point mutations such as the 3 nonsense mutations found in this study cohort 
as well as the splice mutation in intron 18 (c.2293-1G>A), and the missense 
mutation in exon 7 (c.587T>C). This is an attractive option, as the repair takes place 
at the genomic level and as such, should permanently restore of the wild type 
protein. However, much research is still required for optimal ODN design and 
improved efficacy and efficiency of delivery and the resulting levels of expression 
(Bertoni, 2005; Robinson, 2009).  
 
The 3 patients in this study cohort shown to carry nonsense mutations, could also 
be eligible for potential readthrough therapy (DMD552.1RIC, DMD352.2BRE and 
DMD411.1PET). Recently much hope was placed on the results of the double blind, 
placebo-controlled phase IIb clinical trial for Ataluren, shown to be an effective read-
through agent for nonsense mutations in vitro and in animal models (Welch et al., 
2007). The trial results were disappointing, with no statistically significant change in 
the primary endpoint of the 6 minute walking distance, noted within the 48 week 
duration of the study (Guglieri & Bushby, 2010). However, the data gathered on the 
effect of the therapy on the subgroup of patients receiving a lower drug dose is 
under further scrutiny, leaving a glimmer of hope for future studies of similar 
compounds (www.ptcbio.com). In this vein, a newly developed aminoglycoside 
(NB54) is under investigation as a readthrough agent, with a higher read-through 
efficacy and an improved toxicity profile in different cell lines, as compared to 
gentamicin (which was the initial stimulus for this line of research) (Nudelman et al., 
2009). Two of the patients with nonsense mutations detected here (c.620T>G and 
c.4729C>T), carry TGA stop codons (though neither has a pyrimidine base in the +1 
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position) which showed the best readthrough response in animal and muscle cell 
culture models for both gentamicin and Ataluren studies, making them good 
candidates for possible future application of readthrough therapies (Welch et al., 
2007; Peltz et al., 2009).   
 
The therapeutic options for 2 patients in this cohort were difficult to predict. The 
point substitution in the Dp427 promoter/exon 1 of patient DMD548.1THE presents 
a dilemma, due to the uncertain downstream effect of this mutation, which could 
only be elucidated by mRNA from muscle tissue. Gene editing or in particular gene 
replacement therapy which is currently undergoing intensive research with hopeful 
results, could present a possible option (Trollet et al., 2009). The large deletion of 
exons 61 – 79, on the other hand, which may extend beyond the DMD gene, makes 
patient DMD306.1GV ineligible for any of the gene-modification therapies discussed 
above, since the entire 3’ end of the gene is deleted. If the mutation extends beyond 
the DMD gene, even its replacement may be of limited value, as the disease 
phenotype may be linked to other gene/s.  
 
It must be emphasised that the prediction regarding eligibility for therapy were made 
superficially, using results of DNA-based analyses which do not necessarily reflect 
the mutational effect on the transcript. It was a purely academic exercise of interest, 
in view of the current research and clinical trials. Also, consideration was given 
mostly to gene-modification approaches closer to clinical application at this time, as 
opposed to gene replacement or progenitor cell therapies which have shown 
promising results in animal models but are more distant from clinical application 
(Harper et al., 2002; Guglieri & Bushby, 2010).  
    
Application of the emerging personalized, genetic therapies for DMD begins with 
precise mutation detection and knowledge of the downstream effects of this 
mutation in each patient. This information can be obtained only by studying the 
mRNA from the primary expression site of the gene i.e. muscle, in each DMD 
patient, as it has been shown that similar mutations detected in DNA, can have 
different downstream effects in different patients, even within the same families 
(Muntoni et al., 2003a; Aartsma-Rus et al., 2006). Sampling a muscle biopsy 
however, is an invasive procedure, which can be traumatic to a child and which 
carries its own risks. For this reason clinical protocols in many centres recommend 
taking biopsy specimens only from patients who require confirmation of diagnosis 
with immunohistochemistry and dystrophin staining i.e. those with no genetic 
diagnosis.   
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It is therefore likely, that until genetic therapy becomes a reality, testing of DNA from 
blood lymphocytes will remain the mainstay of genetic diagnostics in DMD. There is 
however every indication that gene therapy is within sight, making the effort of 
establishing methodologies and protocols for detection of both large and small 
lesions in the DMD gene mandatory, albeit limited to one centre in the country. The 
information gained with DNA testing in the meanwhile, can be used for improved 
genetic counselling of the families and will give an edge when the time comes for 
therapy assessment and additional testing of muscle biopsy material. While the 
findings of this study may not have a direct therapeutic impact on many of the 
patients tested in this study, the information gathered here may serve their families 





























CHAPTER 5: CONCLUDING REMARKS  
 
Since the initial description of Duchenne and Becker muscular dystrophy in 1851, 
much progress has been made in establishing intervention strategies for this 
debilitating childhood disorder. While a cure remains elusive, the currently available 
treatments focus on early diagnosis and timeous management of symptoms and 
complications, allowing many D/BMD patients to live productively into their third 
decade.  
 
The development of genetic therapies for DMD adopting the traditional gene 
replacement approach has been slow and fraught with setbacks, though it has seen 
a revival in recent years with mini- and micro-dystrophin or full-length utrophin 
replacement showing promise. At this time, however, the gene modification avenue 
appears closest to clinical application, with AON-induced exon skipping and 
nonsense read-through reaching the stage of clinical trials.   
 
As opposed to gene replacement, the gene modification therapy is mutation-specific 
and as such, goes hand in hand with mutation detection. Determining eligibility and 
taylor-making of a particular brand of therapy is wholly reliant on the precise 
characterization of the disease-causing mutation and its downstream effects, 
necessitating availability of comprehensive diagnostic testing protocols. 
 
Since the identification and characterization of the DMD gene in 1987 (Koenig et al., 
1987), technological advancements in molecular science have greatly influenced 
diagnostic testing protocols. Current methods for detection of exonic 
rearrangements, which cause the disease in 70% of all B/DMD patients, offer highly 
accurate diagnostic testing and carrier status assessment for female relatives. 
Detection of small/point mutations, implicated in 30% of all B/DMD cases, has 
however been slow in reaching the diagnostic setting, due to the logistical and 
financial issues involved in interrogation of the vast DMD gene. While not yet 
included in most diagnostic protocols, point mutation detection has been the focus of 
a considerable amount of research and development in recent years, particularly in 
view of the prospects for availability of gene-based therapies for DMD.     
 
With that in mind, the main focus of this study lay in detection and characterisation 
of all pathogenic mutations in the coding region of the DMD gene by screening for 
both exonic rearrangements and small/point mutations in each of the 24 patients of 
the cohort. Detection of small/point mutations was a particularly significant aspect of 
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the study, as the methodology and the technological platform employed (hrMCA), if 
successful, was to result in prompt translation into the local diagnostic service for 
DMD, complementary to the already offered MLPA® screen for large lesions. 
Detection of 10 pathogenic mutations with hrMCA was of special significance in this 
study not only because it provided the patients and their families with previously 
unavailable genetic diagnoses, but also because it signified successful fulfilment of 
its main aim. However, it must be emphasised that while research involving point 
mutation detection in the DMD gene has been conducted in this centre before, this 
is the first study in South Africa, to take an all-encompassing approach of profiling all 
mutations in the coding region of the DMD gene i.e. point mutations, as well as 
exonic rearrangements.   
 
Availability of genetic diagnosis plays an important part in the clinical protocol, as 
early testing allows for effective monitoring and timely intervention, prolonging the 
patient’s ambulation and life span. In cases with no family history, knowledge of the 
mutation type and its location could also help to anticipate the severity of the 
disorder and aid in adoption of appropriate patient management strategies. Also, 
availability of effective testing for carrier status is invaluable to female relatives, 
especially the mothers of isolated cases, whose carrier status could only be 
established empirically in the past. Implementation of the MLPA® at the NHLS GSH, 
with its quantitative component, has made a significant impact in carrier testing, as 
the referral base consists largely of isolated DMD cases. Extending the service 
further to small/point mutation detection with hrMCA, will offer additional testing 
options to deletion/duplication negative patients and their families, providing 
previously unavailable information and a more comprehensive genetic service for 
DMD.  
 
The experience of this study also brought forth the increasing role of bioinformatic 
analyses and the need for bioinformatic training in the diagnostic environment, 
particularly in view of the “private” nature of the small/point mutations found in the 
DMD gene. While certain types of mutations are clearly disease-causing e.g. 
nonsense and frameshifts, their precise downstream effects as well as the disease 
association of other types of changes eg. missense, are difficult to determine in the 
absence of RNA-based studies. This also applies to characterisation of the effect of 
intronic mutations, the detection of which is becoming more frequent with the 
availability of ever improving technological platforms, and which have also been 
shown to play a part in the disease pathogenesis of some DMD patients.  Analysis 
of novel, previously uncharacterised changes requires competency in using 
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bioinformatic software and ability to interpret the output, which are skills still largely 
confined to the research environment.  
 
The superior nature of RNA extracted from muscle material, as the basis for 
definitive determination of the downstream effects of mutations was repeatedly 
highlighted in this study. Future laboratory protocols for ascertaining eligibility for 
mutation-based therapies are likely to incorporate RNA analysis as an essential part 
of the process. This will necessarily lead to changes in clinical protocols regarding 
biopsy sampling, as at present, muscle biopsies in DMD patients are not routinely 
performed due to the invasive nature of the procedure. Until such time however, 
DNA extracted from blood lymphocytes is likely to remain the mainstay of 
diagnostics testing and the results thus obtained will be of value to the patients and 
their families now, and at a time of more extensive therapy eligibility testing in the 
future.  
 
The main findings of this study include: 
 16 pathogenic mutations detected in respective patients:  
o 6  exonic rearrangements (4 deletions and 2 duplications)  
o 10 small/point mutations (8 novel): 
 3 nonsense 
 3 frameshits 
 1 splice 
 1 compound mutation (a GGTG duplication and a missense) 
 1 missense  
 1 point substitution in the Dp427m/exon1 promoter region of the 
DMD gene.     
 39 polymorphisms 
 4 changes of uncertain significance 
 
The work presented in this thesis provides the foundation for establishing 
comprehensive and specific diagnostic tests for each DMD family. It also provides 
the basis for further research efforts into defining the effects of the changes found at 
the transcript level. Furthermore, defining mutations underlying the DMD phenotype 
in the South African population will also facilitate establishing trends within the 
various population subgroups of South Africa, possibly correlating molecular 
features to the disease course and facilitating a more strategised approach to the 
clinical and laboratory diagnostic protocols. The knowledge of the disease-causing 
mutations detected during this study, provides patients and their families with a 
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considerable head-start in the future, when mutation-based genetic therapy 
becomes a veritable therapeutic avenue. Also, the experience and results obtained 
by employing hrMCA as a mutation scanning tool, demonstrated its aptitude for high 
throughput mutation detection in a sensitive, yet cost efficient way, thus presenting a 
possible method of choice for point mutation detection in the DMD gene, at this time.  
 
In conclusion, the promising outcomes of research into several strategies of gene-
based therapy for DMD show every indication of crossing the divide between the 
laboratory and the clinic in the not-so-distant future. Availability of a comprehensive 
testing protocol, capable of determining the genetic basis of the disease in most 
patients is therefore emphasized as a primary requirement in determining suitability 
for any mutation-based therapy. The resulting broader scope and range of testing 
will necessarily increase the detection rate, providing previously unavailable genetic 
diagnoses, better family counseling and definitive determination of carrier status for 
female relatives. The information gained as a result, will help fill the hollows in the 
international DMD mutation databases and increase the body of knowledge on the 
incidence and prevalence of mutation types and their effects on the gene, the 
protein and the phenotype. Thus gathered data will add to the general body of 
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Figure A.2 The NHLS consent form for genetic testing and/or research (printed the reverse of 












































1. ADVANTAGES OF MLPA® 
 A major advantage of this technology is that it is a quantitative scan of the 
entire DMD gene for exonic rearrangements in two multiplex, PCR-based 
reactions. It can therefore detect duplications in males and determine carrier 
status in females.  
 The use of a single primer pair allows for amplification of up to 45 targets in a 
single multiplex reaction. It is therefore capable of amplifying all 79 exons of 
the DMD gene (in two reactions) and not just those located in the mutation 
hotspots.  
 MLPA® is superior to other quantitative analyses, such as the qPCR and 
Southern blot, as the former is difficult to optimise in multiplex, and the latter 
is expensive, labour intensive and time consuming. The MLPA® reaction is 
easy to perform, robust and fast, as results are available within 48hrs. It is 
also relatively inexpensive at ~ EUR15 per reaction (as per price in 2009).  
 The MLPA® is internally quality-controlled by inclusion of control fragments 
and probes in every probe set. Also, consecutive exons are amplified in 
different probe mixes and are not adjacently lined up on the 
electropherogram, due to clever fragment size regulation by probe design. 
This also helps to authenticate any changes found.    
 Only 20ng of human genomic DNA is required.    
 
2. LIMITATIONS OF MLPA® 
 MLPA for DMD is primarily designed to identify deletions/duplications, not 
point mutations.  
 MLPA® is more sensitive to sample impurities than an ordinary PCR. 
 Sample uniformity is important. It is advisable to compare DNA extracted 
with the same extraction method and diluted with the same diluent. Also, 
DNA sample in a batch should be of similar concentration, which requires 
pre-test sample preparation.   
 A single exon deletion must be confirmed with an independent method, such 
as a separate PCR with an individual set of primes. The lack of probe signal 
could be caused by incomplete sample denaturation, failed ligation or 
another artefact.    
 Point mutations and polymorphisms can interfere with probe hybridization 
and mimic single-exon deletions. For this reason, cycle sequencing should 
be performed on PCR products of single exons presenting as deleted with 
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®. This however, can be seen as an advantage, since a disease-
causing point mutation can be detected in this way.  
 
3. MLPA® QUALITY CONTROL 
The control probes and fragments are part of the test design, acting as an internal 
quality control of each MLPA® assay. Each assay run is also controlled externally by 
inclusion of control samples of known genotype.  
 Q-fragments (quantity controls of 64, 70, 76 and 82 nt) are present in low 
quantities and are not ligation-dependent. In a reaction with sufficient amount 
of DNA (Figure B1(C)), the Q-fragments are barely visible, as they are dwarfed 
by the MLPA® probes. If the amount of sample DNA is below 20ng or if the 
ligation reaction fails, the Q-fragments co-vary together and become more 
prominent (higher than half of the D-fragment and the MLPA® probe peaks), 
rendering the MLPA® results unreliable (Figure B1 (A) and (B)) 
(www.mlpa.com).  
 D-fragments (denaturation controls 88, 92 and 96 nt) are DNA- and ligation-
dependent with peak sizes comparable to those of the MLPA® probes (Figure 
B.2(A) and B.3). Invisible or significantly reduced D-fragments indicate 
insufficient sample denaturation and unsuccessful ligation (Figure B.2 (B) and 
(C)). The 88 and 96 nt D-fragments target difficult to denature sequences in 
CpG islands. A peak height 40% lower than that of the 92 nt D-fragment and 
the other MLPA® probes, is a possible indication of incomplete sample 
denaturation. Deletions of probes close to CpG islands should always be 
treated with caution and special attention paid to the signals of the D-
fragments. The 92 nt D-fragment, is present in lower quantities and is a 
measure of hybridization efficiency. A peak size significantly lower than that of 
the 88 and 96 nt D-fragments, is an indication of incomplete probe-to-target 
hybridization (www.mlpa.com).   
 The X and Y-specific fragments can be used for sex determination and can 
in some cases locate sample switch. 
 Reference probes consist of chromosomal sequences, which do not show 
frequent copy number changes. It is unlikely (though not impossible) to see 
deletions or duplications of reference probes or non-neighbouring target-
specific probes and such findings may indicate unreliable MLPA® results. 
 Reference samples (wild type DNA) are included in every MLPA® run and are 
essential for data normalization and quantitation analysis. MRC-Holland 
recommends using at least three reference samples, all extracted by the same 
method and diluted to a concentration similar to that of the tests samples. 
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 Mutation-positive control samples are useful for testing the integrity of the 
MLPA® run but are not essential for data analysis.  
 No-DNA control reactions included as a test for contamination of tests or 
capillary electrophoresis reagents. These reactions are not completely blank 
as the Q-fragments, along with some longer aspecific amplification products 
are sometimes present. However, the results of the no-DNA control reactions 




Figure B.1 Effect of DNA quantity on Q-fragments.  
MLPA® results with 5 ng (A), 10 ng (B), 20 ng (C). Peaks of the Q-fragments decrease when the 





Figure B.2 Effect of a poor denaturation (due to a high salt concentration) on D-fragments. 
MLPA® P002 (BRCA1) probes signals from DNA in TE (A), with 50mM NaCl (B), 75 mM NaCl (C). 
Peak size of control fragments 88, 96 and probes for exon A, B and C are reduced in the presence of a 
high salt concentration due to incomplete denaturation. 64-96 nt: quality control fragments, c: control 
probe, 1-5: BRCA1 probes for exons 1-5 (www.mlpa.com). 
 
             Q-frag, D-frag                                                    MLPA® probes 
          
 
Figure B.3 Capillary electrophoresis pattern from a sample of approximately 50 ng human male 
control DNA analyzed with SALSA MLPA® kit P035-A2 DMD (lot 0508) (www.mlpa.com). 
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4. SALSA MLPA® PROBES FOR DMD  
 
Table B.1 SALSA MLPA® P034-A2 DMD probe mix.  
 Length (nt)  SALSA MLPA® probe  
Chromosomal position                 
reference                                         DMD 
64-70-76-82  Q-fragments: DNA quantity; only visible with less than 100 ng sample DNA   
88-92-96*  D-fragments: Low signal of 88 or 96 nt fragment indicates incomplete denaturation   
100*  X-fragment: Specific for the X chromosome   
105*  Y-fragment: Specific for the Y chromosome   
             118 Y-fragment: Specific for the Y chromosome   
130 Reference probe 1690-L00423  Xq11.2  
138 DMD probe 1353-L01001  Exon 1 
146 DMD probe 1354-L01002  Exon 41 
154 DMD probe 1355-L01615  Exon 21 
162 DMD probe 1356-L01004  Exon 61 
170 DMD probe 1357-L01005  Exon 2 
178 DMD probe 1711-L01279  Exon 42 
186 DMD probe 1359-L01007  Exon 22 
194 DMD probe 1897-L01008  Exon 62 
202 Reference probe 1691-L00465  Xp22  
210 DMD probe 1361-L01009  Exon 3 
218 DMD probe 1362-L01010  Exon 43 
226 DMD probe 1363-L01011  Exon 23 
234 DMD probe 1364-L01012  Exon 63 
242 DMD probe 1365-L01013  Exon 4 
250 DMD probe 1366-L01014  Exon 44 
258 DMD probe 1958-L01518  Exon 24 
266 DMD probe 1368-L01016  Exon 64 
274 Reference probe 1768-L01617  Xq28  
282 DMD probe 1954-L01574  Exon 5 
290 DMD probe 1370-L01287  Exon 45 
298 DMD probe 1371-L01019  Exon 25 
306 DMD probe 1372-L01020  Exon 65 
314 DMD probe 1373-L01021  Exon 6 
322 DMD probe 1374-L01288  Exon 46 
330 DMD probe 1375-L01023  Exon 26 
338 DMD probe 1376-L01024  Exon 66 
354 DMD probe 1713-L01281  Exon 7 
362 DMD probe 1378-L01026  Exon 47 
370 DMD probe 1379-L01616  Exon 27 
378 DMD probe 1960-L01520  Exon 67 
386 DMD probe 1715-L01283  Exon 8 
394 DMD probe 1382-L01030  Exon 48 
402 DMD probe 1716-L01284  Exon 28 
410 DMD probe 2482-L02710  Exon 68 
418 Reference probe 3766-L03227  Xq13  
426 DMD probe 1385-L01033  Exon 9 
434 DMD probe 1717-L01285  Exon 49 
442 DMD probe 1387-L01035  Exon 29 
450 DMD probe 1388-L01036  Exon 69 
458 DMD probe 1718-L01286  Exon 10 
466 DMD probe 1390-L01038  Exon 50 
474 DMD probe 1391-L01039  Exon 30 
482 DMD probe 1392-L01040  Exon 70 
490 Reference probe 1692-L01531  Xq28  
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Table B.2 SALSA MLPA® PO35 - A2 DMD probe mix. 
 Length (nt) SALSA MLPA® probe 
                 Chromosomal position                 
reference                                          DMD 
64-70-76-82  Q-fragments: DNA quantity; only visible with less than 100 ng sample DNA 
88-92-96  D-fragments: Low signal of 88 or 96 nt fragment indicates incomplete denaturation 
100  X-fragment: Specific for the X chromosome 
105  Y-fragment: Specific for the Y chromosome 
130 Reference probe 1690-L00423 Xq11.2 
138 DMD probe 1393-L01041 Exon 11
146 DMD probe 1394-L01042  Exon 51
154 DMD probe 1395-L01371  Exon 31
162 DMD probe 1396-L01044  Exon 71
170 DMD probe 1397-L01608  Exon 12
178 DMD probe 2059-L01571  Exon 52
186 DMD probe 1399-L01609  Exon 32
194 DMD probe 1949-L01610  Exon 72
202 Reference probe 1691-L00465  Xp22 
210 DMD probe 1899-L01049  Exon 13
218 DMD probe 1892-L01050  Exon 53
226 DMD probe 1900-L01051  Exon 33
234 DMD probe 1893-L01052  Exon 73
242 DMD probe 1950-L01573  Exon 14
250 DMD probe 1894-L01054 Exon 54
258 DMD probe 1901-L01055  Exon 34
266 DMD probe 1902-L01611  Exon 74
274 Reference probe 1768-L01617  Xq28 
282 DMD probe 1410-L01057  Exon 15
290 DMD probe 1411-L01058  Exon 55
298 DMD probe 1412-L01059  Exon 35
306 DMD probe 1413-L01060  Exon 75
314 DMD probe 2060-L01572 Exon 16
322 DMD probe 1415-L01062  Exon 56
330 DMD probe 1416-L01063  Exon 36
338 DMD probe 1417-L01612  Exon 76
354 DMD probe 1952-L01065 Exon 17
362 DMD probe 1419-L01066  Exon 57
370 DMD probe 3038-L02508  Exon 37
378 DMD probe 1421-L01068  Exon 77
386 DMD probe 1891-L01069  Exon 18
394 DMD probe 1423-L01070  Exon 58
402 DMD probe 1896-L01071  Exon 38
410 DMD probe 1425-L01072  Exon 78
418 Reference probe 3766-L03227  Xq13 
426 DMD probe 1426-L01073  Exon 19
434 DMD probe 1427-L01074  Exon 59
442 DMD probe 1955-L01613  Exon 39
450 DMD probe 1429-L01076 Exon 79
458 DMD probe 1430-L01077  Exon 20
466 DMD probe 1431-L01614  Exon 60
474 DMD probe 1432-L01079  Exon 40
482 DMD probe 1433-L01080 Exon DP427C








MLPA®A probe  DMD exon 
Ligation site 
M18533  
Partial sequence   
(20 nt adjacent 




P034/P035            






ATGCTTTCAG  127.9 Kb  
138 *  1353-L01001  Exon 1  26-27  
CCCCCTACAG-
GACTCAGATC  191.3 Kb  
170 *  1357-L01005  Exon 2  266-267  
CAAAAGAAAA-
CATTCACAAA  170.4 Kb  
210 1361-L01009  Exon 3  335-336  
CTCTTCAGTG-
ACCTACAGGA  5.0 Kb  
242 1365-L01013  Exon 4  435-436  
CCCTGAACAA-
TGTCAACAAG  21.5 Kb  
282 1954-L01574  Exon 5  517-518  
AGATGGAAAT-
CATAAACTGA  6.7 Kb  
314 1373-L01021  Exon 6  618-619  
CCAACAGTGA-
AAAGATTCTC  7.0 Kb  
354 1713-L01281  Exon 7  765-766  
GGAATAGTGT-
GGTTTGCCAG  110.4 Kb  
386 1715-L01283  Exon 8  951-952  
TTGAAGCCAT-
CCAGGAAGTG  1.2 Kb  
426 1385-L01033  Exon 9  1066-1067  
ACAGGGATAT-
GAGAGAACTT  52.8 Kb  
458 1718-L01286  Exon 10  1195-1196  
AGACAAGTCA-
TTTGGCAGTT  0.8 Kb  
138 1393-L01041  Exon 11  1382-1383  
TTGACAGCCC-
ATCAGGGCCG  29.9 Kb  
170 1397-L01608  Exon 12  1647-1648  
AGCCTCTTGG-
ACCTGATCTT  18.5 Kb  
210 1899-L01049  Exon 13  1762-1763  
GGTAGTTGAT-
GAATCTAGTG  22.0 Kb  
242 1950-L01573  Exon 14  1836-1837  
GGGCAAACAT-
CTGTAGATGG  0.2 Kb  
282 1410-L01057  Exon 15  1937-1938  
TGGCTTTCAG-
AAAAAGAAGA  7.8 Kb  
314 2060-L01572  Exon 16  2059-2060  
GCAATCCATG-
GGCAAACTGT  20.6 Kb  
354 1952-L01065  Exon 17  2292-2293  
AACAGATCCT-
GGTAAAGCAT  27.2 Kb  
386 1891-L01069  Exon 18  2433-2434  
AAGCTGTGTT-
GCAGAGTCCT  16.3 Kb  
426 1426-L01073  Exon 19  2526-2527  
AAGCTGAGAA-
GTTCAGAAAA  10.4 Kb  
458 1430-L01077  Exon 20  2650-2651  
GTGGATCGAA-
TTCTGCCAGT  6.4 Kb  
154 1355-L01615  Exon 21  2916-2917  
AAGGACAAGG-
ACCCATGTTC  12.7 Kb  
186 1359-L01007  Exon 22  3051-3052  
AGGAGACCAT-
GAGTGCCATC  3.6 Kb  
226 1363-L01011  Exon 23  3200-3201  
GGCCTATACT-
ATCTCAGCAC  4.0 Kb  
258 1958-L01518  Exon 24  3441-3442  
GGCCTGCCCT-
TGGGGATTCA  1.1 Kb  
298 1371-L01019  Exon 25  3554-3555  
CAGAAGATAA-
AGAATGAAGC  8.8 Kb  
330 1375-L01023  Exon 26  3695-3696  
GTAAGCCTCC-
AGAAAGATCT  6.2 Kb  
370 1379-L01616  Exon 27  3871-3872  
TGAGTCTGTA-
AATAGTGTCA  7.3 Kb  
402 1716-L01284  Exon 28  4020-4021  
GGCATGAGTT-
ATTGTCATAC  3.0 Kb  
442 1387-L01035  Exon 29  4198-4199  
ACAGACCCTA-








probe  DMD exon 
Ligation site 
M18533  
Partial sequence    
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474 1391-L01039  Exon 30  4304-4305  
AAGTTGCTTG-
AACAGAGCAT  21.8 Kb  
154 1395-L01371  Exon 31  4519-4520  
GGAGGCTGCC-
CAAAGAGTCC  0.6 Kb  
186 1399-L01609  Exon 32  4674-4675  
CTGCATTGGA-
AACAAAGAGT  3.1 Kb  
226 1900-L01051  Exon 33  4766-4767  
TCTGAAGTGG-
AAATGGTGAT  5.8 Kb  
258 1901-L01055  Exon 34  4947-4948  
GAAAGGAAAT-
GAATGTCTTG  15.5 Kb  
298 1412-L01059  Exon 35  5098-5099  
CCTGAAGAGT-
ATCACAGAGG  0.5 Kb  
330 1416-L01063  Exon 36  5288-5289  
ATCACAAAGT-
GGATCATTCA  1.8 Kb  
370 *  3038-L02508  Exon 37  5498-5497 Rev. 
TGGCTGCAAA-
TCGATGGTTG  14.4 Kb  
402 1896-L01071  Exon 38  5613-5614  
CTGAAATTCA-
GCAGGGGGTG  2.4 Kb  
442 1955-L01613  Exon 39  5700-5701  
TGCAAAGAGG-
AGACAACTTA  2.8 Kb  
474 1432-L01079  Exon 40  5828-5829  
AAGGCTCTAG-
AAATTTCTCA  1.0 Kb  
146 1354-L01002  Exon 41  6019-6020  
GGGCTTGTCT-
GAGGATGGG  32.0 Kb  
178 1711-L01279  Exon 42  6159-6160  
CGATGATGGT-
GATGACTGAA  22.6 Kb  
218 1362-L01010  Exon 43  6403-6404  
ATTGCAAAGT-
GCAACGCCTG  70.6 Kb  
250 1366-L01014  Exon 44  6589-6590  
ACAGTTTCTC-
AGAAAGACAC  248.6 Kb  
290 1370-L01287  Exon 45  6745-6746  
AGATGCCAGT-
ATTCTACAGG  36.3 Kb  
322 1374-L01288  Exon 46  6913-6914  
CATTGCTAGT-
ATCCCACTTG  2.4 Kb  
362 1378-L01026  Exon 47  7017-7018  
TCAAACAATT-
AAATGAAACT  54.4 Kb  
394 1382-L01030  Exon 48  7225-7226  
GTTAAATCAT-
CTGCTGCTGT  38.5 Kb  
434 1717-L01285  Exon 49  7356-7357  
AAGAGATTTT-
GTCTAAAGGG  16.7 Kb  
466 1390-L01038  Exon 50  7455-7456  
TAAACCGTTT-
ACTTCAAGAG  46.0 Kb  
146 1394-L01042  Exon 51  7630-7631  
TCTGGCAGAT-
TTCAACCGGG  44.4 Kb  
178 *  2059-L01571  Exon 52  7837-7836 Rev. 
AGCCTCTTGA-
TTGCTGGTCT  50.2 Kb  
218 1892-L01050  Exon 53  7994-7995  
GAGCAGGTCT-
TAGGACAGGC  21.3 Kb  
250 1894-L01054  Exon 54  8116-8117  
GCAGACAAAT-
GTAGATGTGG  30.3 Kb  
290 1411-L01058  Exon 55  8276-8277  
ACTCATAGAT-
TACTGCAACA  120.5 Kb  
322 1415-L01062  Exon 56  8535-8536  
TCCTGTTACA-
AAGACGTTTG  10.5 Kb  
362 1419-L01066  Exon 57  8686-8687  
GAAAGATGAT-
GAATTAAGCC  17.8 Kb  
394 1423-L01070  Exon 58  8817-8818  
AGACTGTACG-
AATATTTCTG  0.8 Kb  
434 1427-L01074  Exon 59  9005-9006  
GATGAGACCC-








probe  DMD exon 
Ligation site 
M18533  
Partial sequence   
(20 nt adjacent 




466 1431-L01614  Exon 60  9175-9176  
GCCTCTGAAA-
GAGAACGTGA  96.0 Kb  
162 1356-L01004  Exon 61  9325-9326  
GCAGCTGCAT-
GAAGCCCAC  25.0 Kb  
194 1897-L01008  Exon 62  9394-9395  
TCCCTGGGAG-
AGAGCCATCT  62.6 Kb  
234 *  1364-L01012  Exon 63  9453-9454  
AAACAACTTG-
CTGGGACCAT  37.9 Kb  
266 *  1368-L01016  Exon 64  9547-9546 Rev.  
CTGCAGTCTT-
CGGAGTTTCA  13.4 Kb  
306 1372-L01020  Exon 65  9599-9600  
GCTGCATGTG-
ATGCCTTGGA  3.0 Kb  
338 1376-L01024  Exon 66  9806-9807  
CTGTCTTTTA-
AAACTGGCAT  2.6 Kb  
378 *  1960-L01520  Exon 67  9987-9986 Rev.  
ACACTTGGCT-
CAATGTTACT  21.1 Kb  
410 2482-L02710  Exon 68  10064-10065  
GACTGGATGA-
GACTGGAACC  2.4 Kb  
450 1388-L01036  Exon 69  10238-10239  
TTTTTTTCTG-
GTCGAGTTGC  1.7 Kb  
482 1392-L01040  Exon 70  10385-10386  
CCCCGAATGG-
GCTACCTGCC  0.8 Kb  
162 *  1396-L01044  Exon 71  10450-10451  
TCTGATCAAC-
TTCTGGCCAG  4.4 Kb  
194 1949-L01610  Exon 72  10493-10494  
CCTCAGCTTT-
CACACGATGA  1.2 Kb  




ATAAGATCCA  2.9 Kb  
266 1902-L01611  Exon 74  10693-10694  
CCAGATCTTG-
ATTTCCTTAG  22.1 Kb  
306 1413-L01060  Exon 75  10885-10886  
TGAGCTCATT-
GCTGAGGCCA  1.0 Kb  
338 1417-L01612  Exon 76  11063-11064  
ACCTCTCTAC-
AGAGGTCCGA  12.2 Kb  
378 1421-L01068  Exon 77  11164-11165  
CCAGGACACA-
AGCACAGGGT  7.5 Kb  
410 *  1425-L01072  Exon 78  11245-11246  
TGGAAAGCCA-
ATGAGAGAGG  4.8 Kb  
450 1429-L01076  Exon 79  11286-11287  
CCACATGGCA-
GATGATTTGG    
 
*These probes detect the reverse sequence or extend into an intron and are 
expected to give no signal with cDNA. The two exon 1 sequences are present in 
alternative transcripts and may also give a weak or no signal on cDNA (Kesari et al., 
2008).  
 
Tables of probe mixes were adapted from SALSA MLPA® KIT P034-A2 / P035-A2 
DMD / Becker (www.mlpa.com). The identity of the genes detected by the reference 





1. IMPORTANT CONSIDERATIONS FOR HR- MCA ASSAY DESIGN 
 
The HRM platform 
Successful HRM can only be achieved with specialized instrumentation capable of 
collecting data with exceptional real-time and thermo-optical precision. A cross-
platform comparison by Herrmann et al. (2006) effectively highlighted the limitations 
of conventional systems and the unique qualities required for accurate HRM 
analysis, particularly:  
 High intensity illumination 
 High sensitivity optical detection 
 A fast data acquisition rate 
 Exquisite sample temperature control 
 An absolute minimum of sample-to-sample thermal and optical variation 
The first instrument marketed for the sole purpose of exquisitely accurate HRM 
analysis, was the HR-1™ (Idaho Technology), which remains the performance 
benchmark (Reed, Kent, & Wittwer, 2007). However, the HR-1™ is not capable of 
thermal cycling and can only analyze a single sample per run from within a glass 
capillary, making data analysis time consuming. The multi-well LightScanner® (Idaho 
Technology) uses a modified block-based design but is also an HRM-only machine, 
not capable of thermal cycling. Subsequent technological advancements have 
resulted in introduction of machines with real-time cycling as well as HRM capability 
i.e. LightCycler®480 (Roche, Germany) and the RotorGene™6000 (Corbett Life 
Science, Australia) (Figure C.1). A major advantage of this is that the amplification 
efficiency can be monitored in real time, with the initial PCR cycling followed by 
HRM in a closed-tube system, without the need for post-PCR manipulation. In 
addition, the methods used to normalize and display HRM data for intuitive manual 
analysis or automated genotyping are specific and continue to improve.  
 
The Rotor-Gene™6000, used in this study, stands apart from other analysers by 
virtue of its unique centrifugal format. Every tube spins quickly in a chamber of 
moving air. This is especially suitable for HRM, as there is virtually no positional 
temperature variation such as the recognized “edge effect” observed in block-based 
instruments. Optically, the Rotor-Gene™6000 is similarly uniform, because every 
tube moves past identical excitation and detection points (Herrmann et al., 2007; 
White & Potts, 2006). As a result, the Rotor-Gene™000 HRM performance closely 
matches the HR-1™ benchmark.  
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The RotorGene™6000, fulfils the criteria for reliable HRM analysis, with a melting 
rate which can be adjusted manually to the lowest level of the above mentioned 
instruments (0.05°C/sec), and a default of 0.1°C increments with a 2 second hold at 
each step. The Rotor-Gene™6000 has a wide optical range, with 6 channels 
spanning UV to infra-red wavelengths (www.corbettlifescience.com). It offers the 
benefits of real-time PCR along with its HRM capability, successfully tested in a 
number of applications, including:    
 Gene expression analysis 
 Pathogen detection 
 DNA methylation analysis 
 Genotyping 
 Mutation scanning 
 SNP analysis 
 High Resolution Melting Analysis 
 
In an evaluation report by Helen White and Gemma Potts of NGRL, the overall HRM 
sensitivity and specificity of the RotorGene™6000 was found to be 100% and 95% 
respectively, as compared to HR1™ (Idaho Technology) at 98% and 95%, and the 
384-well LightScanner® (Idaho Technology) at 99% and 88% (White & Potts, 2006). 
Other instrumentation with real-time and HRM capabilities have since been 
marketed, but at this time, those mentioned above are most often mentioned in the 









Choice of a dsDNA intercalating dye 
The advancements in intercalating dye technology since Higuchi first demonstrated 
the use of ethidium bromide in qPCR (Higuchi et al., 1993), along with 
instrumentation that allows highly controlled temperature transitions and acquisition, 
have played a major role in the emergence of HRM methodology. Different base 
substitutions produce slight differences in melting behaviour, the resolution of which 
requires an appropriate intercalating dye. SYBR Green® is the most widely used 
intercalating dye for monitoring real-time PCR, but is generally regarded unsuitable 
for use in hrMCA due to its strong tendency to inhibit PCR and promote mispriming 
at high (saturating) concentrations. According to the proposed “dye saturation 
hypothesis” (Wittwer et at., 2003; Liew et al., 2004), SYBR Green dissociates from 
dsDNA during melting, and dynamically re-intercalates into the neighbouring 
duplexes that melt at higher temperatures (Figure C.2), potentially masking small 
differences in melting behaviour, which could then go undetected. Low dye 
concentrations on the other hand, (e.g. < 0.5 μM) can compromise PCR signal 
strength, and the dye redistribution possibly results in an unreliable DNA melt curve. 
“Saturating dyes” are thus defined as those that can be used at concentrations 
sufficiently high to saturate all DNA binding sites without inhibiting the PCR, thereby 
achieving a greater melting curve resolution (Wittwer et al 2003, Liew et al 2004). 
New generation dyes such as LC Green®, LC Green®PLUS, SYTO 9®, BEBO, 
CHROMOFY® and Eva Green™, show minimal PCR toxicity at high levels and allow 











Figure C.2 The dye re-distribution theory and the 2nd and 3rd generation dsDNA   
intercalating dyes (Cor-Protocol-6000-1-July06).  
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The dye redistribution theory however, has been contested, as evidence for this 
theory was collected by a pre-HRM era LightCycler® (Roche Molecular Systems) 
using templates which included a low mass DNA size ladder (Wittwer et al., 2003; 
Liew et al., 2004). According to Corbett Research, saturation levels of SYBR Green® 
are not required when using the Rotor-Gene™6000. The experimental data shows 
good HRM results and the authors encourage users not to dismiss SYBR Green® as 
a dye for HRM, provided that access to an appropriate instrument is available. 
Corbett Research do however concede that while saturating dye levels appear 
unnecessary for HRM on the Rotor-Gene™6000 (when apparently required on other 
instrument systems), the reason for this is not clear. They suggest that the 
explanation may lie in the centrifugal rotary format of the instrument, as that is what 
sets it apart from other HRM machines.   
The dsDNA intercalating utalised in this project, EvaGreen™ (Biotum), is included in 
the HRM Sensimix kit, optimised by Quantace specifically for use on the 
RotorGene™6000. EvaGeen is a green fluorescent nucleic acid dye useful in qPCR, 
hrMCA, real-time monitoring of thermophilic helicase-dependent amplification 
(tHDA), routine solution DNA quantification and capillary gel electrophoresis. It is 
also compatible with multiplex PCR, as no dye migration from amplicon to amplicon 
takes place when used at the recommended concentration. EvaGreen™ is 
essentially nonfluorescent by itself, but becomes highly fluorescent upon binding to 
dsDNA. Once bound, it has excitation and emission spectra similar to fluorescein 
(FAM) or SYBR Green® 1 and is therefore readily compatible with instruments 
equipped with the 488 nm argon laser or any visible light excitation filter with a 
wavelength in that region. It is thus compatible with all major brand qPCR 
instruments and enzyme systems.  The extreme thermal, hydrolytic and photo-
stability of EvaGreen™ provides convenience during routine handling, as the dye 
can withstand repeated cycles of freezing and thawing, does not decompose in PCR 
buffer at 95-100°C for 48 hours and is highly stable under either alkaline or acidic 
condition. Compared with SYBR Green®, EvaGreen™ is generally less inhibitory 
toward PCR and less likely to cause non-specific amplification. Unlike SYBR 
Green®, which enters cells rapidly and is known to be a powerful mutation-enhancer, 
EvaGreen™ is nonmutagenic and noncytotoxic by being completely impermeable to 
cell membranes (Ohta et al., 2001; Mao et al., 2007; White et al., 2007).  Regardless 
of the validity of the dye redistribution theory, EvaGreen can be used at a much 




PCR design and optimisation 
Besides the availability of an appropriate HRM platform and choice of a dsDNA 
intercalating dye, the success of any hrMCA assay is highly dependant on the 
design and optimisation of the pre-HRM PCR reaction, as the presence of non-
specific products and primer dimmers significantly reduces HRM performance. Use 
of a real-time thermocycler is recommended, particularly when optimizing or 
troubleshooting an assay, as information on amplicon quality can be monitored in 
real time. 
 
Primer design  
The PCR product should not include sequence variations other than the one 
investigated e.g. polymorphic regions, as their presence will alter the melting curve. 
Also, secondary structure formation of the primers and the amplicon will affect the 
amplification efficiency and should be avoided. Optimal primer design and checking 
for formation of secondary structures can be achieved with software such as 
Primer3 and the DINAmelt Servers from the Rensselaer Polytechnic Institute, 
respectively (Markham & Zuker, 2005). HR-MCA of polymorphic regions however, 
has been successfully performed but involves inclusion of known, genotype-specific 
controls (White & Potts, 2006). PCR reaction optimisation for HRM, may require a 
significant increase in the annealing temperatures (2C – 10C), because of the 
presence of dsDNA intercalating dye. 
 
MgCl2 concentration 
The amount of MgCl2 has a strong effect on the melting behaviour of dsDNA and 
should be optimized carefully. Generally, a higher concentration of MgCl2 is needed 
in a PCR for HR-MCA, which includes a dsDNA intercalating dye, as opposed to an 
ordinary PCR, where no dye is present. The general guidelines also indicate that the 
required MgCl2 concentration varies according to the specific dye chosen e.g. 1.5 
mM MgCl2 with SYTO
® 9, or 3 mM MgCl2 with LCGreen
® or EvaGreen™ 
(www.corbettlifescience.com)  
 
PCR reagents  
It is recommended to use PCR reagents validated or optimized for HRM analysis, 
when available, although this may be more expensive. Hot start enzymes, generally 
included in HRM mixes such as the AmpliTaq Gold 360 Master Mix (Applied 
Biosysems, USA) or the HRM Sensimix (Quantace), are also recommended, as they 
increase primer specificity. 
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2. FACTORS AFFECTING THE MELTING CURVE AND RELIABILITY OF hrMCA 
 
DNA and amplicon quality/quantity  
The effect of DNA quality on an HRM assay was clearly demonstrated in an 
experiment by White et al. (2003), where amplifiability of DNA samples of variable 
quality was assessed by using a multiplexed control gene primer set which amplifies 
products of 100, 200, 300, 400 and 600bp with equal intensity. Loss of the higher 
molecular weight products was seen as an indicator of poor DNA quality. It was 
shown that samples in which products of 200bp or less were amplified, gave false 
positive results when analysed by HRM.  
 
The use of spectral analysis for determining DNA concentration and purity is 
recommended, as the amount of starting template should be similar between 
samples in a run, since it affects the amount of generated PCR product. At 260 nm 
one absorbance unit is equal to 50 μg/mL of DNA and pure DNA will provide a 260 
nm to 280 nm ratio of 2. The amplicon concentration in turn, affects its melting 
temperature(TM) and the outcome of HRM analysis. The threshold cycle (CT) of an 
efficient amplification plot, should not exceed 30 cycles, as amplification log phase 
starting beyond that point, is typically due to insufficient amount of starting template 
or presence of degradation effects. Allowing every reaction to amplify to the plateau 
phase is important, as a similar extent of amplification for all tests should be 
achieved irrespective of their starting amount. However, poor reaction might result in 
a plateau with a different quantity of product, due to factors such as inconsistent 
assay set-up (e.g. insufficient amount of primer).  
 
Monitoring of the amplification curve in real time is a valuable trouble-shooting tool 
in hrMCA, as problems and inconsistencies involving the quality and quantity of 
DNA, the amplicon and the reaction set up can be readily identified. They manifest 
as late amplification, curves with log-linear phase that is not steep, is jagged, or 
reaches a low signal plateau as compared to other reactions in the run. HRM data 
from such samples can be inconclusive and should be excluded from analysis.  
 
Amplicon size 
Differentiation of variant melting curves is best achieved in smaller PCR fragments 
(~100bp). HrMCA analysis of products larger than 300bp can be analyzed 
successfully but usually with lower resolution. This is simply because a single base 
variation affects the melting behavior of a 100 bp amplicon more than a 500 bp 
amplicon and will therefore be easier to detect (www.corbettlifescience.com). Large 
amplicons are also more likely to have complex melting curves with two or more 
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melting domains, complicating the analysis and making it less reliable. Ideally, a 
PCR fragment should have a single melting domain, otherwise each domain must 
be analysed separately, by manual adjustment of the normalisation regions. Optimal 
amplicon design and subsequent optimisation are therefore crucial to the success of 
HRM. For this reason a number of exons in the DMD gene were split into two or 
more fragments i.e. exons 23, 48, 53, 61, 67, 68, 76 and 79 thus creating 96 sets of 
PCR primers to amplify 79 exons of the DMD gene.  
 
Primer dimers  
Like other non-specific products, presence of primer-dimmers may affect the melting 
curve characteristics and therefore primer concentration should generally not 
exceed 300nM. 
 
Effect of mutation type or the surrounding sequence context 
The position of a mutation within a PCR fragment per se, does not appear to have a 
significant effect on HRM-based mutation detection. However, an experiment carried 
out as part of a cross HRM platform comparison by White et al. (2006) showed that 
certain mutations, such as the 110A>G and 588delA mutations in exons 1 and 7 
respectively, are intrinsically difficult to detect by HRM, possibly because they are 
sited in regions which, when melted, produce only subtle overall changes in 
fluorescent intensity. Interestingly, it was shown that differences in data handling 
between the compared platforms (HR-1™, Light Scanner™ and RotorGene™6000), 
also affect variant detection efficiency of some mutations. Specifically, 1459 C>T, 
1451 delA and 1409+14G>A sequence variants in exon13, appear to alter the 
melting temperature rather than the overall shape of the melting curve. Data from 
the HR-1 ™ and Light Scanner™ is first normalised and then temperature shifted. 
When the data are temperature shifted these curves become superimposed on the 
wild type samples, making detection difficult. Data from the RotorGene™6000 is 
normalized, but not temperature shifted, and therefore such mutations can be more 
easily detected as the melt curves do not become overlaid on the wild type curve 
(White & Potts, 2006). 
 
Homo- and hemizygous changes appear to have similar effect on the melting 
dynamic of the DNA fragment i.e. they appear to alter the temperature at which the 
amplicon melts rather than the shape of the melt curve (Kwok et al., 2007; Yan et 
al., 2010). Temperature-shifting for data analysis, causes the curves of homozygous 
samples to become superimposed on the wild type masking the change. As 
mentioned above, this effect does not take place during analysis with the 
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RotorGene™6000, as the data is normalized but not temperature shifted and 
homozygous mutations are readily detected.  
 
Sample-to-sample uniformity 
Consistency in reaction setup and reagent use is critical to the success hrMCA. 
Reaction volume and the amount of dye in each tube must be the same. Similarly, 
identical reaction tubes from the same manufacturer should be used to avoid 
variations in plastic thickness and autofluorescence properties. DNA melting 
behavior is affected by salts in the reaction mix, so concentration of buffers, MgCl2 
and other salts should be kept uniform in all samples. The various available DNA 
extraction methods utalise different chemistries and elution buffers, which may affect 
the DNA melting behavior. It is therefore best to compare samples extracted with the 
same method, which is an important consideration when attempting analysis of 
archival samples or samples from other laboratories.  
 
Temperature range during melting   
HRM data points over a window of approximately 10°C (or greater), should be 
captured, centered around the observed TM of the fragment under analysis This 
provides enough baseline data points for effective curve normalization and will result 
in tight replicates and easier data interpretation.  
 
Regions of normalisation 
The data analysis software on the RotorGene™6000 allows for both visual and 
auto-calling of genotypes. Two normalization regions are used to normalize 
fluorescencece (Y axis), represented by vertical cursors placed pre-melt (region 1) 
and post-melt (region 2) phases (Figure C.3).  
 
Figure C.3 Adjustable normalisation regions.  
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The cursors are placed at default positions, which can be manually adjusted. 
Shifting the cursors can alter the appearance of a normalised curve and cause 
differences in both qualitative manual calling and automated mutation calling. 
Therefore, in a diagnostic setting, criteria for positioning the cursors for different 
amplicons should be incorporated into standard operating procedures to ensure 
minimal data analysis variability between operators. Corbett Research recommend 
that these default settings be changed only to avoid certain parts of the curve, such 
as when analysing complicated curves with multiple melting domains. In such 
instances, the pre-melt region 1 should be set at a point where all samples in a run 
show uniform melting (seen as parallel lines), and the post-melt region 2 should be 
set after complete melting of all samples, so that the normalisation range should 
stretch across approximately 10°C.      
 
The four classes of base changes  
Detection of a single base alteration, as the smallest genetic change underlies the 
sensitivity of an HRM analysis. Single Nucleotide Polymorphisms (SNPs) often used 
for genotyping have been divided into 4 classes according to their rarity and difficulty 
in detection. As presented in Table C.1 below, the A:T to G:C interchange, which is 
the most common single base variation in the human genome also results in the 
greatest difference in Tm (>0.5), which is readily detected. Other base changes give 
rise to smaller differences in Tm, resulting in lower specificity that depends on the 
exact base change and also on the surrounding sequence.    
 
Table C.1 Classification of SNPs (Venter et al., 2001). 
SNP Class Base Change Typical TM Melt Curve Shift 
Rarity 
(in the human genome) 
1 C/T and G/A 64% 
2 C/A and G/T 30% 










        3. PRIMER SEQUENCES   
 
        Table C.2 HRM and sequencing primers  






EX01-F TGTAAAACGACGGCCAGTGCAGGTCCTGGAATTTGA                                             405 61Cº 
 
EX01-R CAGGAAACAGCTATGACCCAAACTAAACGTTATGCCACA                                           
 
EX02-F TGTAAAACGACGGCCAGTCACTAACACATCATAATGG                                            269 61Cº 
 
EX02-R CAGGAAACAGCTATGACCGATACACAGGTACATAGTC                                               
 
EX03 A-F TGTAAAACGACGGCCAGTTCATCCGTCATCTTCGGCAGATTAA                             176 61Cº 
 
EX03 A-R CAGGAAACAGCTATGACCCAGGCGGTAGAGTATGCCAAATGAAAATCA                   
 
EX03B-F TCTTCAGTGACCTACAGGATGG 184 64Cº 
 
EX03B-R CGCCCGCCGtgctgtttcaatcagtacctagtca     
 
EX04-F TGTAAAACGACGGCCAGTTTGTCGGTCTCTCTGCTGGTCAGTG                          233 60Cº 
 
EX04-R CAGGAAACAGCTATGACCCCAAAGCCCTCACTCAAAC                                               
 
EX05-F TGTAAAACGACGGCCAGTCAACTAGGCATTTGGTCTC                                           261 61Cº 
 
EX05-R CAGGAAACAGCTATGACCTTGTTTCACACGTCAAGGG                                               
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        Table C.2 HRM and sequencing primers cont.   
 
EX06-F TGTAAAACGACGGCCAGTTGGTTCTTGCTCAAGGAATG                                         335 61Cº 
 
EX06-R CAGGAAACAGCTATGACCTGGGGAAAAATATGTCATCAG                                          
 
EX07-F TGTAAAACGACGGCCAGTCTATGGGCATTGGTTGTC                                            296 60Cº 
 
EX07-R CAGGAAACAGCTATGACCAAAAGCAGTGGTAGTCCAG                                              
 
EX08-F TGTAAAACGACGGCCAGTTCGTCTTCCTTTAACTTTG                                             343 61Cº 
 
EX08-R CAGGAAACAGCTATGACCTCTTGAATAGTAGCTGTCC                                                
 
EX09-F TGTAAAACGACGGCCAGTTCTATCCACTCCCCCAAACC                                         318 61Cº 
 
EX09-R CAGGAAACAGCTATGACCAACAAACCAGCTCTTCAC     
 
EX10-F CGACGTTGTAAAACGACGGCCAGTGGAACAATCTGCAAAGAC                              350 61Cº 
 
EX10-R CAGGAAACAGCTATGACCAAAGGATGACTTGCCATTATAAC                                      
 
EX11-F TGTAAAACGACGGCCAGTCAAATAAAACTCAAAACCACACC                                  337 61Cº 
 
EX11-R CAGGAAACAGCTATGACCCTTCCAAAACTTGTTAGTCTTC                                         
 
EX12-F TGTAAAACGACGGCCAGTCTTTCAAAGAGGTCATAATAGG                                   305 61Cº 
 
EX12-R CAGGAAACAGCTATGACCCATCTGTGTTACTGTGTATAGG                                        
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          Table C.2 HRM and sequencing primers cont.   
 
EX13-F TGTAAAACGACGGCCAGTGCAAATCATTTCAACACAC                                            387 60Cº 
 
EX13-R CAGGAAACAGCTATGACCTCTTTAAATCACAGCACTTC                                              
 
EX14-15-F TGTAAAACGACGGCCAGTTGGCAAATTATTCATGCCATT                                       548 63Cº 
 
EX14-15-R CAGGAAACAGCTATGACCTGATCCAAGCAAAAATAAACATT                                      
 
EX16-F TGTAAAACGACGGCCAGTATGCAACCCAGGCTTATTC                                           286 61Cº 
 
EX16-R CAGGAAACAGCTATGACCCTGTAGCATGATAATTGGTATCAC                                   
 
EX17-F TGTAAAACGACGGCCAGTTTTTCCTTTGCCACTCCAAG                                          362 61Cº 
 
DEX17-R CAGGAAACAGCTATGACCCACCACCAACAAAACTGCTG                                           
 
EX18-F CGACGTTGTAAAACGACGGCCAGTTGTCAGGCAGGAGTCTCAGAT 339 63Cº 
 
EX18-R CAGGAAACAGCTATGACCCGGAGTTTACAAGCAGCACA                                           
 
EX19-F TGTAAAACGACGGCCAGT gattcacgtgataagctgacaga   286 63Cº 
 
EX19-R CAGGAAACAGCTATGACCCGCCCGCCGCGCttcagctgataaatatgaacctatgtg     
 
EX20-F TGTAAAACGACGGCCAGTTGGCTTTCAGATCATTTCTTTC                                     393 61Cº 
 
EX20-R CAGGAAACAGCTATGACCAAATACCTATTGATTATGCTCC                                       
     
     
 
 140 
        Table C.2 HRM and sequencing primers cont. 
 
EX21-F TGTAAAACGACGGCCAGTGCAAAATGTAATGTATGCAAAG                                    355 63Cº 
 
EX21-R CAGGAAACAGCTATGACCATGTTAGTACCTTCTGGATTTC                                       
 
EX22-F TGTAAAACGACGGCCAGTAGGAAAACATGGCAAAGTGTG                                     370 63Cº 
 
EX22-R CAGGAAACAGCTATGACCTGCTCAATGGGCAAACTACC                                           
 
EX23 A-F TGTAAAACGACGGCCAGTACTCATCAATTATTATTCATCAATTAGGGT 126 61Cº 
 
EX23 A-R CAGGAAACAGCTATGACCCATCTCTTTCACAGTGGTGC     
 
EX23 B-F TGTAAAACGACGGCCAGTAGCAACAAAGTGGCCTATAC  135 61Cº 
 
EX23 B-F CAGGAAACAGCTATGACCGCTGGGAGGAGAGCTTC     
 
EX23 C-F TGTAAAACGACGGCCAGTTTGAAGAAATTGAGGGACGC  175 61Cº 
 
EX23C-R CAGGAAACAGCTATGACCCTTTACAGTTTACAGTGTATCGTTAGG     
 
EX24-F TGTAAAACGACGGCCAGTTTGGGCCTGTGTTTAGACATA                                      327 63Cº 
 
EX24-R CAGGAAACAGCTATGACCAAATCCACCCCAGCTGTAAAA                                         
 
EX25-F TGTAAAACGACGGCCAGTTGTGGCAGTAATTTTTTTCAG                                       296 61Cº 
 
EX25-R CAGGAAACAGCTATGACCAGGAAATCTTAGTTAAGTACG                                          




         Table C.2 HRM and sequencing primers cont.  
 
EX26-F TGTAAAACGACGGCCAGTTGAGTGTATCTGATCCCCATGA  438 61Cº 
 
EX26-R CAGGAAACAGCTATGACCTGTTGCATTTCTTTCTTTTTC                                            
 
EX27-F TGTAAAACGACGGCCAGTTGGGATGTTGTGAGAAAGAA                                        365 63Cº 
 
EX27-R CAGGAAACAGCTATGACCTGACCATGTATTGACATATCATTGA                                 
 
EX28-F TGTAAAACGACGGCCAGTGAAGTTTTAATAATGAAATGGCAAAA 311 61Cº 
 
EX28-R CAGGAAACAGCTATGACCTGACCTCTTTTAATACTGCATAT    
 
EX29-F TGTAAAACGACGGCCAGTCCAATGTATTTAGAAAAAAAAGGAG                             279 63Cº 
 
EX29-R CAGGAAACAGCTATGACCGCAAATTAGATTAAAGAGATTTTTCAC    
 
EX30-F TGTAAAACGACGGCCAGTTACAGAAAAGCTATCAAGAG                                         297 61Cº 
 
EX30-R CAGGAAACAGCTATGACCAAAAACAAAAGAATGGAAGC                                           
 
EX31-F TGTAAAACGACGGCCAGTATGGTAGAGGTGGTTGAGGA                                       296 61Cº 
 
EX31-R CAGGAAACAGCTATGACCTATAATGCCCAACGAAAACA                                            
 
EX32-F TGTAAAACGACGGCCAGTCAGTTATTGTTTGAAAGGCAAA                                    322 61Cº 
 
EX32-R CAGGAAACAGCTATGACCCTTCTTAATGAGGAAAGTCAAGG                                    




         Table C.2 HRM and sequencing primers cont.   
 
EX33-F CGACGTTGTAAAACGACGGCCAGTTGGAATAGCAATTAAGGG 393 60Cº 
 
EX33-R CAGGAAACAGCTATGACCGCTAAGACTCTAATCATAC                                              
 
EX34-F TGTAAAACGACGGCCAGTCAGAAATATAAAAGTTCCAAATAAGTG 374 61Cº 
 
EX34-R CAGGAAACAGCTATGACCCATGTTAATACTTCCTTACAAAATC                                 
 
EX35-F TGTAAAACGACGGCCAGTCCGTTTCATAAGCATTAAATC                                       307 61Cº 
 
EX35-R CAGGAAACAGCTATGACCAGCTTCTAGCCTTTTCTC                                                  
 
EX36-F CGACGTTGTAAAACGACGGCCAGTTGTCTAACCAATAATGCCATG                       257 64Cº 
 
EX36-R CAGGAAACAGCTATGACCCTGGTGTACAATTTGGACA                                              
 
EX37-F CGACGTTGTAAAACGACGGCCAGTCTTTCTCACTCTTCTCGCTCAC                     377 61Cº 
 
EX37-R CAGGAAACAGCTATGACCTTCGCAAGAGACCATTTAGCAC                                       
 
EX38-F TGTAAAACGACGGCCAGTTTTAGCAACAGGAGGTTGAA                                       267 64Cº 
 
EX38-R CAGGAAACAGCTATGACCTTCTTTCCAAATATTTATTTCCACT                                   
 
EX39-F TGTAAAACGACGGCCAGTCTCTGTTAACAATGTACAGCTTTTT  365 64Cº 
 
EX39-R CAGGAAACAGCTATGACCAAAAACCACAGGCAAGGTAT     
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        Table C.2 HRM and sequencing primers cont. 
 
EX40-F TGTAAAACGACGGCCAGTTACAAAAAGATGAGGGAC                                             387 61Cº 
 
EX40-R CAGGAAACAGCTATGACCAATAGAAACAAGAACATCAAC    
 
EX41-F TGTAAAACGACGGCCAGTGTTAGCTAACTGCCCTGGGCCCTGTATTG                  311 61Cº 
 
EX41-R CAGGAAACAGCTATGACCTAGAGTAGTAGTTGCAAACACATACGTGG                     
 
EX42-F TGTAAAACGACGGCCAGTATGGAGGAGGTTTCACTGTT                                        408 61Cº 
 
EX42-R CAGGAAACAGCTATGACCCCATGTGAAAGTCAAAATGC                                            
 
EX43-F TGTAAAACGACGGCCAGTTTTCTATAGACAGCTAATTCATTTTT                             287 63Cº 
 
EX43-R CAGGAAACAGCTATGACCACAGTTCCCTGAAAACAAATC     
 
EX44-F TGTAAAACGACGGCCAGTGTTACTTGAAACTAAACTCTGCAAATG                       444 61Cº 
 
EX44-R CAGGAAACAGCTATGACCACAACAACAGTCAAAAGTAATTTCCATC                         
 
EX45-F TGTAAAACGACGGCCAGTTTCTTTGCCAGTACAACTGC 357 61Cº 
 
EX45-R CAGGAAACAGCTATGACCTCTGCTAAAATGTTTTCATTCC                                         
 
EX46-F TGTAAAACGACGGCCAGTCCAGTTTGCATTAACAAATAGTTTGAG                        409 64Cº 
 
EX46-R CAGGAAACAGCTATGACCAGGGTTAAGAAGAAATAAAGTTGTGAG                         
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         Table C.2 HRM and sequencing primers cont.   
 
EX47-F TGTAAAACGACGGCCAGTTGATAGACTAATCAATAGAAGCAAAGAC 399 61Cº 
 
EX47-R CAGGAAACAGCTATGACCAACAAAACAAAACAACAATCCACATACC                         
 
EX48 A-F TGTAAAACGACGGCCAGTTTTGGCTTATGCCTTGAGAAT  175 61Cº 
 
EX48 A-R CAGGAAACAGCTATGACCATAACCACAGCAGCAGATG     
 
EX48 B-F TGTAAAACGACGGCCAGTGCTTGAAGACCTTGAAGAGC  185 61Cº 
 
EX48 B-R CAGGAAACAGCTATGACCAAATGAGAAAATTCAGTGATATTGCC     
 
EX49-F TGTAAAACGACGGCCAGTGTGCCCTTATGTACCAGGCAGAAATTG                       475 61Cº 
 
EX49-R CAGGAAACAGCTATGACCGCAATGACTCGTTAATAGCCTTAAGATC                        
 
EX50-F TGTAAAACGACGGCCAGTCACCAAATGGATTAAGATGTTCATGAAT                      307 64Cº 
 
EX50-R CAGGAAACAGCTATGACCTCTCTCTCACCCAGTCATCACTTCATAG    
 
EX51-F TGTAAAACGACGGCCAGTGAAATTGGCTCTTTAGCTTGTGTTTC                           424 64Cº 
 
EX51-R CAGGAAACAGCTATGACCGGAGAGTAAAGTGATTGGTGGAAAATC                         
 
EX52-F TGTAAAACGACGGCCAGTGTGTTTTGGCTGGTCTCACA 298 63Cº 
 
EX52-R CAGGAAACAGCTATGACCCATGCATCTTGCTTTGTGTGT                                          
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         Table C.2 HRM and sequencing primers cont.  
 
EX53 A-F TGTAAAACGACGGCCAGTAAGAATCCTGTTGTTCATCATCCTAGC  252 64Cº 
 
EX53 A-R CAGGAAACAGCTATGACCCCAGCCATTGTGTTGAATCCTTTAAC      
 
EX53 B-F TGTAAAACGACGGCCAGTAGTACAAGAACACCTTCAGAACCG    278 64Cº 
 
EX53 B-R CAGGAAACAGCTATGACCACTTTACATTAAACATCATTAAATTACAATCTATGG     
 
EX54-F CGACGTTGTAAAACGACGGCCAGTGTATTCTGACCTGAGGATTC                         378 61Cº 
 
EX54-R CAGGAAACAGCTATGACCCATGGTCCATCCAGTTTC                                                 
 
EX55-F TGTAAAACGACGGCCAGTAATTTAGTTCCTCCATCTTTCTCT                                 445 61Cº 
 
EX55-R CAGGAAACAGCTATGACCAAATACATCAGGCTGTATAAAAGC                                  
 
EX56-F TGTAAAACGACGGCCAGTATTCTGCACATATTCTTCTTCCTGC                              353 63Cº 
 
EX56-R CAGGAAACAGCTATGACCGGATGATTTACGTAGACATGTGAG                                 
 
EX57-F TGTAAAACGACGGCCAGTCAATGGAATTGTTAGAATCATCA                                  320 63Cº 
 
EX57-R CAGGAAACAGCTATGACCCACTGGATTACTATGTGCTTAACAT                                
 
EX58-F TGTAAAACGACGGCCAGTTTTTGAGAAGAATGCCACAAGCC                                315 63Cº 
 
EX58-R CAGGAAACAGCTATGACCAAAATATGAGAGCTATCCAGACCC                                  
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        Table C.2 HRM and sequencing primers cont.   
 
EX59-F TGTAAAACGACGGCCAGTAAAGAATGTGGCCTAAAACC                                        433 64Cº 
 
EX59-R CAGGAAACAGCTATGACCTTGTGGGAAGATAACACTGC                                           
 
EX60-F TGTAAAACGACGGCCAGTTAAATATTCTCATCTTCCAATTTGC                               267 63Cº 
 
EX60-R CAGGAAACAGCTATGACCTTACTGTAACAAAGGACAACAATG                                  
 
EX61A-F TGTAAAACGACGGCCAGTCGCCCGCCGCttgctttagtgttctcagtcttgg  169 63Cº 
 
EX61A-R CAGGAAACAGCTATGACCAAAGTCCCTGTGGGCTTCAT                                      
 
EX61B-F TGTAAAACGACGGCCAGTCGTCGAGGACCGAGTCAG  210 63Cº 
 
EX61B-R CAGGAAACAGCTATGACCCGCCCGCCGCcaggatgatttatgcttctactgc                             
 
EX62-F TGTAAAACGACGGCCAGTTAATGTTGTCTTTCCTGTTTGCG 221 63Cº 
 
EX62-R CAGGAAACAGCTATGACCATACAGGTTAGTCACAATAAATGC                                  
 
EX63-F TGTAAAACGACGGCCAGTTACTCATTGTAAATGCTAAAGTC                                   229 63Cº 
 
EX63-R CAGGAAACAGCTATGACCTAGCAAGTAACTTTCACACTGC                                      
 
EX64-F TGTAAAACGACGGCCAGTTTCTGATGGAATAACAAATGCT 322 61Cº 
 
EX64-R CAGGAAACAGCTATGACCCATTCTAGGCAAACTCTAGGC    
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        Table C.2 HRM and sequencing primers cont.   
 
EX65-F TGTAAAACGACGGCCAGTagtgtggttcacgtttggt  386 64Cº 
 
EX65-R CAGGAAACAGCTATGACCtgtacgctaagcctcctgtg     
 
EX66-F TGTAAAACGACGGCCAGTGTCAGTAATTGTTTTCTGCTTTG                                   246 61Cº 
 
EX66-R CAGGAAACAGCTATGACCATAAGAACAGTCTGTCATTTCCC                                    
 
EX67 A-F TGTAAAACGACGGCCAGTTCAGGTTCTGCTGGCATC  172 60Cº 
 
EX67 A-R CAGGAAACAGCTATGACCTGCAACTTCACCCAACTGTC     
 
EX67 B-F TGTAAAACGACGGCCAGTGCCTCCTTCTGCATGATT  187 61Cº 
 
EX67 B-R CAGGAAACAGCTATGACCAGAAAACGAAGCTCTGTGG     
 
EX68 A-F TGTAAAACGACGGCCAGTCGCCCGCCcagcctagctttgcaaccat  249 61Cº 
 
EX68 A-R CAGGAAACAGCTATGACCACTGGGGTTCCAGTCTCATC     
 
EX68 B-F TGTAAAACGACGGCCAGTAGCGGCCCTCTTCCTAGACT  236 61Cº 
 
EX68 B-R CAGGAAACAGCTATGACCCGCCCGC taacagcaactggcacagga     
 
EX69-F TGTAAAACGACGGCCAGTGAACGTGGTAGAAGGTTTATTAAA                               267 61Cº 
 
EX69-R CAGGAAACAGCTATGACCCTAACTCTCACGTCAGGCTG                                           
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         Table C.2 HRM and sequencing primers cont. 
 
EX70-F TGTAAAACGACGGCCAGTTGGTCATTAGTTTTGAAATCATC                                   273 63Cº 
 
EX70-R CAGGAAACAGCTATGACCCATCAAACAAGAGTGTGTTCTG                                       
 
EX71-F TGTAAAACGACGGCCAGTGGCTGAGTTTGCGTGTGTCT                                       174 61Cº 
 
EX71-R CAGGAAACAGCTATGACCGAGCGAATGTGTTGGTGGTA                                           
 
EX72-F TGTAAAACGACGGCCAGTAAGCATTCTAGGCCATGTGT  261 61Cº 
 
EX72-R CAGGAAACAGCTATGACCGGTTAGCTTTCCTTGGTTAGTT     
 
EX73-F TGTAAAACGACGGCCAGTACGTCACATAAGTTTTAATGAGC                                  238 63Cº 
 
EX73-R CAGGAAACAGCTATGACCATGCTAATTCCTATATCCTGTGC                                     
 
EX74-F TGTAAAACGACGGCCAGTATAAGGGGGGGAAAAAAC                                            290 63Cº 
 
EX74-R CAGGAAACAGCTATGACCTGCAAGTGTATGCACTCTG                                              
 
EX75-F TGTAAAACGACGGCCAGTTCTTTTTTACTTTTTTGATGC                                        380 60Cº 
 
EX75-R CAGGAAACAGCTATGACCAGTGCTCTCTGAGGTTTAG                                              
 
EX76 A-F TGTAAAACGACGGCCAGTacaatctttgggagggcttc  231 63Cº 
 
EX76 A-R CAGGAAACAGCTATGACCCTGACTGCTGTCGGACCTCT     
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        Table C.2 HRM and sequencing primers cont. 
 
EX76 B-F TGTAAAACGACGGCCAGTCACAACGGTGTCCTCTCCTT  216 63Cº 
 
EX76 B-R CAGGAAACAGCTATGACCttcagtggctccctgatacc     
 
EX77-F TGTAAAACGACGGCCAGTTAATCATGGCCCTTTAATATCTG                                   306 63Cº 
 
EX77-R CAGGAAACAGCTATGACCGATACTGCGTGTTGGCTTCC                                           
 
EX78-F TGTAAAACGACGGCCAGTTTCTGATATCTCTGCCTCTTCC                                     267 61Cº 
 
EX78-R CAGGAAACAGCTATGACCCATGAGCTGCAAGTGGAGAGG                                       
 
EX79 A-F TGTAAAACGACGGCCAGTAGAGTGATGCTATCTATCTGCAC                                 385 61Cº 
 
EX79 A-R CAGGAAACAGCTATGACCTGCATAGACGTGTAAAACCTGCC                                   
 
EX79B 1–F TGTAAAACGACGGCCAGTTTGTGAAGGGTAGTGGTATTATACTG 323 60Cº 
 
EX79B 1–R CAGGAAACAGCTATGACCTGCCTCAAAGTTTTGTGTGTG    
 
EX79B 2–F TGTAAAACGACGGCCAGTCGCCCGCCGAACGCATTTTGGGTTGTTT 284 60Cº 
 
EX79B 2–R CAGGAAACAGCTATGACCTCAAATGAGCAGTGTGTAGTAGTCA    
 
EX79C1-F TGTAAAACGACGGCCAGTCTTCCTCTACCACCACACCAA 242 60Cº 
 
EX79 C1-R CAGGAAACAGCTATGACCAAGCAGGTAAGCCTGGATGA    
  




        Table C.2 HRM and sequencing primers cont. 
 
EX79 C2-F TGTAAAACGACGGCCAGTTGTTCATGTCACATCCTAATAGAAA 309 60Cº 
 
EX79 C2-R CAGGAAACAGCTATGACCCGCCCGCCGTAGCAGCAGGAAGCTGAATG    
 
EX79D 1-F TGTAAAACGACGGCCAGTCGCCCGCCGCGAGTAATCGGTTGGTTGGTTGA 265 60Cº 
 
EX79D 1-R CAGGAAACAGCTATGACC TCCTTCACTTAAAGAGTGGCCTA    
 
EX79D 2 -F TGTAAAACGACGGCCAGTGCTGGAGGGCTATGGATTC 280 60Cº 
 
EX79D 2 -R CAGGAAACAGCTATGACCCGCCCGCCGTCACAAATGTGATGGGGCTA    
 
EX79E -F TGTAAAACGACGGCCAGTAATAAACTTTGGGAAAAGGTG 536 64Cº 
 
EX79E -R CAGGAAACAGCTATGACCGAAGCCGTGTTTGATGTTAAT      
 
EX79F-F TGTAAAACGACGGCCAGTGAGAGTGGGCTGACATCAA 532 61Cº 
 
EX79F-R CAGGAAACAGCTATGACCTCACTCCAGAGCTAATGTGTCT    
 
EX79G-F TGTAAAACGACGGCCAGTAGTAAGTTTCATTCTAAAATCAGAGG 531 61Cº 
 
EX79G-R CAGGAAACAGCTATGACCGTGTTTTCACTGTCTTTCTGGA     
 
M13 F 
 
TGTAAAACGACGGCCAGT  
  
 
M13 R 
  
CAGGAAACAGCTATGACC 
  
 
 
 
